Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated populations during the Omicron (B.1.1.529) variant surge in UK.

Supplementary appendix

Contents

METHODS:	4
Missing data	4
Pillar 1 and 2 cases among various age groups in England for weeks 13-17 in 2022 28-May 1, 2022):	
Validation of the impact of unvaccinated population in England for vaccine effectiveness:	5
RESULTS:	6
SARS-CoV2 cases, SARS-CoV2 Hospitalizations (in England) and SARS-CoV2 de (England and Wales) among age groups	
Vaccine effectiveness among over 50 years NIMS population in UK	7
Vaccine effectiveness of the third dose population prior to December 20, 2021	9
Comparative analysis to study the impact of unvaccinated population on vaccine effectives database denominator versus England vaccination database denominator data from the U virus dashboard):	K corona
Public health restrictions, lockdowns and reopening in the United Kingdom (UK):	12
DISCUSSION	13
Figures and Tables	15
Figures S1a: SARS-CoV2 cases per 100,000 population from August 16, 2021-May	•
Figures S1b: SARS-CoV2 hospitalizations per 100,000 population from August 16, 27, 2022	-
Figures S1c: SARS-CoV2 deaths per 100,000 population from August 16, 2021-Ma	•
Table S1a-c: SARS-CoV2 cases and hospitalization in England, SARS-CoV2 deaths in England among age groups	l and Wales
Table S2: Pre-existing condition among deaths during the Omicron variant surge in England	d25
Table S3a: NIMS database with vaccination status of all age groups , over 18 and 50 years of	of age 27
Table S3b: Vaccination status of racial ethnic minorities and vaccination status based on IN the over 18 years of age	
Table S3c: Vaccination status of all ages (entire population) of England based on England v	
Table S4: Population of United Kingdom based on mid 2020 census estimate	36
Table S5: Outcomes of Confirmed Delta variant cases, Hospitalizations and deaths	37

	Table S6a: SARS-CoV2 cases reported by specimen date (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status40
	Table S6b: SARS-CoV2 Hospitalization within 28 days of a positive test resulting in overnight inpatient admission in NIMS-database based on vaccination status
	Table S6c: SARS-CoV2 deaths within 28 days of positive COVID-19 test by date of death in NIMS-database based on vaccination
	Table S7a: Vaccine effectiveness of over 18 years of age NIMS population53
	Table S7b: Vaccine effectiveness of over 50 years of age confirmed Delta variant SARS-CoV2 cases reported by Public Health England
	Table S7c: Vaccine effectiveness of over 50 years of age NIMS population57
	Table S7d: The comparable SARS-CoV2 cases per 100,000 population of entire population (all ages), based on the NIMS population estimate and England vaccinated population database estimate 60
	Table S7e: The comparable vaccine effectiveness of entire population (all ages) based on the NIMS population denominator estimate and the England vaccinated population database denominator estimate
	Table S8a-f: Proportion test of SARS-CoV2 cases, hospitalizations and deaths among NIMS vaccinated population of over 18 and over 50 years of age
R	EFERENCES:80

METHODS:

The following are the additional details to methods that are described in in the manuscript.

Missing data: The UKHSA regularly publishing the SARS-CoV2 outcomes as an aggregate total for prior four weeks period (SARS-CoV2 cases, hospitalizations and deaths) among various vaccinated age groups weekly from August 16, 2021 to March 27, 2022. The UKHSA did not publish the outcomes for the SARS-CoV2 cases, hospital admissions and deaths among vaccinated population for the four weeks period; from November 23 to December 20, 2021 (week 48-51) and the hospital admissions among vaccinated groups for the four weeks for the period January 31, 2022 to February 27, 2022 (week 5-8). However, the aggregate four weeks outcomes for the prior and later weeks were available, thereby limiting the impact of missing data only to those missing week(s). The UKHSA stopped reporting the data of SARS-CoV2 cases, hospitalizations and deaths among NIMS population in the weekly vaccine surveillance reports. We are therefore unable to report vaccine effectiveness or the proportionality test results from March 28-May 1, 2022 period.

Pillar 1 and 2 cases among various age groups in England for weeks 13-17 in 2022 (March 28-May 1, 2022): The National Flue and COVID-19 surveillance reports were published rolling two weekly pillar 1 (public health laboratories and hospitals) and pillar 2 (community testing) SARS-CoV2 cases among age groups from September 28, 2020 to March 27, 2022. Since March 28, 2022 only weekly pillar 1 and 2 SARS-CoV2 cases per 100,000 were published in the weekly National Flue and COVID-19 surveillance reports. We computed weekly SARS-CoV2 cases (pillar 1 and 2) among various age groups in England for the period March 28-May 1, 2022 (week 13-17) using mid-year 2020 census estimate of England (Table S4) and case rates (pillar 1 and 2) per 100,000 population for each age group.

Validation of the impact of unvaccinated population in England for vaccine effectiveness:

We used the regularly published data (SARS-CoV2 cases, hospitalizations, and deaths among the age groups based on the vaccination status) by the UK Health Security Agency (UKHSA) in their weekly UK vaccine surveillance reports (in between August 16, 2021 to March 27, 2022) derived from the population linked to the National Immunization Management Service (NIMS)¹. We used the National Immunization Management Service (NIMS) databases population denominator that was published weekly in the National Flue and COVID-19 surveillance reports to calculate the vaccination rates and to calculate the rates of SARS-CoV2 infections, hospitalizations and deaths among the age groups based on the vaccination status². The NIMS data was also used by UKHSA to publish the rates of SARS-CoV2 infections, hospitalizations and deaths based on the vaccination status¹. Of the two potential sources of population denominators, the NIMS can potentially overestimate the unvaccinated population in some age groups and the Office for National Statistics (ONS) denominator can underestimate the unvaccinated populations in some age groups¹.

We used the England vaccinated population database of all ages (age specific denominators other than over 12 years of age are not published) from the UK corona virus dashboard and compared it with the NIMS database population of all ages^{2,3}. We calculated the denominator for vaccination groups (1 dose only, 2 doses only and third dose) based on the raw data for each week. We used the mid 2020 England census estimated population to derive the unvaccinated population for England vaccination database (UK corona virus dashboard)⁴. We used the NIMS total population to derive unvaccinated population for the NIMS database².

We used the weekly published total SARS-CoV2 cases (all ages) based on the vaccination status that was published by UKHSA between August 16, 2021 to March 27, 2022 in the vaccine surveillance reports and the Delta variant verified cases in England published by the Public Health England in between February 1 – September 12, 2021 to validate the two databases^{1,5}. The incidence rate per 100,000 population

among the vaccination groups and the vaccine effectiveness was calculated using both databases' denominators for the comparative analysis.

RESULTS:

SARS-CoV2 cases, SARS-CoV2 Hospitalizations (in England) and SARS-CoV2 deaths (England and Wales) among age groups (Figures 2a-c; Tables S1a-c):

Analysis of SARS-CoV2 cases (Figure 2a and Table S1a) in England among various age group showed significantly increased percent of SARS-CoV2 cases among <30 years (0-19 years, 20-29 years) during the transition from the Alpha variant surge to the initial part of the Delta variant surge. During the latter part of the Delta variant surge, the over 50 years of age (particularly over 70 years of age) have significantly increased cases with decreased cases among 20-29 years of age. The analysis of various age groups SARS-CoV2 hospitalizations (Figure 2b and Table S1b) showed significantly increased hospitalizations among under 55 years of age (particularly among 0-34 years of age) during the initial part of Delta variant surge. During the latter part of Delta variant surge, hospitalizations among over 55 years of age (particularly over 65 years) significantly increased with significantly decreased hospitalization among the other age groups. The same was observed during the latter part of Omicron variant surge (February 28-May 1, 2022) for the ≥75 years of age group. Analysis of deaths among various age groups in England and Wales (Figure 2c and Table S1c) showed a significantly increased deaths among under 70 years of age (particularly among under 50 years) during the Delta variant surge until August 1, 2021, significantly increased deaths noted among over 70 years of age, and significantly decreased deaths among < 70 years of age during the latter part of Delta variant surge (August 2-December 5, 2021). Similarly, during the latter part of the Omicron variant surge (February 28-May 1, 2022), significantly increased deaths were noted among over 75 years of age and significantly decreased deaths among under 75 years of age. The significantly

increased SARS-CoV2 cases during the latter part of the Alpha variant surge and the initial part of Delta variant surge among <50 years of age groups were associated with significantly increased deaths during the same period.

Vaccine effectiveness among over 50 years NIMS population in UK (Table S7b-c and Figure 4)

The Public Health England reported the outcomes among the Delta variant cases (confirmed and provisional) in the UK technical briefings until September 12, 2022. The UK vaccine surveillance reports started publishing from August 16, 2021 until March 27, 2022. As shown in Table S3, about 66.7% of the over 50 years of age NIMS population was vaccinated with two doses of primary vaccination by May 23, 2021 during the beginning of the Delta variant surge. The vaccine effectiveness for ≥50 years of age NIMS population vaccinated with two doses was 53.1% (95%CI 48.4%-57.2%) for the period ending in June 20, 2021. Since June 21, 2021 period as shown in Table S7b, the vaccine effectiveness declined to 18.0% - 23.2% among ≥50 years of age vaccinated with two doses and was in the negative territory with incidence rate (IR) of cases higher among the vaccinated with two doses versus the unvaccinated since August 16, 2021 period. The vaccine effectiveness of the ≥50 years of age vaccinated with two doses was also in the negative territory since August 16, 2021 among the four weekly running cases that were reported in the weekly vaccine surveillance reports. In addition, the IR of cases among those vaccinated with two doses was higher than the unvaccinated. Since the rolling four weekly cases from December 20, 2021 to June 16, 2021, the vaccinated with the third dose among ≥50 years of age was also in the negative. The two-proportions test with continuity check (henceforth proportions test) also showed that the proportion of SARS-CoV2 cases were higher among the vaccinated population versus the unvaccinated since August 16, 2021 among the Delta variant cases (vaccinated with two doses; $X^2 = 2.9683$, df = 1, p = 0.042 and all vaccinated $X^2 =$ 4.4235, df = 1, p-value = 0.01772). We observed the same with the NIMS population of ≥50 years of age (two doses cases; X^2 = 708.94, df = 1, p<0.001; all vaccinated cases; X^2 = 688.86, df = 1, p<0.001). Since the reporting period of December 20, 2021, those

over 50 years of age vaccinated with third dose have significantly higher proportion of cases (X^2 = 7987, df = 1, p<0.001) than the unvaccinated and since Jan 31, 2022, the third dose population has a significantly higher proportion of cases than the two doses population (X^2 = 309.3, df = 1, p<0.001). The proportions test on the hospitalization among ≥50 years of age showed that vaccinated with two doses population (X^2 = 678.34, df = 1, p<0.001) has a significantly higher proportion of hospitalizations than the unvaccinated since December 6. The third dose population of \geq 50 years of age (X^2 = 5.523, df = 1, p = 0.009384) and all vaccinated population (X^2 = 10.468, df = 1, p<0.001) have a significantly higher proportion of hospitalizations than the unvaccinated since February 28, 2022. Similarly, the proportions test on the SARS-CoV2 deaths within 28 days of the positive test among those vaccinated with two doses were higher than the unvaccinated ($X^2 = 39.061$, df = 1, p<0.001) since November 8, 2021. On the contrary, the third dose population does not have a significantly higher proportion of deaths versus the unvaccinated as of March 27, 2022. Using the available data from vaccine surveillance reports, we compared the case fatality rate (CFR) and risk of hospitalizations(RH) during the Omicron variant surge (December 27, 2021-March 20, 2022) with the Delta variant surge (August 16-December 5, 2021). Our comparative analysis shows a significant decline in case fatality rate (all ages [0.21% vs 0.39%; RR 0.54 (0.52-0.55); p<0.001], over 18 years of age [0.25% vs 0.58%; RR 0.44 (0.43-0.45); p<0.001], and over 50 years of age [0.72% vs 1.57%; RR 0.46 (0.45-0.47); P<0.001]) and the risk of hospitalizations (all ages [0.62% vs 0.99%; RR 0.63 (0.62-0.64); p<0.001], over 18 years of age [0.67% vs 1.38%; RR 0.484 (0.476-0.492); p<0.001], and over 50 years of age [1.45% vs 2.81%; RR 0.52 (0.51-0.53); p<0.001]). There was a significantly decreased CFR among all persons (0.72% vs 1.57%; RR 0.46 (0.45-0.47); P<0.001), unvaccinated (2.99% vs 5.18%; RR 0.58 (0.54-0.61); p<0.001), and all vaccinated (0.68 vs 1.44%; RR 0.47 (0.46-0.48); p<0.001) populations of over 50 years of age during the Omicron variant surge (December 27, 2021 to March 20, 2022) compared to the Delta variant surge (August 16-December 5, 2021). Similarly, the RH was significantly decreased among all persons (1.45% vs 2.81%; RR 0.52 (0.51-0.53); p<0.001), unvaccinated (5.48% vs 11.35%; RR 0.48 (0.46-0.50); p<0.001), allvaccinated (1.38% vs 2.44%; RR 0.57 (0.55-0.58); p<0.001) populations of over 50

years of age during the Omicron variant surge compared to Delta variant surge. Among those over 50 years of age vaccinated with two doses, the CFR significantly increased (1.75% vs 1.41%; RR 1.24 (1.19-1.30); p<0.001) with no significant change in the RH (2.42% vs 2.40%; RR 1.01 (0.97-1.04); p=0606) during the Omicron variant surge compared to the Delta variant surge. As shown in Table 1c, the significantly decreased SARS-CoV2 cases in unvaccinated [53,365 of 1,544,744 (3.5%) vs 42,796 of 757,942 (5.6%); RR 0.61 (0.60-0.62); p<0.001] during the Omicron variant surge (December 27, 2021 to March 20, 2022) among over 50 years of age was associated with significantly decreased hospitalizations [2,924 of 22,456 (13.0%) vs 4,859 of 21,300 (22.8%); RR 0.57 (0.55-0.60); p<0.001] and significantly decreased SARS-CoV2 deaths [1,595 of 11,184 (14.3% vs 2,216 of 11,912 (18.6%); RR 0.77 (0.72-0.81); p<0.001] versus the Delta variant surge (August 16-December 5, 2021). Similarly, a significantly increased SARS-CoV2 cases among the all vaccinated population [1,410,754 of 1,544,744 (91.3%) vs 669,847 of 757,942 (88.4%); RR 1.033 (1.032-1.034); p<0.001] during the Omicron variant surge was associated with significantly increased SARS-CoV2 hospitalizations [19,452 of 22,456 (86.6%) vs. 16,330 of 21,300 (76.7%); RR 1.13 (1.12-1.14); p<0.001] and significantly increased SARS-CoV2 deaths [9,528 of 11,184 (85.2%) vs. 9,613 of 11,912 (80.7%); RR 1.06 (1.04-1.07); p<0.001].

Analysis of the SARS-CoV2 deaths in England and Wales showed that 97.95% and 80.07% of the deaths during the latter part of the Omicron variant surge occurred among ≥50 years and ≥75 years of age groups, respectively. The pre-existing conditions were present in 95.6% of deaths among all ages and 96.2% of deaths ≥60 years of age during the Omicron variant surge in England. The deaths among the elderly vaccinated population have to be considered in the context of their advanced age along with the pre-existing conditions.

Vaccine effectiveness of the third dose population prior to December 20, 2021:

Since the third dose vaccination approval in September 2021, about 77.3% of the ≥50 years of age NIMS population were vaccinated with the third dose by December 19,

2021. The UKHSA did not report the third dose outcomes until December 20, 2021 in their weekly reports. In our study, we analyzed the 999,064 pillar 2 cases among over 18 years old reported from a UKHSA publication with 336,046 cases among the third dose (booster), 484,742 among the two doses, and 137,478 cases among the unvaccinated⁶. Using the third dose weekly vaccinated populations between December 26, 2021, January 2, 2022, and January 9,2022, the best vaccine effectiveness for the third dose was 13.8%, 18.4%, and 22.2%, respectively. During the same period (November 27, 2021-January 12, 2022) England reported 52,369 SARS-CoV2 hospitalizations and 4,101 COVD-19 deaths among over 18 years of age^{7,8}.

Comparative analysis to study the impact of unvaccinated population on vaccine effectiveness (NIMS database denominator versus England vaccination database denominator data from the UK corona virus dashboard):

The percentage of unvaccinated disparities among the two databases

The comparison of the percent of the unvaccinated population in the NIMS database (Table S3a) and the England vaccination database data from the UK corona virus dashboard (Table S3c) show that the NIMS unvaccinated population is 8.4% (as of August 15, 2021) to 9.0% (as of March 27, 2022) higher than the England vaccination database.

The SARS-CoV2 cases per 100,000 population among the vaccinated groups We studied the SARS-CoV2 cases incidence rate per 100,000 population among the confirmed Delta variant cases of all ages in England (February 1 – September 12, 2021) and SARS-CoV2 cases all ages from NIMS linked population published in the COVID-19 vaccine surveillance reports (August 16, 2021 – March 27, 2022) as shown in Table S7d. The incidence rate of the SARS-CoV2 cases per 100,000 did not vary much among the vaccinated population (1 dose, two doses only, or third dose) as shown in Table S7d. However, the incidence rate of SARS-CoV2 cases per 100,000 unvaccinated population was underestimated using the NIMS database as the

denominator. The same was overestimated using the England vaccinated database as the denominator.

Impact on vaccine effectiveness using comparative analysis of each of the two databases population as denominator

Vaccine effectiveness (VE) two doses among confirmed Delta variant cases in England by Public Health England (Table S7e): The vaccine effectiveness for those vaccinated with two doses during Feb 1-June 20, 2021 was 84.4% (95% CI 83.9% to 84.8%) using the NIMS database and 88.8% (95% CI 88.0% to 88.7%) using the England database as the denominators with a difference of 4.4% of underestimation of VE with the NIMS database. During the subsequent four weeks period ending in July 18, 2021, the VE of those vaccinated with two doses was 70.3% (using NIMS database as the denominator) and 78.8% (England DB as the denominator) with a difference of 8.5%. During the subsequent two weeks period ending in August 1, 2021, the VE for those with two doses were 53.4% and 67.0%, respectively with a difference of 13.6%. During the subsequent six weeks, there was a decline in VE among those vaccinated with two doses using both the databases; for the two weeks period ending in September 12, 2021 the VE for those vaccinated with two doses was 27.8% (95% CI 26.1% to 29.3%) using the NIMS database as the denominator and 50.0% (95% CI 48.9% to 51.1%) using the England vaccination database as the denominator (NIMS underestimates VE versus the England database up to 22.3%).

Vaccine effectiveness (VE) two doses and third dose among NIMS linked SARS-CoV2 cases reported in UKHSA vaccine surveillance reports (Table S7e): Since the first reporting period for those vaccinated with two doses starting August 16 – Sept 12, 2021 four weeks period the VE was 31.4% (95% CI 30.9% to 32.0%) and 52.5% (95% CI 52.2% to 53.0%), respectively using the NIMS and England DB as the denominators with a 21.1% difference; since then the variation is steadily increasing. Since November 22, 2021 the VE values among those vaccinated with two doses using both the databases are in the negative. The third dose reporting period started from December

20, 2021 to January 16, 2022 four-week period. The third dose VE values (all ages) were 12.9% (95% CI 12.4% to 13.3%) and 44.0% (95% CI 43.7% to 44.3%), respectively using the NIMS and England DB as the denominators with a difference of 31.1%. Since then, there was a decline in the VE values in both the databases and by Feb 7- Mar 6, 2022, the VE for the third dose using both the database denominators was in the negative with a difference between the two databases as high as 86.9%.

In summary, when the VE for those vaccinated with two doses of the entire population of England (all ages) during the Feb 1-August 1, 2021 was good *when* the VE using both databases (NIMS vs England vaccination DB) was above the FDA recommended VE of >50%. The variation in VE among these databases was 4.0% to 13.6% with a lowest variation of 4.0% when the VE in both databases was greater than 80% and 13.6% variation when the VE was in the 53.4% to 67.0% range. The third dose VE since the December 20, 2021 was <50% in both databases (12.9% using NIMS as denominator and 44.0% using England DB as denominator), with the variation of 31.1%. The variation increased to 86.9% by March 27, 2022 and the VE for the third dose using both the databases as denominators was in negative since February 7, 2022.

Public health restrictions, lockdowns and reopening in the United Kingdom (UK): The UK instituted the first lockdown during the beginning of the pandemic on March 23, 2020. The second lockdown (October 30, 2020) and the third lockdown (December 22, 2020) were instituted during the second wave and the surge in cases during the Alpha variant surge.

The phased easing of restriction in UK started with reopening of the schools and colleges effective March 8, 2021 (week 10). The step 2 of the reopening became effective since April 12, 2021 and step 3 of the reopening since May 17, 2021 and by May 2021 the outdoor social contact were to be removed, two households or six people were allowed to meet indoors, and indoor hospitality services were provided and hotels were opened^{9–12}. The UK government announced that most restrictions including face

masks mandates, social distancing measures and capacity limitations in venues were lifted in England by July 19, 2021 and these were replaced by recommendations^{11,12}.

DISCUSSION

Based on the UKHSA reliance on the NIMS database linked outcomes (weekly reported number of SARS-CoV2 cases, hospitalizations, and deaths among various age groups based on the vaccination status and these outcomes per 100, 000 population based on the vaccination status) in the regular weekly vaccine surveillance reports, we also believe the NIMS database population is a better database that can be used as the denominator for an effective outcomes assessment¹.

The UKHSA describes the NIMS databases as "dynamic database of named individuals, where the numerator and the denominator come from the same source and there is a record of each individual's vaccination status. Additionally, NIMS contains key sociodemographic variables for those who are targeted and then receive the vaccine, providing a rich and consistently coded data source for evaluation of the vaccine programme. Large scale efforts to contact people in the register will result in the identification of people who may be overcounted, thus affording opportunities to improve accuracy in a dynamic fashion that feeds immediately into vaccine uptake statistics and informs local vaccination efforts"¹³.


The UKHSA also describes the advantages and disadvantages of using potential sources of the denominator data from either NIMS or Office for National Statistics (ONS) mid-year population estimates¹³. According the UKHSA, the "NIMS may overestimate denominators in some age groups, for example because people are registered with the NHS but may have moved abroad. However, as it is a dynamic register, such patients, once identified by the NHS, are able to be removed from the denominator. On the other hand, ONS data uses population estimates based on the 2011 census and other sources of data. When using ONS, vaccine coverage exceeds 100% of the

population in some age groups, which would in turn lead to a negative denominator when calculating the size of the unvaccinated population"¹³.

Based on the above UKHSA assessment of available databases, we believe the NIMS database population is a reliable population denominator with a possibility of overestimation only when the population moved abroad, and checks and balances to remove them from database are identified. Based on our comparative analysis of VE using the two database denominators, the NIMS underestimates the VE and the England vaccination database overestimates the VE, especially during the period when the VE was waning fast. Additionally, the variation between the database denominators were in low range (4.0% to 13.6%) when the VE was above the FDA cutoff point of greater than 50% and both the database denominators variability is only in 4% range when the VE is greater than 80%. Based on this data, our use of NIMS database as the denominator may have underestimated the vaccine effectiveness by about 5.0 to 12.5% range during the Omicron variant surge. Since both databases denominators show a negative VE for the third dose, and the cases for 100,000 population among those vaccinated with the third dose are higher than those vaccinated with two doses and unvaccinated during the latter part of the Omicron variant surge since February 2022, it is of utmost importance not to overestimate vaccine effectiveness especially in the elderly population.

Our use of the NIMS denominator did not alter the outcomes reported in our data analysis (SARS-CoV2 cases, hospitalizations and deaths per 100,000 population among the vaccinated populations and their trends in comparison with other vaccinated groups including the unvaccinated population trends). The increasing proportion of SARS-CoV2 cases, hospitalizations, and deaths in the vaccinated population (including the third dose) and decreasing proportion of SARS-CoV2 cases, hospitalizations, and deaths in the unvaccinated population during the Omicron variant surge as shown in Figure 6 (Table S6a-c) are not affected by the NIMS denominator population.

Figures and Tables






Figure S1a: SARS-CoV2 cases per 100,000 population among over 50 years of age group based on the vaccination status from August 16, 2021 to March 27, 2022.






Figure S1b: SARS-CoV2 hospitalizations per 100,000 population among over 50 years of age group based on the vaccination status from August 16, 2021 to March 27, 2022.






Figure S1c: SARS-CoV2 deaths per 100,000 population among over 50 years of age group based on the vaccination status from August 16, 2021 to March 27, 2022.

Table S1a-c: SARS-CoV2 cases and hospitalization in England, SARS-CoV2 deaths in England and Wales among age groups

	Pre-Alpha	Alpha va	riant surge	Delta vari	iant surge	Omicron va	riant surge
Study period	Sept 28, 2020- Dec 6, 2020	Dec 7,2020-Feb 28, 2021	Mar 1, 2021-May 23, 2021	May 24, 2021-Aug 1, 2021	Aug 2, 2021-Dec 5, 2021	Dec 6, 2021-Feb 27, 2022	Feb 28, 2022-May 1, 2022
COVID-19 cases; All ages (n=)	1,055,142	2,074,606	235,582	1,243,075	3,721,600	5,459,340	2,460,597
0-19 yrs (n=%)	190,310 (18.0%)	289,018 (13.9%)	65,475 (27.8%)	368,060 (29.6%)	1,395,180 (37.5%)	1,380,507 (25.3%)	345,279 (14.0%)
20-29 yrs (n=%)	201,561 (19.1%)	380,818 (18.4%)	39,470 (16.8%)	353,755 (28.5%)	418,792 (11.3%)	913,345 (16.7%)	300,745 (12.2%)
30-49 yrs (n=%)	332,709 (31.5%)	728,813 (35.1%)	81,706 (34.7%)	355,519 (28.6%)	1,091,029 (29.3%)	1,873,509 (34.3%)	823,063 (22.4%)
50-69 yrs (n=%)	238,349 (22.6%)	487,939 (23.5%)	38,921 (16.5%)	138,527 (11.1%)	655,025 (17.6%)	994,954 (18.2%)	687,604 (27.9%)
≥ 50 yrs (n=%)	330,562 (31.3%)	675,957 (32.6%)	48,931 (20.8%)	165,741 (13.3%)	816,599 (21.9%)	1,291,979 (23.7%)	991,510 (40.3%)
≥ 70 yrs (n=%)	92,213 (8.7%)	188,018 (9.1%)	10,010 (4.2%)	27,214 (2.2%)	161,574 (4.3%)	297,025 (5.4%)	303,905 (12.4%)
≥80 yrs (n=%)	46,640 (4.4%)	101,056 (4.9%)	4,845 (2.1%)	8,910 (0.7%)	48,156 (1.3%)	110,302 (2.0%)	115,288 (4.7%)
Statistical analysis		(Δ) from prior period	(Δ) from prior period	(Δ) from prior period			
0-19 yrs [RR (95%CI); p va	lue]	0.77 (0.77-0.78); p<0.001	2.00 (1.98-2.01); p<0.001	1.07 (1.06-1.07); p<0.001	1.27 (1.26-1.27); p<0.001	0.67 (0.67-0.68); p<0.001	0.55 (0.55-0.56); p<0.001
20-29 yrs [RR (95%CI); p v	alue]	0.96 (0.96-0.97); p<0.001	0.91 (0.90-0.92); p<0.001	1.70 (1.68-1.71); p<0.001	0.40 (0.39-0.40); p<0.001	1.48 (1.48-1.49); p<0.001	0.73 (0.72-0.73); p<0.001
30-49 yrs [RR (95%CI); p v	alue]	1.11 (1.11-1.12); p<0.001	0.99 (0.98-0.99); p<0.001	0.82 (0.82-0.83); p<0.001	1.03 (1.02-1.03); p<0.001	1.17 (1.168-1.172); p<0.001	0.97 (0.97-0.98); p<0.001
50-69 yrs [RR (95%CI); p v	alue]	1.04 (1.04-1.05); p<0.001	0.70 (0.69-0.71); p<0.001	0.67 (0.66-0.68); p<0.001	1.58 (1.57-1.59); p<0.001	1.03 (1.03-1.04); p<0.001	1.53 (1.52-1.54); p<0.001
≥ 50 years [RR (95%CI); p \	/alue]	1.04 (1.03-1.04); p<0.001	0.64 (0.63-0.64); p<0.001	0.64 (0.63-0.65); p<0.001	1.65 (1.63-1.65); p<0.001	1.07 (1.07-1.08); p<0.001	1.70 (1.70-1.71); p<0.001
≥ 70 yrs [RR (95%CI); p val	ue]	1.04 (1.03-1.04); p<0.001	0.47 (0.46-0.48); p<0.001	0.52 (0.50-0.53); p<0.001	1.98 (1.95-2.01); p<0.001	1.25 (1.24-1.26); p<0.001	2.27 (2.26-2.28); p<0.001
≥ 80 yrs [RR (95%CI); p val	ue]	1.10 (1.09-1.11); p<0.001	0.42 (0.41-0.43); p<0.001	0.35 (0.37-0.36); p<0.001	1.81 (1.76-1.85); p<0.001	1.56 (1.54-1.58); p<0.001	2.32 (2.30-2.34); p<0.001

Table S1a: SARS-CoV2 cases in England among age groups in between September 28, 2020 to May 1, 2022. The total SARS-CoV2 cases for each study period and the proportion of SARS-CoV2 cases among the various age groups (n=%) for the specific period shown on the table. The

statistical analysis is shown on the lower portion of table for the specified time period. The analysis provides the proportion of change (Δ) in SARS-CoV2 infections in a particular age group compared to the prior period represented as relative risk (RR), 95% confidence interval (95% CI) and p-value.

	Pre-Alpha	Alpha variant su	ırge	Delta variant s	urge	Omicron varian	t surge
Time period	Oct 12, 2020-Dec 6, 2020	Dec 7, 2020-Feb 28, 2021	Mar 1, 2021- May 23, 2021	May 24-Aug 1, 2021	Aug 2-Dec 5, 2021	Dec 6,2021-Feb 27,2022	Feb 28-May 1, 2022
COVID-19 Hospitalizations; All							
ages (n=)	65,419	179,599	17,295	24,880	87,823	106,834	95,278
0-17 yrs (n=%)	952 (1.5%)	2,496 (1.4%)	599 (3.5%)	1,602 (6.4%)	4,779 (5.4%)	7,396 (6.9%)	4,971 (5.2%)
18-34 yrs (n=%)	3,440 (5.3%)	9,942 (5.5%)	1,924 (11.1%)	5,784 (23.2%)	9,994 (11.4%)	13,775 (12.9%)	7,933 (8.3%)
25 54 vmc (*		20 492 (16 49/)	2 750 (21 70/)	6 021 /27 50/\	18,847	16 710 (15 60/)	10,362 (10.9%)
35-54 yrs (n=%) 55-64 yrs (n=%)	8,970 (13.7%) 8,669 (13.3%)	29,483 (16.4%)	3,759 (21.7%) 2,697 (15.6%)	6,831 (27.5%) 3,028 (12.2%)	(21.5%) 12,189 (13.9%)	16,710 (15.6%) 11,580 (10.8%)	9,210 (9.7%)
65-74 yrs (n=%)	12,107 (18.5%)	32,426 (18.1%)	2,540 (14.7%)	2,770 (11.1%)	14,944 (17.0%)	15,466 (14.5%)	14,794 (15.5%)
≥ 75 yrs (n=%)	30,586 (46.8%)	76,831 (42.8%)	5,761 (33.3%)	4,806 (19.3%)	27,047 (30.8%)	41,875 (39.2%)	47,970 (50.3%)
Statistical analysis		(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period
0-17 yrs [RR (95% CI); p	value]	0.96 (0.88-1.02); p<0.223	2.49 (2.28-2.72); p<0.001	1.86 (1.70-2.03); p<0.001	0.85 (0.80-0.89); p<0.001	1.27 (1.22-1.31); p<0.001	0.75 (0.72-0.78); p<0.001
18-34 yrs [RR (95% CI); ¡	o value]	1.05 (1.01-1.09); p=0.007	2.01 (1.91-2.10); p<0.001	2.09 (1.99-2.19); p<0.001	0.49 (0.47-0.50); p<0.001	1.13 (1.10-1.16); p<0.001	0.65 (0.62-0.66); p<0.001
35-54 yrs [RR (95% CI); ¡	o value]	1.20 (1.17-1.22); p<0.001	1.32 (1.28-1.36); p<0.001	1.26 (1.22-1.31); p<0.001	0.78 (0.76-0.80); p<0.001	0.73 (0.71-0.74); p<0.001	0.70 (0.67-0.71); p<0.001
55-64 yrs [RR (95% CI); ¡	o value]	1.19 (1.16-1.21); p<0.001	0.99 (0.95-1.03); p=0.699	0.78 (0.74-0.82); p<0.001	1.14 (1.10-1.18); p<0.001	0.78 (0.76-0.80); p<0.001	0.89 (0.86-0.91); p<0.001
65-74 yrs [RR (95% CI); ¡	o value]	0.98 (0.95-0.99); p=0.010	0.81 (0.78-0.84); p<0.001	0.76 (0.72-0.80); p<0.001	1.53 (1.47-1.59); p<0.001	0.85 (0.83-0.87); p<0.001	1.07 (1.05-1.09); p<0.001
≥ 75 yrs [RR (95% CI); p v	alue]	0.92 (0.90-0.92); p<0.001	0.78 (0.76-0.80); p<0.001	0.58 (0.56-0.60); p<0.001	1.59 (1.55-1.64); p<0.001	1.27 (1.25-1.29); p<0.001	1.28 (1.27-1.30); p<0.001

Table S1b: SARS-CoV2 hospitalizations in England among age groups in between October 12, 2020 to May 1, 2022. The total SARS-CoV2 hospitalizations for each study period and the proportion of SARS-CoV2 hospitalizations among the various age groups (n=%) for the specific

period shown on the table. The statistical analysis is shown on the lower portion of table for the specified time period. The analysis provides the proportion of change (Δ) in SARS-CoV2 hospitalizations in a particular age group compared to the prior period represented as relative risk (RR), 95% confidence interval (95% CI) and p-value.

			Alpha v	ariant surge	Delta va	riant surge	Omicron	variant surge
Study period	Feb 24-Aug 16, 2020	Aug 17-Dec 6, 2020	Dec 7,2020-Feb 28, 2021	Mar 1, 2021- May 23, 2021	May 24, 2021- Aug 1, 2021	Aug 2, 2021- Dec 5, 2021	Dec 6, 2021- Feb 27, 2022	Feb 28, 2022- May 1, 2022
COVID-19 deaths, all ages (n=)	52,410	19,082	63,118	7,281	1,719	13,980	12,063	7,787
0-19 yrs (n= %)	15 (0.03%)	2 (0.01%)	16 (0.03%)	4 (0.05%)	6 (0.35%)	33 (0.24%)	27 (0.22%)	12 (0.15%)
20-29 yrs (n= %)	76 (0.15%)	21 (0.11%)	74 (0.12%)	16 (0.22%)	14 (0.81%)	51 (0.36%)	35 (0.29%)	14 (0.18%)
30-49 yrs (n= %)	886 (1.69%)	266 (1.39%)	1,153 (1.83%)	241 (3.31%)	114 (6.63%)	611 (4.37%)	399 (3.31%)	118 (1.52%)
50-69 yrs (n= %)	7,468 (14.25%)	2,600 (13.63%)	9,887 (15.66%)	1,785 (24.52%)	468 (27.23%)	3,302 (23.62%)	2,241 (18.58%)	793 (10.18%)
70-74 yrs (n= %)	4,817 (9.19%)	1,956 (10.25%)	6,077 (9.63%)	708 (9.72%)	166 (9.66%)	1,619 (11.58%)	1,933 (16.02%)	599 (7.69%)
≥ 50 yrs (n= %)	51345 (97.97%)	18,765 (98.34%)	61,771 (97.87%)	6,987 (95.96%)	1,570 (91.33%)	13,215 (94.53%)	11,546 (95.71%)	7,627 (97.95%)
≥ 75 yrs (n= %)	39060 (74.53%)	14,209 (74.46%)	45,807 (72.57%)	4,494 (61.72%)	936 (54.45%)	8,294 (59.33%)	8,189 (67.89%)	6,235 (80.07%)
Statistical analysis	3	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period	(Δ) from prior period
0-19 yrs [RR (95% CI); p value]	0.36 (0.08- 1.60); p=0.182	2.42 (0.55-10.51); p=0.238	2.17 (0.72-6.48); p=0.166	6.35 (1.79- 22.49); p=0.004	0.68 (0.28- 1.61); p=0.377	0.95 (0.57- 1.58); p=0.837	0.69 (0.35-1.36); p=0.281
20-29 yrs [RR (95% (CI); p value]	0.75 (0.46- 1.23); p=0.263	1.07 (0.66-1.73); p=0.797	1.87 (1.09-3.22); p=0.022	3.71 (1.81-7.57); p=0.0003	0.45 (0.24- 0.80); p=0.007	0.80 (0.51- 1.22); p=0.296	0.62 (0.33-1.15); p=0.130
30-49 yrs [RR (95% (CI); p value]	0.82 (0.72- 0.944); p=0.005	1.31 (1.15-1.49); p=0.001	1.81 (1.58-2.08); p<0.001	2.00 (1.61-2.49); p<0.001	0.66 (0.54- 0.80); p<0.001	0.76 (0.66- 0.86); p<0.001	0.46 (0.37-0.56); p<0.001
50-69 yrs [RR (95% (CI); p value]	0.96 (0.92- 0.99); p=0.034	1.15 (1.10-1.12); p<0.001	1.57 (1.49-1.64); p<0.001	1.11 (1.02-1.21); p=0.018	0.87 (0.79- 0.94); p=0.001	0.79 (0.75- 0.82); p<0.001	0.41 (0.38-0.45); p<0.001
70-74 yrs [RR (95% (70-74 yrs [RR (95% CI); p value]		0.94 (0.89-0.98); p=0.011	1.01 (0.93-1.09); p=0.792	0.99 (0.84-1.17); p=0.932	1.20 (1.03- 1.39); p=0.019	1.38 (1.30- 1.47); p<0.001	0.48 (0.44-0.52); p<0.001
≥ 50 yrs [RR (95% CI)	≥ 50 yrs [RR (95% CI); p value]		0.995 (0.993- 0.997); p<0.001	0.98 (0.97-0.99); p<0.001	0.95 (0.93-0.97); p<0.001	1.04 (1.01- 1.05); p<0.001	1.01 (1.01- 1.02); p<0.001	1.02 (1.02-0.03); p<0.001
≥ 75 yrs [RR (95% CI)); p value]	0.99 (0.98- 1.01); p=0.860	0.97 (0.96-0.98); p<0.001	0.85 (0.83-0.87); p<0.001	0.88 (0.84-0.92); p<0.001	1.09 (1.04- 1.14); p=0.001	1.14 (1.12- 1.17); p<0.001	1.18 ((1.16- 1.20); p<0.001

Table S1c: SARS-CoV2 deaths in England and Wales among age groups in between February 24, 2020 to May 1, 2022. The total SARS-CoV2 deaths for each study period and the proportion of SARS-CoV2 deaths among the various age groups (n=%) for the specific period shown on the table. The statistical analysis is shown on the lower portion of table for the specified time period. The analysis provides the proportion of change (Δ) in SARS-CoV2 deaths in a particular age group compared to the prior period represented as relative risk (RR), 95% confidence interval (95% CI) and p-value.

Table S2: Pre-existing condition among deaths during the Omicron variant surge in England

	ditions during the Omicron varia						
Age group	Total CARC COV2 double		Pre-existing conditions among the SARS-CoV2 deaths				
(yrs)	Total SARS-COV2 deaths						
		Present	Absent				
All ages	17,142	16,387 (95.6%)	755 (4.4%)				
0 - 19	39	27 (69.2%)	12 (30.8%)				
20 - 39	198	164 (82.8%)	34 (17.2%)				
40 - 59	1,206	1,093 (90.6%)	113 (9.4%)				
60 - 79	5,803	5,537 (95.4%)	266 (4.6%)				
80+	9,895	9,566 (96.7%)	329 (3.3%)				
60+	15,698	15,103 (96.2%)	595 (3.8%)				
Pre-existing cor	ditions during the entire pandem	nic					
		Count of all	Doothe with no				
Date	Due suistine condition	deaths since	Deaths with pre-				
introduced	Pre-existing condition	condition	existing condition				
		introduced	(n=%)				
31-Mar-20	Diabetes	115,463	29,572 (25.6%)				
31-Mar-20	Chronic Kidney Disease	115,463	19,548 (16.9%)				
31-Mar-20	Chronic Pulmonary Disease	115,463	18,455 (16.0%)				
31-Mar-20	Dementia	115,463	17,011 (14.7%)				
1-May-20	Ischaemic Heart Disease	96,645	12,468 (12.9%)				
31-Mar-20	Asthma	115,463	8,690 (7.5%)				
31-Mar-20	Rheumatological Disorder	115,463	3,904 (3.4%)				
31-Mar-20	Chronic Neurological Disorder	115,463	2,934 (2.5%)				
	Received treatment for a Mental	·					
24-Mar-20	Health condition	117,059	2,653 (2.3%)				

24-Mar-20	Learning Disability and or Autism	117,059	1,397 (1.2%)
31-Mar-20	Other	115,463	84,544 (73.2%)

Table S2: Pre-existing condition among deaths during the Omicron variant surge in England. The lower portion of the table represent the cumulative (n=%) for each diagnosis since the condition date was introduced for the analysis. The age specific breakdown of the pre-existing condition diagnosis is not available. However, 95.71% to 97.5% of the total SARS-CoV2 deaths occurred among the over 50 years of age during the Omicron variant surge as noted in the Table S1c. During the initial and latter part of the Omicron variant surge 67.89% and 80.07% of total deaths occurred respectively among those over 75 years of age as shown the same table.

week endin g	All ages,	on status; n=	-population		≥ 18 yrs. of age vaccination status; n=population (%)				≥ 50 yrs. of age vaccination status; n=population (%)			
8	2 doses (no 3 rd)	Third dose	1 dose only	Unvaccinate d	2 doses (no 3 rd)	Third dose	1 dose only	Unvaccinate d	2 doses (no 3 rd)	Third dose	1 dose only	Unvaccinate d
3-Jan-	29,783	uose	1,108,851	61,961,296	29,775	uose	1,108,534	49,085,900	18,145	uose	873,796	21,607,893
3-Jan- 21	(0.05%)		(1.8%)	(98.2%)	(0.1%)		(2.2%)	(97.7%)	(0.1%)		(3.9%)	(96.0%)
10-Jan-	402,102		1,661,407	61,036,379	402,058		1,660,718	48,161,391	354,641		1,207,864	20,937,311
21	(0.6%)		(2.6%)	(96.7%)	(0.8%)		(3.3%)	(95.9%)	(1.6%)		(5.4%)	(93.1%)
17-Jan-	442,698		3,174,888	59,482,270	442,647		3,173,666	46,607,822	384,361		2,349,075	19,766,359
	,		(5.0%)	(94.3%)			(6.3%)	(92.8%)	(1.7%)			(87.9%)
21 24-Jan-	(0.7%)		, ,	, ,	(0.9%)		_ ` '	, , , , , , , , , , , , , , , , , , ,	· /		(10.4%)	,
24-Jan- 21	450,064		5,359,396	57,290,372	450,010		5,357,481	44,416,620	388,937		4,123,495	17,987,350
	(0.7%)		(8.5%)	(90.8%)	(0.9%)		(10.7%)	(88.4%)	(1.7%)		(18.3%)	(79.9%)
31-Jan-	460,029		7,513,401	55,126,358	459,963		7,510,529	42,253,575	394,382		5,924,604	16,180,765
21	(0.7%)		(11.9%)	(87.4%)	(0.9%)		(15.0%)	(84.1%)	(1.8%)		(26.3%)	(71.9%)
7-Feb-	470,877		9,874,536	52,754,344	470,811		9,870,576	39,882,649	400,108		7,960,696	14,138,919
21	(0.7%)		(15.6%)	(83.6%)	(0.9%)		(19.7%)	(79.4%)	(1.8%)		(35.4%)	(62.8%)
14-Feb-	490,579		12,141,76	50,467,364	490,500		12,136,09	37,597,390	411,497		9,906,334	12,181,858
21	(0.8%)		3 (19.2%)	(80.0%)	(1.0%)		5 (24.2%)	(74.9%)	(1.8%)		(44.0%)	(54.1%)
21-Feb-	515,699		14,167,95	48,416,011	515,602		14,157,86	35,550,470	425,363		11,453,744	10,620,547
21	(0.8%)		2 (22.5%)	(76.7%)	(1.0%)		9 (28.2%)	(70.8%)	(1.9%)		(50.9%)	(47.2%)
28-Feb-	606,844		16,326,97	46,165,791	606,671		16,307,12	33,310,091	477,899		12,897,769	9,123,957
21	(1.0%)		6 (25.9%)	(73.2%)	(1.2%)		8 (32.5%)	(66.3%)	(2.1%)		(57.3%)	(40.6%)
7-Mar-	804,235		17,915,49	44,379,802	803,960		17,892,58	31,527,266	619,281		13,951,393	7,928,897
21	(1.3%)		9 (28.4%)	(70.3%)	(1.6%)		9 (35.6%)	(62.8%)	(2.8%)		(62.0%)	(35.2%)
14-	1,117,297		19,298,91	42,683,207	1,116,884		19,272,70	29,834,110	837,736		14,951,636	6,710,129
Mar-21	(1.8%)		2 (30.6%)	(67.6%)	(2.2%)		1 (38.4%)	(59.4%)	(3.7%)		(66.5%)	(29.8%)
21-	1,612,580		21,881,71	39,604,914	1,611,856		21,852,25	26,759,378	1,168,952		16,952,088	4,378,368
Mar-21	(2.6%)		9 (34.7%)	(62.8%)	(3.2%)		8 (43.5%)	(53.3%)	(5.2%)		(75.3%)	(19.5%)
28-	2,799,963		22,724,93	37,574,058	2,798,602		22,689,61	24,735,019	2,061,993		17,281,497	3,155,746
Mar-21	(4.4%)		2 (36.0%)	(59.5%)	(5.6%)		1 (45.2%)	(49.2%)	(9.2%)		(76.8%)	(14.0%)
4-Apr-	4,323,280]	22,014,10	36,761,369	4,321,262		21,975,77	23,925,992	3,275,787		16,413,863	2,809,437
21	(6.9%)		3 (34.9%)	(58.3%)	(8.6%)		7 (43.8%)	(47.6%)	(14.6%)		(73.0%)	(12.5%)
11-Apr-	6,297,786		20,384,85	36,415,884	6,294,836		20,344,81	23,583,147	4,894,124		14,902,291	2,702,514
21	(10.0%)		0 (32.3%)	(57.7%)	(12.5%)		6 (40.5%)	(47.0%)	(21.8%)		(66.2%)	(12.0%)

18-Apr-	8,436,940	18,769,54	35,891,780	8,432,628	18,728,62	23,061,287	6,685,917	13,190,927	2,621,896
21	(13.4%)	4 (29.7%)	(56.9%)	(16.8%)	8 (37.3%)	(45.9%)	(29.7%)	(58.6%)	(11.7%)
25-Apr-	10,680,33	17,186,76	35,230,749	10,674,31	17,145,97	22,401,838	8,595,553	11,356,042	2,546,853
21	7 (16.9%)	4 (27.2%)	(55.8%)	2 (21.3%)	9 (34.1%)	(44.6%)	(38.2%)	(50.5%)	(11.3%)
2-May-	12,822,57	15,718,25	34,556,605	12,814,31	15,678,22	21,729,174	10,380,47	9,621,020	2,496,624
21	7 (20.3%)	2 (24.9%)	(54.8%)	2 (25.5%)	8 (31.2%)	(43.3%)	9 (46.1%)	(42.8%)	(11.1%)
9-May-	14,872,85	14,359,97	33,864,269	14,859,44	14,323,50	21,038,422	11,930,95	8,108,973	2,457,945
21	2 (23.6%)	0 (22.8%)	(53.7%)	6 (29.6%)	4 (28.5%)	(41.9%)	2 (53.0%)	(36.0%)	(10.9%)
16-									
May-	17,003,35	13,255,20	32,838,081	16,979,88	13,223,27	20,017,762	13,397,39	6,692,260	2,407,916
21	2 (26.9%)	7 (21.0%)	(52.0%)	6 (33.8%)	3 (26.3%)	(39.9%)	3 (59.6%)	(29.7%)	(10.7%)
23-									
May-	19,266,07	12,201,72	31,628,350	19,238,43	12,169,33	18,812,657	15,002,86	5,141,253	2,353,113
21	1 (30.5%)	8 (19.3%)	(50.1%)	5 (38.3%)	9 (24.2%)	(37.5%)	3 (66.7%)	(22.9%)	(10.5%)
30-									
May-	21,501,13	11,106,52	30,487,981	21,469,88	11,074,83	17,675,195	16,624,52	3,585,879	2,286,459
21	3 (34.1%)	1 (17.6%)	(48.3%)	3 (42.7%)	9 (22.1%)	(35.2%)	7 (73.9%)	(15.9%)	(10.2%)
6-Jun-	23,480,37	9,997,612	29,617,087	23,446,39	9,964,995	16,807,969	17,991,86	2,251,444	2,253,174
21	7 (37.2%)	(15.8%)	(46.9%)	5 (46.7%)	(19.8%)	(33.5%)	4 (80.0%)	(10.0%)	(10.0%)
13-Jun-	25,151,89	9,383,450	28,558,988	25,113,93	9,350,595	15,754,083	18,951,55	1,317,673	2,226,792
21	1 (39.9%)	(14.9%)	(45.3%)	5 (50.0%)	(18.6%)	(31.4%)	7 (84.2%)	(5.9%)	(9.9%)
20-Jun-	26,287,67	9,504,211	27,301,589	26,246,20	9,469,778	14,501,789	19,393,71	900,099	2,201,669
21	9 (41.7%)	(15.1%)	(43.3%)	1 (52.3%)	(18.9%)	(28.9%)	9 (86.2%)	(4.0%)	(9.8%)
27-Jun-	27,168,99	9,798,677	26,124,962	27,124,12	9,763,129	13,329,676	19,567,59	750,506	2,176,842
21	8 (43.1%)	(15.5%)	(41.4%)	1 (54.0%)	(19.4%)	(26.5%)	3 (87.0%)	(3.3%)	(9.7%)
4-Jul-	28,061,61	9,648,230	25,382,133	28,013,51	9,611,624	12,591,124	19,666,12	671,838	2,156,617
21	3 (44.5%)	(15.3%)	(40.2%)	8 (55.8%)	(19.1%)	(25.1%)	1 (87.4%)	(3.0%)	(9.6%)
11-Jul-	28,950,15	9,242,451	24,898,854	28,898,87	9,205,675	12,111,194	19,739,27	617,709	2,137,378
21	0 (45.9%)	(14.6%)	(39.5%)	6 (57.5%)	(18.3%)	(24.1%)	9 (87.8%)	(2.7%)	(9.5%)
18-Jul-	29,966,24	8,554,088	24,570,647	29,911,28	8,517,418	11,786,568	19,798,53	575,609	2,120,034
21	7 (47.5%)	(13.6%)	(38.9%)	7 (59.6%)	(17.0%)	(23.5%)	6 (88.0%)	(2.6%)	(9.4%)
25-Jul-	30,932,50	7,821,016	24,336,996	30,874,69	7,783,137	11,556,979	19,843,30	543,956	2,106,761
21	4 (49.0%)	(12.4%)	(38.6%)	1 (61.5%)	(15.5%)	(23.0%)	3 (88.2%)	(2.4%)	(9.4%)
1-Aug-	31,852,32	7,098,507	24,139,246	31,791,04	7,058,043	11,365,276	19,883,63	515,571	2,094,646
21	1 (50.5%)	(11.2%)	(38.3%)	8 (63.3%)	(14.1%)	(22.6%)	6 (88.4%)	(2.3%)	(9.3%)
8-Aug-	32,756,02	6,373,113	23,960,443	32,691,19	6,320,771	11,201,905	19,916,77	493,433	2,083,467
21	4 (51.9%)	(10.1%)	(38.0%)	9 (65.1%)	(12.6%)	(22.3%)	8 (88.5%)	(2.2%)	(9.3%)
15-	33,727,54	5,611,293	23,750,160	33,659,12	5,490,998	11,063,176	19,944,74	475,305	2,073,405
Aug-21	5 (53.5%)	(8.9%)	(37.6%)	0 (67.0%)	(10.9%)	(22.0%)	8 (88.7%)	(2.1%)	(9.2%)
22-	34,687,26	4,942,094	23,459,028	34,615,29	4,655,978	10,941,417	19,969,18	459,499	2,064,546
Aug-21	9 (55.0%)	(7.8%)	(37.2%)	2 (68.9%)	(9.3%)	(21.8%)	7 (88.8%)	(2.0%)	(9.2%)

29-	35,479,76		4,423,944	23,184,181	35,404,65		3,972,304	10,835,225	19,992,04		444,528	2,056,504
Aug-21	3 (56.2%)		(7.0%)	(36.7%)	8 (70.5%)		(7.9%)	(21.6%)	3 (88.9%)		(2.0%)	(9.1%)
5-Sep-	36,118,11	12,738	3,977,545	22,991,593	36,039,89	12,713	3,428,983	10,742,682	20,008,54	7,045	434,345	2,049,929
21	8 (57.2%)	(0.02%)	(6.3%)	(36.4%)	5 (71.8%)	(0.03%)	(6.8%)	(21.4%)	1 (88.9%)	(0.03%)	(1.9%)	(9.1%)
12-Sep-	36,632,60	14,276	3,593,049	22,860,063	36,551,52	14,248	3,005,016	10,653,480	20,024,67	7,995	423,866	2,043,327
21	6 (58.1%)	(0.02%)	(5.7%)	(36.2%)	9 (72.8%)	(0.03%)	(6.0%)	(21.2%)	2 (89.0%)	(0.04%)	(1.9%)	(9.1%)
19-Sep-	36,984,09	43,185	3,326,622	22,746,097	36,899,86	43,126	2,709,140	10,572,142	20,018,49	30,591	414,203	2,036,574
21	0 (58.6%)	(0.1%)	(5.3%)	(36.0%)	5 (73.5%)	(0.1%)	(5.4%)	(21.0%)	2 (89.0%)	(0.1%)	(1.8%)	(9.1%)
26-Sep-	36,865,26	432,235	3,178,256	22,624,237	36,777,08	432,070	2,518,065	10,497,056	19,709,29	357,852	402,771	2,029,942
21	6 (58.4%)	(0.7%)	(5.0%)	(35.9%)	2 (73.2%)	(0.9%)	(5.0%)	(20.9%)	5 (87.6%)	(1.6%)	(1.8%)	(9.0%)
3-Oct-	36,136,12	1,360,104	3,162,512	22,441,257	36,043,13	1,359,758	2,387,178	10,434,202	18,940,07	1,145,668	389,978	2,024,141
21	1 (57.3%)	(2.2%)	(5.0%)	(35.6%)	5 (71.8%)	(2.7%)	(4.8%)	(20.8%)	3 (84.2%)	(5.1%)	(1.7%)	(9.0%)
10-Oct-	35,097,67	2,575,568	3,202,469	22,224,278	34,992,71	2,574,955	2,287,832	10,368,771	17,922,16	2,179,876	380,041	2,017,779
21	9 (55.6%)	(4.1%)	(5.1%)	(35.2%)	5 (69.7%)	(5.1%)	(4.6%)	(20.6%)	4 (79.7%)	(9.7%)	(1.7%)	(9.0%)
17-Oct-	33,924,69	3,913,065	3,278,275	21,983,963	33,800,59	3,912,076	2,206,454	10,305,147	16,792,82	3,323,957	371,757	2,011,326
21	1 (53.8%)	(6.2%)	(5.2%)	(34.8%)	6 (67.3%)	(7.8%)	(4.4%)	(20.5%)	0 (74.6%)	(14.8%)	(1.7%)	(8.9%)
24-Oct-	32,526,36	5,461,045	3,382,332	21,730,254	32,383,55	5,459,513	2,141,948	10,239,261	15,452,29	4,679,006	364,458	2,004,099
21	3 (51.5%)	(8.7%)	(5.4%)	(34.4%)	1 (64.5%)	(10.9%)	(4.3%)	(20.4%)	7 (68.7%)	(20.8%)	(1.6%)	(8.9%)
31-Oct-	31,082,16	7,035,752	3,464,949	21,517,133	30,921,58	7,033,556	2,086,992	10,182,138	14,066,96	6,077,670	358,133	1,997,095
21	0 (49.3%)	(11.2%)	(5.5%)	(34.1%)	7 (61.6%)	(14.0%)	(4.2%)	(20.3%)	2 (62.5%)	(27.0%)	(1.6%)	(8.9%)
7-Nov-	29,391,86	8,847,251	3,601,201	21,259,682	29,217,61	8,844,063	2,034,479	10,128,118	12,477,51	7,680,221	352,272	1,989,852
21	0 (46.6%)	(14.0%)	(5.7%)	(33.7%)	3 (58.2%)	(17.6%)	(4.1%)	(20.2%)	5 (55.5%)	(34.1%)	(1.6%)	(8.8%)
14-	27,527,38	10,841,33	3,684,054	21,047,221	27,339,40	10,836,40	1,977,027	10,071,440	10,769,33	9,403,246	345,025	1,982,256
Nov-21	2 (43.6%)	7 (17.2%)	(5.8%)	(33.4%)	3 (54.4%)	3 (21.6%)	(3.9%)	(20.1%)	3 (47.9%)	(41.8%)	(1.5%)	(8.8%)
21-	25,605,74	12,884,76	3,723,869	20,885,612	25,402,40	12,877,48	1,927,847	10,016,534	9,072,178	11,116,35	337,097	1,974,233
Nov-21	9 (40.6%)	4 (20.4%)	(5.9%)	(33.1%)	4 (50.6%)	8 (25.6%)	(3.8%)	(19.9%)	(40.3%)	2 (49.4%)	(1.5%)	(8.8%)
28-	23,621,27	15,029,38	3,695,318	20,754,017	23,366,74	15,019,48	1,876,521	9,961,516	7,387,515	12,824,31	321,984	1,966,050
Nov-21	5 (37.4%)	4 (23.8%)	(5.9%)	(32.9%)	8 (46.5%)	8 (29.9%)	(3.7%)	(19.8%)	(32.8%)	1 (57.0%)	(1.4%)	(8.7%)
5-Dec-	21,594,19	17,253,86	3,632,098	20,619,836	21,261,36	17,240,89	1,824,939	9,897,079	5,774,535	14,461,14	307,839	1,956,339
21	1 (34.2%)	9 (27.3%)	(5.8%)	(32.7%)	3 (42.3%)	2 (34.3%)	(3.6%)	(19.7%)	(25.7%)	7 (64.3%)	(1.4%)	(8.7%)
12-	19,265,73	19,773,94	3,566,118	20,494,204	18,864,31	19,757,26	1,774,889	9,827,809	4,272,802	15,982,96	298,816	1,945,282
Dec-21	1 (30.5%)	1 (31.3%)	(5.7%)	(32.5%)	5 (37.6%)	0 (39.3%)	(3.5%)	(19.6%)	(19.0%)	0 (71.0%)	(1.3%)	(8.6%)
19-	14,761,02	24,518,70	3,513,151	20,307,117	14,283,11	24,492,87	1,735,265	9,713,027	2,894,226	17,384,40	293,512	1,927,721
Dec-21	2 (23.4%)	4 (38.9%)	(5.6%)	(32.2%)	1 (28.4%)	0 (48.8%)	(3.5%)	(19.3%)	(12.9%)	1 (77.3%)	(1.3%)	(8.6%)
26-	12,144,70	27,318,27	3,467,929	20,169,079	11,601,91	27,283,93	1,712,801	9,625,630	2,301,915	17,991,95	290,631	1,915,357
Dec-21	9 (19.2%)	7 (43.3%)	(5.5%)	(32.0%)	0 (23.1%)	2 (54.3%)	(3.4%)	(19.2%)	(10.2%)	7 (80.0%)	(1.3%)	(8.5%)
2-Jan-	10,944,96	28,675,14	3,432,361	20,047,524	10,325,49	28,634,73	1,706,797	9,557,243	2,051,827	18,250,87	290,032	1,907,122
22	9 (17.3%)	0 (45.4%)	(5.4%)	(31.8%)	9 (20.6%)	4 (57.0%)	(3.4%)	(19.0%)	(9.1%)	9 (81.1%)	(1.3%)	(8.5%)
9-Jan-	9,977,945	29,846,06	3,371,664	19,904,318	9,255,079	29,798,03	1,691,094	9,480,068	1,844,119	18,468,98	288,108	1,898,647
22	(15.8%)	7 (47.3%)	(5.3%)	(31.5%)	(18.4%)	2 (59.3%)	(3.4%)	(18.9%)	(8.2%)	6 (82.1%)	(1.3%)	(8.4%)

16-Jan-	9,546,563	30,459,19	3,307,547	19,786,685	8,725,007	30,401,73	1,684,402	9,413,125	1,739,053	18,582,41	286,899	1,891,489
22	(15.1%)	9 (48.3%)	(5.2%)	(31.4%)	(17.4%)	9 (60.5%)	(3.4%)	(18.7%)	(7.7%)	9 (82.6%)	(1.3%)	(8.4%)
23-Jan-	9,390,117	30,805,72	3,217,300	19,686,848	8,454,911	30,734,48	1,677,190	9,357,687	1,685,346	18,642,85	285,949	1,885,709
22	(14.9%)	9 (48.8%)	(5.1%)	(31.2%)	(16.8%)	5 (61.2%)	(3.3%)	(18.6%)	(7.5%)	6 (82.9%)	(1.3%)	(8.4%)
30-Jan-	9,296,619	31,087,43	3,117,686	19,598,253	8,243,011	31,004,98	1,668,538	9,307,741	1,639,123	18,695,45	284,923	1,880,357
22	(14.7%)	6 (49.3%)	(4.9%)	(31.1%)	(16.4%)	3 (61.7%)	(3.3%)	(18.5%)	(7.3%)	7 (83.1%)	(1.3%)	(8.4%)
6-Feb-	9,262,440	31,274,87	3,032,392	19,530,287	8,110,384	31,184,76	1,654,914	9,274,215	1,611,069	18,728,23	283,227	1,877,333
22	(14.7%)	5 (49.6%)	(4.8%)	(31.0%)	(16.1%)	0 (62.1%)	(3.3%)	(18.5%)	(7.2%)	1 (83.2%)	(1.3%)	(8.3%)
13-Feb-	9,241,569	31,442,36	2,950,014	19,466,044	7,995,490	31,345,39	1,634,487	9,248,902	1,589,530	18,754,37	280,876	1,875,076
22	(14.6%)	7 (49.8%)	(4.7%)	(30.8%)	(15.9%)	4 (62.4%)	(3.3%)	(18.4%)	(7.1%)	8 (83.4%)	(1.2%)	(8.3%)
20-Feb-	9,209,801	31,581,86	2,892,982	19,415,347	7,902,747	31,476,58	1,615,652	9,229,290	1,572,678	18,775,25	278,643	1,873,280
22	(14.6%)	4 (50.1%)	(4.6%)	(30.8%)	(15.7%)	4 (62.7%)	(3.2%)	(18.4%)	(7.0%)	9 (83.4%)	(1.2%)	(8.3%)
27-Feb-	9,175,261	31,712,91	2,842,449	19,369,372	7,824,511	31,592,29	1,598,003	9,209,460	1,556,155	18,795,47	276,809	1,871,421
22	(14.5%)	2 (50.3%)	(4.5%)	(30.7%)	(15.6%)	9 (62.9%)	(3.2%)	(18.3%)	(6.9%)	5 (83.5%)	(1.2%)	(8.3%)
6-Mar-	9,156,404	31,823,14	2,787,551	19,332,897	7,767,075	31,683,45	1,580,454	9,193,286	1,543,289	18,811,62	274,926	1,870,025
22	(14.5%)	2 (50.4%)	(4.4%)	(30.6%)	(15.5%)	8 (63.1%)	(3.1%)	(18.3%)	(6.9%)	0 (83.6%)	(1.2%)	(8.3%)
13-	9,141,789	31,926,56	2,731,039	19,300,602	7,717,387	31,766,82	1,561,398	9,178,666	1,532,248	18,825,91	272,981	1,868,713
Mar-22	(14.5%)	4 (50.6%)	(4.3%)	(30.6%)	(15.4%)	2 (63.2%)	(3.1%)	(18.3%)	(6.8%)	8 (83.7%)	(1.2%)	(8.3%)
20-	9,131,054	32,024,76	2,672,836	19,271,344	7,672,917	31,844,16	1,541,996	9,165,195	1,522,702	18,838,82	270,793	1,867,541
Mar-22	(14.5%)	0 (50.8%)	(4.2%)	(30.5%)	(15.3%)	5 (63.4%)	(3.1%)	(18.2%)	(6.8%)	4 (83.7%)	(1.2%)	(8.3%)
27-	9,117,101	32,115,50	2,622,602	19,244,791	7,629,664	31,915,63	1,525,760	9,153,218	1,511,149	18,853,41	269,098	1,866,201
Mar-22	(14.4%)	0 (50.9%)	(4.2%)	(30.5%)	(15.2%)	1 (63.5%)	(3.0%)	(18.2%)	(6.7%)	2 (83.8%)	(1.2%)	(8.3%)

Table S3a: NIMS database with vaccination status of all age groups, over 18 and 50 years of age. The weekly number of population in each vaccination group and percentage represented for each week based on the age. The total NIMS cohort of all age groups (n=63,099,994); over 18 years of age (n=50,224,273) and over 50 years of age (n=22,499,860) as of March 27, 2022. For the entire population (all ages), the NIMS database have 8.9% to 9.0% more percentage of unvaccinated population than the England database as shown on Table S3c in between December 19, 2021 to March 27, 2022.

Table S3b: Vaccination status of racial ethnic minorities and vaccination status based on IMD score of the over 18 years of age

18+ years of age			Vaccination sta	tus; n=population (%)	
Ethnicity status	Denominator	1 dose only	2 doses only	Third dose	Unvaccinated
White - British	30,755,212	654,705 (2.1%)	3,847,492 (12.5%)	23,506,318 (76.4%)	2,746,697 (8.9%)
White - Irish	305,107	6,836 (2.2%)	32,959 (10.8%)	212,706 (69.7%)	52,606 (17.2%)
White - Other	4,364,388	117,373 (2.7%)	758,638 (17.4%)	2,011,587 (46.1%)	1,476,790 (33.8%)
Mixed - White and Black Caribbean	163,185	7,854 (4.8%)	34,452 (21.1%)	58,500 (35.8%)	62,379 (38.2%)
Mixed - White and Black African	125,836	6,193 (4.9%)	32,845 (26.1%)	50,148 (39.9%)	36,650 (29.1%)
Mixed - White and Asian	141,390	5,274 (3.7%)	26,766 (18.9%)	78,564 (55.6%)	30,786 (21.8%)
Mixed - Any other mixed background	307,921	12,813 (4.2%)	60,728 (19.7%)	148,242 (48.1%)	86,138 (28.0%)
Asian or Asian British - Indian	1,459,219	46,807 (3.2%)	268,328 (18.4%)	896,598 (61.4%)	247,486 (17.0%)
Asian or Asian British - Pakistani	1,047,413	60,910 (5.8%)	387,666 (37.0%)	366,405 (35.0%)	232,432 (22.2%)
Asian or Asian British - Bangladeshi	379,935	18,740 (4.9%)	117,464 (30.9%)	176,429 (46.4%)	67,302 (17.7%)
Asian or Asian British - Any other Asian background	885,577	36,255 (4.1%)	192,281 (21.7%)	483,804 (54.6%)	173,237 (19.6%)
Black or Black British - Caribbean	413,011	16,529 (4.0%)	79,798 (19.3%)	145,374 (35.2%)	171,310 (41.5%)
Black or Black British - African	911,671	50,450 (5.5%)	264,944 (29.1%)	317,774 (34.9%)	278,503 (30.5%)
Black or Black British - Any other Black background	346,270	18,713 (5.4%)	88,468 (25.5%)	108,548 (31.3%)	130,541 (37.7%)
Chinese	451,559	24,059 (5.3%)	52,763 (11.7%)	203,476 (45.1%)	171,261 (37.9%)
Other ethnic groups - Any other ethnic group	1,122,853	46,019 (4.1%)	238,690 (21.3%)	475,598 (42.4%)	362,546 (32.3%)
Not Stated/Unknown	6,461,320	323,991 (5.0%)	949,393 (14.7%)	2,956,131 (45.8%)	2,231,805 (34.5%)
Non-white ethnic groups (all)	12,425,335	350,616 (4.5%)	1,845,193 (23.8%)	3,509,460 (45.2%)	2,050,571 (26.4%)
18+ years of Age			Vaccination sta	tus; n=population (%)	1
IMD decile		1 dose only	2 doses only	Third dose	Unvaccinated
1 (most deprived)		231,099 (5.6%)	1,036,060 (25.2%)	2,266,843 (55.2%)	13.9%
2		206,422 (4.8%)	1,000,801 (23.2%)	2,575,207 (59.7%)	12.3%
3		192,948 (4.3%)	954,499 (21.1%)	2,853,084 (63.0%)	11.6%

4	172,467 (3.7%)	853,092 (18.5%)	3,117,666 (67.7%)	10.0%
5	144,138 (3.2%)	750,866 (16.4%)	3,289,305 (72.0%)	8.4%
6	130,418 (2.8%)	688,136 (14.9%)	3,491,214 (75.4%)	6.9%
7	110,690 (2.5%)	610,577 (13.6%)	3,539,976 (78.6%)	5.3%
8	103,928 (2.3%)	582,920 (13.0%)	3,637,946 (81.1%)	3.6%
9	86,911 (2.0%)	522,274 (11.9%)	3,672,750 (83.4%)	2.8%
10 (least deprived)	74,766 (1.7%)	440,433 (10.2%)	3,744,140 (86.7%)	1.4%

Table S3b: Vaccination status of racial ethnic minorities and vaccination status based on IMD score of the over 18 years of age NIMS population as of May 1, 2022.

Table S3c: Vaccination status of all ages (entire population) of England based on England vaccination database.

	England vaccination database-All ages, Vaccination status; n=population (%)			
Week ending	Two doses (no 3 rd dose)	Third dose	1 dose only	Unvaccinated
1/10/2021	374,613 (0.7%)		1,584,538 (2.8%)	54,590,987 (96.5%)
1/17/2021	427,386 (0.8%)		3,092,670 (5.5%)	53,030,082 (93.8%)
1/24/2021	441,684 (0.8%)		5,286,009 (9.3%)	50,822,445 (89.9%)
1/31/2021	460,907 (0.8%)		7,621,448 (13.5%)	48,467,783 (85.7%)
2/7/2021	471,636 (0.8%)		10,048,093 (17.8%)	46,030,409 (81.4%)
2/14/2021	490,722 (0.9%)		12,372,187 (21.9%)	43,687,229 (77.3%)
2/21/2021	513,435 (0.9%)		14,444,639 (25.5%)	41,592,064 (73.5%)
2/28/2021	599,935 (1.1%)		16,612,869 (29.4%)	39,337,334 (69.6%)
3/7/2021	797,321 (1.4%)		18,218,176 (32.2%)	37,534,641 (66.4%)
3/14/2021	1,129,444 (2.0%)		19,662,394 (34.8%)	35,758,300 (63.2%)
3/21/2021	1,621,547 (2.9%)		22,233,315 (39.3%)	32,695,276 (57.8%)
3/28/2021	2,806,124 (5.0%)		23,097,658 (40.8%)	30,646,356 (54.2%)
4/4/2021	4,344,251 (7.7%)		22,401,788 (39.6%)	29,804,099 (52.7%)
4/11/2021	6,338,332 (11.2%)		20,769,258 (36.7%)	29,442,548 (52.1%)
4/18/2021	8,518,498 (15.1%)		19,110,081 (33.8%)	28,921,559 (51.1%)
4/25/2021	10,791,851 (19.1%)		17,497,445 (30.9%)	28,260,842 (50.0%)
5/2/2021	12,972,758 (22.9%)		15,993,178 (28.3%)	27,584,202 (48.8%)
5/9/2021	15,031,521 (26.6%)		14,620,033 (25.9%)	26,898,584 (47.6%)
5/16/2021	17,172,209 (30.4%)		13,471,265 (23.8%)	25,906,664 (45.8%)
5/23/2021	19,427,631 (34.4%)		12,399,174 (21.9%)	24,723,333 (43.7%)
5/30/2021	21,719,461 (38.4%)		11,219,035 (19.8%)	23,611,642 (41.8%)
6/6/2021	23,710,646 (41.9%)		10,089,461 (17.8%)	22,750,031 (40.2%)
6/13/2021	25,391,916 (44.9%)		9,459,223 (16.7%)	21,698,999 (38.4%)
6/20/2021	26,534,936 (46.9%)		9,566,842 (16.9%)	20,448,360 (36.2%)

6/27/2021	27,414,725 (48.5%)		9,861,169 (17.4%)	19,274,244 (34.1%)
7/4/2021	28,324,385 (50.1%)		9,719,772 (17.2%)	18,505,981 (32.7%)
7/11/2021	29,204,296 (51.6%)		9,324,907 (16.5%)	18,020,935 (31.9%)
7/18/2021	30,213,335 (53.4%)		8,650,475 (15.3%)	17,686,328 (31.3%)
7/25/2021	31,181,649 (55.1%)		7,922,798 (14.0%)	17,445,691 (30.8%)
8/1/2021	32,110,377 (56.8%)		7,198,835 (12.7%)	17,240,926 (30.5%)
8/8/2021	33,004,783 (58.4%)		6,490,321 (11.5%)	17,055,034 (30.2%)
8/15/2021	33,971,458 (60.1%)		5,737,867 (10.1%)	16,840,813 (29.8%)
8/22/2021	34,927,576 (61.8%)		5,076,721 (9.0%)	16,545,841 (29.3%)
8/29/2021	35,715,918 (63.2%)		4,572,956 (8.1%)	16,261,264 (28.8%)
9/5/2021	36,352,855 (64.3%)		4,137,264 (7.3%)	16,060,019 (28.4%)
9/12/2021	36,865,490 (65.2%)		3,765,715 (6.7%)	15,918,933 (28.2%)
9/19/2021	37,244,704 (65.9%)		3,508,137 (6.2%)	15,797,297 (27.9%)
9/26/2021	37,510,886 (66.3%)		3,362,885 (5.9%)	15,676,367 (27.7%)
10/3/2021	36,409,103 (64.4%)	1,298,612 (2.3%)	3,332,894 (5.9%)	15,509,529 (27.4%)
10/10/2021	35,449,302 (62.7%)	2,426,155 (4.3%)	3,334,052 (5.9%)	15,340,629 (27.1%)
10/17/2021	34,340,945 (60.7%)	3,695,991 (6.5%)	3,362,399 (5.9%)	15,150,803 (26.8%)
10/24/2021	32,950,633 (58.3%)	5,235,928 (9.3%)	3,469,279 (6.1%)	14,894,298 (26.3%)
10/31/2021	31,489,596 (55.7%)	6,826,159 (12.1%)	3,577,930 (6.3%)	14,656,453 (25.9%)
11/7/2021	29,820,842 (52.7%)	8,616,120 (15.2%)	3,714,085 (6.6%)	14,399,091 (25.5%)
11/14/2021	27,813,943 (49.2%)	10,776,175 (19.1%)	3,858,390 (6.8%)	14,101,630 (24.9%)
11/21/2021	25,879,170 (45.8%)	12,830,865 (22.7%)	3,907,598 (6.9%)	13,932,505 (24.6%)
11/28/2021	23,863,068 (42.2%)	14,995,780 (26.5%)	3,901,108 (6.9%)	13,790,182 (24.4%)
12/5/2021	21,803,895 (38.6%)	17,242,093 (30.5%)	3,867,342 (6.8%)	13,636,808 (24.1%)
12/12/2021	19,487,030 (34.5%)	19,745,991 (34.9%)	3,818,248 (6.8%)	13,498,869 (23.9%)
12/19/2021	15,100,851 (26.7%)	24,376,660 (43.1%)	3,772,998 (6.7%)	13,299,629 (23.5%)
12/26/2021	12,361,345 (21.9%)	27,312,396 (48.3%)	3,728,022 (6.6%)	13,148,375 (23.3%)
1/2/2022	11,129,075 (19.7%)	28,706,633 (50.8%)	3,692,190 (6.5%)	13,022,240 (23.0%)
1/9/2022	10,145,018 (17.9%)	29,897,180 (52.9%)	3,636,558 (6.4%)	12,871,382 (22.8%)
1/16/2022	9,700,362 (17.2%)	30,526,563 (54.0%)	3,578,827 (6.3%)	12,744,386 (22.5%)
1/23/2022	9,531,469 (16.9%)	30,888,097 (54.6%)	3,491,555 (6.2%)	12,639,017 (22.4%)

1/30/2022	9,428,375 (16.7%)	31,180,755 (55.1%)	3,398,776 (6.0%)	12,542,232 (22.2%)
2/6/2022	9,390,711 (16.6%)	31,378,540 (55.5%)	3,314,512 (5.9%)	12,466,375 (22.0%)
2/13/2022	9,365,359 (16.6%)	31,553,940 (55.8%)	3,232,663 (5.7%)	12,398,176 (21.9%)
2/20/2022	9,329,464 (16.5%)	31,702,092 (56.1%)	3,172,802 (5.6%)	12,345,780 (21.8%)
2/27/2022	9,294,209 (16.4%)	31,839,752 (56.3%)	3,118,611 (5.5%)	12,297,566 (21.7%)
3/6/2022	9,263,733 (16.4%)	31,966,231 (56.5%)	3,061,901 (5.4%)	12,258,273 (21.7%)
3/13/2022	9,245,305 (16.3%)	32,076,944 (56.7%)	3,001,131 (5.3%)	12,226,758 (21.6%)
3/20/2022	9,228,619 (16.3%)	32,184,060 (56.9%)	2,936,877 (5.2%)	12,200,582 (21.6%)
3/27/2022	9,212,937 (16.3%)	32,279,253 (57.1%)	2,882,600 (5.1%)	12,175,348 (21.5%)

Table S3c: England vaccination database (UK corona virus dashboard) with vaccination status of all age groups in England. The weekly number of population in each vaccination group and percentage represented for each week based on the age. The total England cohort of all age groups (n=56,550,138) derived from the England mid 2020 census estimate as shown on Table S4. Age subgroup information is not available for age groups \geq 18 yrs or \geq 50 yrs of age. For the entire population (all ages), the England database have 8.9% to 9.0% less percentage of unvaccinated population than the NIMS database as shown on Table S3a in between December 19, 2021 to March 27, 2022.

Table S4: Population of United Kingdom based on mid 2020 census estimate

		England and	
	United Kingdom	Wales	England
Total			
population	67,081,234	59,719,724	56,550,138
Age group			
0-19 yrs	15,658,537 (23.3%)	14,032,132 (23.5%)	13,330,355 (23.6%)
20-29 yrs	8,609,788 (12.8%)	7,658,686 (12.8%)	7,244,015 (12.8%)
30-49 yrs	17,321,585 (25.8%)	15,425,743 (25.8%)	14,677,803 (26.0%)
50-69 yrs	16,338,067 (24.4%)	14,434,809 (24.2%)	13,618,246 (24.1%)
≥50 yrs	25,491,324 (38.0%)	22,603,163 (37.8%)	21,297,965 (37.7%)
≥70 yrs	9,153,257 (13.6%)	8,168,354 (13.7%)	7,679,719 (13.6%)
≥75 yrs	5,789,351 (8.6%)	5,172,340 (8.7%)	4,865,591 (8.6%)
≥80 yrs	3,385,592 (5.0%)	3,031,325 (5.1%)	2,855,599 (5.0%)

Table S4: Population of United Kingdom based on mid 2020 census estimate. Age group distribution of population in UK, England; England and Wales.

Table S5: Outcomes of Confirmed Delta variant cases, Hospitalizations and deaths

					Vaccin	ated (n=% of age	e group)	Vaccination status	
Study period	Age (yrs)	Outcome	Total (n= % of all ages)	Unvaccinated (n=% of age group)	All Vaccinated	1 dose*	Two doses [‡]	unknown (n=% of age group)	
Feb 1- June 20, 2021	All ages	Cases	123,620 (100%)	71,932 (58.2%)	37,329 (30.2%)	26,495 (21.4%)	10,834 (8.8%)	14,359 (11.6%)	
		Hospitalizations	1,904 (100%)	1,182 (62.1%)	688 (36.1%)	375 (19.7%)	313 (16.4%)	34 (1.8%)	
		Deaths	257 (100%)	92 (35.8%)	163 (63.4%)	45 (17.5%)	118 (45.9%)	2 (0.8%)	
	<50 yrs	Cases	111,008 (89.8%)	70,664 (63.7%)	27,444 (24.7%)	21,844 (19.7%)	5,600 (5.0%)	12,900 (11.6%)	
		Hospitalizations	1,283 (67.4%)	987 (76.9%)	272 (21.2%)	224 (17.5%)	48 (3.7%)	24 (1.9%)	
		Deaths	26 (10.1%)	21 (80.8%)	5 (19.2%)	3 (11.5%)	2 (7.7%)	0 (0.0%)	
	≥50 yrs	Cases	12,404 (10.0%)	1,267 (10.2%)	9,885 (79.7%)	4,651 (37.5%)	5,234 (42.2%)	1,252 (10.1%)	
		Hospitalizations	615 (32.3%)	195 (31.7%)	416 (67.6%)	151 (24.6%)	265 (43.1%)	4 (0.7%)	
		Deaths	231 (89.9%)	71 (30.7%)	158 (68.4%)	42 (18.2%)	116 (50.2%)	2 (0.9%)	
June 21-July 18, 2021	All ages	Cases	105,598 (100%)	49,470 (46.8%)	45,535 (43.1%)	27,596 (26.1%)	17,939 (17.0%)	10,593 (10.0%)	
		Hospitalizations	1,788 (100%)	970 (54.3%)	788 (44.1%)	258 (14.4%)	530 (29.6%)	30 (1.7%)	
		Deaths	203 (100%)	73 (36.0%)	126 (62.1%)	20 (9.9%)	106 (52.2%)	4 (2.0%)	
	<50 yrs	Cases	94,541 (89.5%)	48,399 (51.2%)	36,546 (38.7%)	26,800 (28.3%)	9,746 (10.3%)	9,586 (10.1%)	
		Hospitalizations	1,044 (58.4%)	725 (69.4%)	292 (28.0%)	200 (19.2%)	92 (8.8%)	27 (2.6%)	
		Deaths	19 (9.4%)	13 (68.4%)	5 (26.3%)	3 (15.8%)	2 (10.5%)	1 (5.3%)	
	≥50 yrs	Cases	10,975 (10.4%)	1,070 (9.7%)	8,988 (81.9%)	795 (7.2%)	8,193 (74.7%)	917 (8.4%)	
		Hospitalizations	750 (41.9%)	245 (32.7%)	496 (66.1%)	58 (7.7%)	438 (58.4%)	9 (1.2%)	
		Deaths	184 (90.6%)	60 (32.6%)	121 (65.8%)	17 (9.2%)	104 (56.5%)	3 (1.6%)	
July 19-Aug 1, 2021	All ages	Cases	70,792 (100%)	29,652 (41.9%)	34,251 (48.4%)	16,016 (22.6%)	18,235 (25.8%)	6,889 (9.7%)	
		Hospitalizations	1,467 (100%)	808 (55.1%)	641 (43.7%)	129 (8.8%)	512 (34.9%)	18 (1.2%)	
		Deaths	282 (100%)	88 (31.2%)	192 (68.1%)	14 (5.0%)	178 (63.1%)	2 (0.7%)	
	<50 yrs	Cases	60,200 (85.0%)	28,549 (47.4%)	25,817 (42.9%)	15,627 (26.0%)	10,190 (16.9%)	5,834 (9.7%)	

		Hospitalizations	757 (51.6%)	578 (76.4%)	169 (22.3%)	85 (11.2%)	84 (11.1%)	10 (1.3%)
		Deaths	26 (9.2%)	14 (53.8%)	11 (42.3%)	2 (7.7%)	9 (34.6%)	1 (3.8%)
	≥50 yrs	Cases	10,357 (14.6%)	1,103 (10.6%)	8,434 (81.4%)	389 (3.8%)	8,045 (77.7%)	820 (7.9%)
		Hospitalizations	709 (48.3%)	230 (32.4%)	472 (66.6%)	44 (6.2%)	428 (60.4%)	7 (1.0%)
		Deaths	255 (90.4%)	74 (29.0%)	181 (71.0%)	12 (4.7%)	169 (66.3%)	- (0.0%)
Aug 2-Aug 15, 2021	All ages	Cases	86,725 (100%)	32,079 (37.0%)	46,214 (53.3%)	19,850 (22.9%)	26,364 (30.4%)	8,432 (9.7%)
		Hospitalizations	2,126 (100%)	1,073 (50.5%)	1,036 (48.7%)	187 (8.8%)	849 (39.9%)	17 (0.8%)
		Deaths	447 (100%)	137 (30.6%)	302 (67.6%)	25 (5.6%)	277 (62.0%)	8 (1.8%)
	<50 yrs	Cases	72,085 (83.1%)	30,628 (42.5%)	34,390 (47.7%)	19,382 (26.9%)	15,008 (20.8%)	7,067 (9.8%)
		Hospitalizations	1,028 (48.4%)	754 (73.3%)	264 (25.7%)	122 (11.9%)	142 (13.8%)	10 (1.0%)
		Deaths	42 (9.4%)	24 (57.1%)	17 (40.5%)	3 (7.1%)	14 (33.3%)	1 (2.4%)
	≥50 yrs	Cases	14,528 (16.8%)	1,451 (10.0%)	11,824 (81.4%)	468 (3.2%)	11,356 (78.2%)	1,253 (8.6%)
		Hospitalizations	1,099 (51.7%)	319 (29.0%)	772 (70.2%)	65 (5.9%)	707 (64.3%)	8 (0.7%)
		Deaths	406 (90.8%)	113 (27.8%)	285 (70.2%)	22 (5.4%)	263 (64.8%)	8 (2.0%)
Aug 16-Aug 29, 2021	All ages	Cases	105,793 (100%)	36,583 (34.6%)	59,364 (56.1%)	18,913 (17.9%)	40,451 (38.2%)	9,846 (9.3%)
		Hospitalizations	2,187 (100%)	1,031 (47.1%)	1,115 (51.0%)	147 (6.7%)	968 (44.3%)	41 (1.9%)
		Deaths	609 (100%)	146 (24.0%)	450 (73.9%)	38 (6.2%)	412 (67.7%)	13 (2.1%)
	<50 yrs	Cases	82,855 (78.3%)	34,749 (41.9%)	40,176 (48.5%)	18,317 (22.1%)	21,859 (26.4%)	7,930 (9.6%)
		Hospitalizations	986 (45.1%)	698 (70.8%)	248 (25.2%)	93 (9.4%)	155 (15.7%)	40 (4.1%)
		Deaths	41 (6.7%)	27 (65.9%)	13 (31.7%)	3 (7.3%)	10 (24.4%)	1 (2.4%)
	≥50 yrs	Cases	22,843 (21.6%)	1,833 (8.0%)	19,188 (84.0%)	596 (2.6%)	18,592 (81.4%)	1,822 (8.0%)
		Hospitalizations	1,201 (54.9%)	333 (27.7%)	867 (72.2%)	54 (4.5%)	813 (67.7%)	1 (0.1%)
		Deaths	568 (93.3%)	119 (21.0%)	437 (76.9%)	35 (6.2%)	402 (70.8%)	12 (2.1%)
Aug 30-Sept 12, 2021	All ages	Cases	101,044 (100%)	37,641 (37.3%)	55,519 (54.9%)	11,942 (11.8%)	43,577 (43.1%)	7,884 (7.8%)
		Hospitalizations	2,935 (100%)	1,239 (42.2%)	1,649 (56.2%)	187 (6.4%)	1,462 (49.8%)	47 (1.6%)
		Deaths	744 (100%)	186 (25.0%)	546 (73.4%)	24 (3.2%)	522 (70.2%)	12 (1.6%)
	<50 yrs	Cases	76,416 (75.6%)	35,814 (46.9%)	34,402 (45.0%)	11,398 (14.9%)	23,004 (30.1%)	6,200 (8.1%)
		Hospitalizations	1,132 (38.6%)	775 (68.5%)	324 (28.6%)	124 (11.0%)	200 (17.7%)	33 (2.9%)

	Deaths	50 (6.7%)	33 (66.0%)	14 (28.0%)	3 (6.0%)	11 (22.0%)	3 (6.0%)
≥50 yrs	Cases	24,480 (24.2%)	1,827 (7.5%)	21,115 (86.3%)	544 (2.2%)	20,571 (84.0%)	1,538 (6.3%)
	Hospitalizations	1,793 (61.1%)	464 (25.9%)	1,325 (73.9%)	63 (3.5%)	1,262 (70.4%)	4 (0.2%)
	Deaths	692 (93.0%)	153 (22.1%)	532 (76.9%)	21 (3.0%)	511 (73.8%)	7 (1.0%)

Table S5: Outcomes of Confirmed Delta variant cases, Hospitalizations and deaths based on the vaccination status reported in Public Health England technical briefings until September 12, 2021. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ‡ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. The age specified denominator (population) for the \geq 50 years of age group based on the vaccination status (1 dose, two doses and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S6a: SARS-CoV2 cases reported by specimen date (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status

	Study period			Unvaccinated	Vaccinated cas))	Vaccination		
	(rolling		Total cases	Cases (n=%					status unknown
Outcome	four	Age	(n=% of cases	for age	All	4 .1 *	-	- 1.*	(n=% for age
	weeks)	(yrs)	all ages)	group)	vaccinated	1 dose*	Two doses [‡]	Third dose ^Ø	group)
Cases	Aug 16-	All ages	711,304 (100%)	711,304 (37.0%)	382,422 (53.8%)	93,143 (13.1%)	289,279 (40.7%)		65,597 (9.2%)
Cases	Sept 12,	ages	711,304 (10070)	711,304 (37.0%)	382,422 (33.870)	81,332	289,279 (40.770)		03,337 (3.270)
	2021	≥18	520,441 (73.2%)	101,867 (19.6%)	369,802 (71.1%)	(15.6%)	288,470 (55.4%)		48,772 (9.4%)
		≥50	170,525 (24.0%)	11,265 (6.6%)	146,085 (85.7%)	3,575 (2.1%)	142,510 (83.6%)		13,175 (7.7%)
	Aug 23-	All	600 500 (4000)	600 500 (40 500)	244 604 (50 624)	67.407.(0.00%)	277 504 (40 620)		CO 0.45 (0.00()
Cases	Sept 19,	ages	680,582 (100%)	680,582 (40.5%)	344,691 (50.6%)	67,187 (9.9%) 55,159	277,504 (40.8%)		60,046 (8.8%)
	2021	≥18	461,551 (67.8%)	87,377 (18.9%)	331,990 (71.9%)	(12.0%)	276,831 (60.0%)		42,184 (9.1%)
		≥50	160,432 (23.6%)	10,247 (6.4%)	138,185 (86.1%)	3,129 (2.0%)	135,056 (84.2%)		12,000 (7.5%)
	Aug 30-	All							
Cases	Sept 26,	ages	699,489 (100%)	699,489 (45.2%)	326,250 (46.6%)	53,070 (7.6%)	273,180 (39.1%)		57,237 (8.2%)
	2021	≥18	425,804 (60.9%)	75,925 (17.8%)	312,932 (73.5%)	40,434 (9.5%)	272,498 (64.0%)		36,947 (8.7%)
		≥50	149,993 (21.4%)	9,131 (6.1%)	130,176 (86.8%)	2,790 (1.9%)	127,386 (84.9%)		10,686 (7.1%)
	Sept 6-	All							
Cases	October	ages	696,281 (100%)	696,281 (48.5%)	305,326 (43.9%)	39,232 (5.6%)	266,094 (38.2%)		53,385 (7.7%)
	3, 2021	≥18	390,853 (56.1%)	64,589 (16.5%)	293,846 (75.2%)	28,361 (7.3%)	265,485 (67.9%)		32,418 (8.3%)
		≥50	140,407 (20.2%)	8,038 (5.7%)	122,880 (87.5%)	2,541 (1.8%)	120,339 (85.7%)		9,489 (6.8%)
	Sept 13-	All							
Cases	Oct 10,	ages	750,518 (100%)	750,518 (49.5%)	325,759 (43.4%)	37,578 (5.0%)	288,181 (38.4%)		53,063 (7.1%)
	2021	≥18	402,004 (53.6%)	60,497 (15.0%)	310,745 (77.3%)	23,218 (5.8%)	287,527 (71.5%)		30,762 (7.7%)
		≥50	147,044 (19.6%)	7,689 (5.2%)	130,192 (88.5%)	2,496 (1.7%)	127,696 (86.8%)		9,163 (6.2%)
Cases		All ages	856,370 (100%)	856,370 (48.5%)	384,997 (45.0%)	44,937 (5.2%)	340,060 (39.7%)		56,264 (6.6%)

	Sept 20-	≥18	458,488 (53.5%)	63,961 (14.0%)	362,555 (79.1%)	23,238 (5.1%)	339,317 (74.0%)	31,972 (7.0%)
	Oct 17,		, (,	(= 112,12)			(* ******)	
	2021							
		≥50	172,442 (20.1%)	8,311 (4.8%)	154,314 (89.5%)	2,802 (1.6%)	151,512 (87.9%)	9,817 (5.7%)
	Sept 27-	All						
Cases	Oct 24,	ages	930,013 (100%)	930,013 (45.7%)	445,585 (47.9%)	54,490 (5.9%)	391,095 (42.1%)	59,414 (6.4%)
	2021	≥18	518,934 (55.8%)	70,006 (13.5%)	414,312 (79.8%)	24,038 (4.6%)	390,274 (75.2%)	34,616 (6.7%)
	2021	≥50	202,169 (21.7%)	9,486 (4.7%)	181,627 (89.8%)	3,066 (1.5%)	178,561 (88.3%)	11,056 (5.5%)
Caraca	Oct 4-Oct	All	075 224 (400%)	075 224 (42 40/)	FO1 070 (F1 40/)	C1 200 (C 20/)	420 700 (45 40/)	C1 024 (C 29()
Cases	31, 2021	ages	975,224 (100%)	975,224 (42.4%)	501,078 (51.4%)	61,288 (6.3%)	439,790 (45.1%)	61,034 (6.3%)
		≥18	577,740 (59.2%)	76,219 (13.2%)	464,265 (80.4%)	25,293 (4.4%)	438,972 (76.0%)	37,256 (6.4%)
	0.144	≥50 All	229,334 (23.5%)	10,573 (4.6%)	206,516 (90.1%)	3,371 (1.5%)	203,145 (88.6%)	12,245 (5.3%)
Cases	Oct 11-	ages	950,837 (100%)	950,837 (39.8%)	513,146 (54.0%)	62,154 (6.5%)	450,992 (47.4%)	59,668 (6.3%)
	Nov 7,	≥18	593,357 (62.4%)	79,516 (13.4%)	475,740 (80.2%)	25,554 (4.3%)	450,186 (75.9%)	38,101 (6.4%)
	2021	≥50	235,549 (24.8%)	11,088 (4.7%)	212,064 (90.0%)	3,431 (1.5%)	208,633 (88.6%)	12,397 (5.3%)
	Oct 18-	All		, , , , ,	, , , , , , , , , , , , , , , , , , , ,			, ,
Cases	Nov 14,	ages	907,478 (100%)	907,478 (37.2%)	513,094 (56.5%)	63,339 (7.0%)	449,755 (49.6%)	57,040 (6.3%)
	2021	≥18	593,762 (65.4%)	81,589 (13.7%)	474,266 (79.9%)	25,350 (4.3%)	448,916 (75.6%)	37,907 (6.4%)
	2021	≥50	232,221 (25.6%)	11,498 (5.0%)	208,679 (89.9%)	3,405 (1.5%)	205,274 (88.4%)	12,044 (5.2%)
	Oct 25-	All	000 440 (4000)	000 440 (25 00)	506 450 (57 00()	62 420 (7 00/)	444.024 (50.00()	55 447 (6.200)
Cases	Nov 21,	ages	888,449 (100%)	888,449 (36.8%)	506,459 (57.0%)	62,428 (7.0%)	444,031 (50.0%)	55,147 (6.2%)
	2021	≥18	588,131 (66.2%)	83,121 (14.1%)	468,060 (79.6%)	24,894 (4.2%)	443,166 (75.4%)	36,950 (6.3%)
		≥50	219,859 (24.7%)	11,586 (5.3%)	197,217 (89.7%)	3,375 (1.5%)	193,842 (88.2%)	11,056 (5.0%)
C	Nov 1-	All	005 267 (400%)	005 267 (20 40/)	F03 F40 (FF C0/)	CE 44E (7.20/)	430 404 (40 40/)	FC 92C /C 20/\
Cases	Nov 28,	ages ≥18	905,267 (100%) 584,205 (64.5%)	905,267 (38.1%) 85,038 (14.6%)	503,519 (55.6%) 461,939 (79.1%)	65,115 (7.2%) 24,489 (4.2%)	438,404 (48.4%) 437,450 (74.9%)	56,836 (6.3%) 37,228 (6.4%)
	2021	210	364,203 (04.370)	85,038 (14.0%)	401,939 (79.170)	24,483 (4.270)	437,430 (74.970)	37,228 (0.470)
		≥50	205,829 (22.7%)	11,804 (5.7%)	183,675 (89.2%)	3,248 (1.6%)	180,427 (87.7%)	10,350 (5.0%)
Cases	Nov 8-	All	997,322 (100%)	997,322 (39.1%)	544,391 (54.6%)	73,786 (7.4%)	470,605 (47.2%)	62,835 (6.3%)
Cases	Dec 5,	ages ≥18	628,872 (63.1%)	92,746 (14.7%)	495,707 (78.8%)	26,242 (4.2%)	469,465 (74.7%)	40,419 (6.4%)
	2021	-10	020,072 (03.170)	32,740 (14.770)	733,707 (70.070)	20,242 (4.2/0)	703,403 (74.770)	+0,+13 (0.+/0)
		≥50	204,824 (20.5%)	12,754 (6.2%)	181,506 (88.6%)	3,447 (1.7%)	178,059 (86.9%)	10,564 (5.2%)

	Nov 15-	All	1,086,083	1,086,083					
Cases	Dec 12,	ages	(100%)	(38.5%)	597,751 (55.0%)	79,378 (7.3%)	518,373 (47.7%)		70,726 (6.5%)
	2021	≥18	697,726 (64.2%)	104,612 (15.0%)	546,335 (78.3%)	29,274 (4.2%)	517,061 (74.1%)		46,779 (6.7%)
	2021	≥50	201,843 (18.6%)	13,710 (6.8%)	177,349 (87.9%)	3,615 (1.8%)	173,734 (86.1%)		10,784 (5.3%)
	Nov 22-	All	1,371,157	1,371,157					
Cases	Dec 19,	ages	(100%)	(32.5%)	832,918 (60.7%)	94,734 (6.9%)	738,184 (53.8%)		92,902 (6.8%)
	2021	≥18	975,822 (71.2%)	132,809 (13.6%)	775,634 (79.5%)	39,618 (4.1%)	736,016 (75.4%)		67,379 (6.9%)
	2021	≥50	233,191 (17.0%)	15,774 (6.8%)	204,398 (87.7%)	4,116 (1.8%)	200,282 (85.9%)		13,019 (5.6%)
	Dec 6,	All	2,556,580	2,556,580	1,827,454	163,826	1,663,628		
Cases	2021-Jan	ages	(100%)	(21.5%)	(71.5%)	(6.4%)	(65.1%)		180,064 (7.0%)
		>10	2 127 (92 20/)	240.970 (11.29/)	1,738,627	04 102 (4 00/)	1,654,525		147.010 (7.00/)
	2, 2022	≥18	2,127 (83.2%)	240,879 (11.3%)	(81.7%)	84,102 (4.0%)	(77.8%)		147,919 (7.0%)
		≥50	560,458 (21.9%)	27,116 (4.8%)	500,304 (89.3%)	8,046 (1.4%)	492,258 (87.8%)		33,038 (5.9%)
Cases	Dec 13,	All	3,161,258 (100%)	3,161,258 (20.3%)	2,291,288 (72.5%)	202,336 (6.4%)	2,088,952 (66.1%)		229,101 (7.2%)
Cases	2021-Jan	ages	(100%)	(20.5%)	2,177,293	103,771	2,073,522		229,101 (7.270)
	9, 2022	≥18	2,659 (84.1%)	292,438 (11.0%)	(81.9%)	(3.9%)	(78.0%)		189,614 (7.1%)
	7,	≥50	749,614 (23.7%)	33,156 (4.4%)	670,870 (89.5%)	9,977 (1.3%)	660,893 (88.2%)		45,588 (6.1%)
	Dec 20,	All	3,183,566	3,183,566	2,254,937	206,329	1,112,775		
Cases	2021-Jan	ages	(100%)	(21.9%)	(70.8%)	(6.5%)	(35.0%)	935,833 (29.4%)	230,878 (7.3%)
		>10	2 605 (91 99/)	205 049 (11 00/)	2,131,103 (81.8%)	100,960 (3.9%)	1,095,228 (42.0%)	024 045 (25 00/)	100 677 (7 30/)
	16, 2022	≥18	2,605 (81.8%)	285,948 (11.0%)				934,915 (35.9%)	188,677 (7.2%)
		≥50 All	786,950 (24.7%)	33,742 (4.3%)	704,355 (89.5%)	10,093 (1.3%) 199,979	153,439 (19.5%)	540,823 (68.7%)	48,853 (6.2%)
Cases	Dec 27,	ages	3,034,409 (100%)	3,034,409 (25.1%)	2,058,948 (67.9%)	(6.6%)	844,861 (27.8%)	1,014,108 (33.4%)	213,040 (7.0%)
0000	2021-Jan		(20075)	(201270)	1,926,523	(0.075)	011,002 (271070)	2,02 :,200 (00: :/0)	220,010 (71070)
	23, 2022	≥18	2,351 (77.5%)	255,701 (10.9%)	(81.9%)	88,213 (3.8%)	825,293 (35.1%)	1,013,017 (43.1%)	168,964 (7.2%)
		≥50	735,711 (24.2%)	30,660 (4.2%)	659,811 (89.7%)	8,958 (1.2%)	114,649 (15.6%)	536,204 (72.9%)	45,240 (6.1%)
		All	2,872,077	2,872,077	1,832,328	205,387			
Cases	Jan 3-Jan	ages	(100%)	(29.4%)	(63.8%)	(7.2%)	607,331 (21.1%)	1,019,610 (35.5%)	195,470 (6.8%)
		≥18	2,057 (71.6%)	231,750 (11.3%)	1,677,414 (81.5%)	75,802 (3.7%)	583,313 (28.3%)	1,018,299 (49.5%)	148,566 (7.2%)
	30, 2022	≥50							
	+	≥50 All	600,808 (20.9%) 2,293,771	25,917 (4.3%) 2,293,771	535,661 (89.2%) 1,426,498	7,130 (1.2%) 171,086	74,353 (12.4%)	454,178 (75.6%)	39,230 (6.5%)
Cases		ages	(100%)	(31.7%)	(62.2%)	(7.5%)	369,295 (16.1%)	886,117 (38.6%)	140,444 (6.1%)
			()	()	1,281,180		=======================================		5, (5.2)
		≥18	1,544 (67.3%)	159,596 (10.3%)	(83.0%)	51,615 (3.3%)	344,772 (22.3%)	884,793 (57.3%)	103,389 (6.7%)

ĺ	Jan 10-	I	I	I	I		I		1
	Feb 6,								
	1								
	2022	>50	449 940 (10 69/)	10 EOE (4 10/)	402 612 (90 79/)	E 060 (1 10/)	42 512 (0 70/)	254 040 (79 09/)	27 722 (6 20/)
	1	≥50 All	448,840 (19.6%) 1,980,778	18,505 (4.1%) 1,980,778	402,612 (89.7%) 1,277,533	5,060 (1.1%) 146,856	43,512 (9.7%)	354,040 (78.9%)	27,723 (6.2%)
Cases	Jan 17-	ages	(100%)	(29.8%)	(64.5%)	(7.4%)	289,924 (14.6%)	840,753 (42.4%)	113,796 (5.7%)
	Feb 13,		,	()	1,145,794	, ,			-, (,
	2022	≥18	1,358 (68.6%)	128,278 (9.4%)	(84.3%)	42,017 (3.1%)	264,366 (19.5%)	839,411 (61.8%)	84,457 (6.2%)
		≥50	402,677 (20.3%)	14,945 (3.7%)	365,185 (90.7%)	4,197 (1.0%)	32,500 (8.1%)	328,488 (81.6%)	22,547 (5.6%)
	Jan 24-	All	1,578,203	1,578,203	1,086,434	109,803			
Cases	Feb 20,	ages	(100%)	(25.6%)	(68.8%)	(7.0%)	224,505 (14.2%)	752,126 (47.7%)	87,739 (5.6%)
	2022	≥18	1,153 (73.1%)	100,923 (8.7%)	984,555 (85.4%)	33,209 (2.9%)	200,489 (17.4%)	750,857 (65.1%)	68,036 (5.9%)
		≥50	366,989 (23.3%)	12,308 (3.4%)	335,767 (91.5%)	3,484 (0.9%)	25,606 (7.0%)	306,677 (83.6%)	18,914 (5.2%)
	Jan 31-	All	1,154,859	1,154,859					
Cases	Feb 27,	ages	(100%)	(21.2%)	846,616 (73.3%)	67,669 (5.9%)	162,998 (14.1%)	615,949 (53.3%)	63,930 (5.5%)
	2022	≥18	910,456 (78.8%)	74,831 (8.2%)	783,337 (86.0%)	24,454 (2.7%)	144,037 (15.8%)	614,846 (67.5%)	52,288 (5.7%)
	2022	≥50	314,123 (27.2%)	9,821 (3.1%)	288,812 (91.9%)	2,775 (0.9%)	19,389 (6.2%)	266,648 (84.9%)	15,490 (4.9%)
	Feb 7-	All							
Cases	Mar 6,	ages	927,841 (100%)	927,841 (18.0%)	710,601 (76.6%)	41,523 (4.5%)	124,333 (13.4%)	544,745 (58.7%)	49,838 (5.4%)
	2022	≥18	774,595 (83.5%)	59,904 (7.7%)	672,261 (86.8%)	18,878 (2.4%)	109,575 (14.1%)	543,808 (70.2%)	42,430 (5.5%)
	2022	≥50	291,177 (31.4%)	8,351 (2.9%)	269,443 (92.5%)	2,305 (0.8%)	16,012 (5.5%)	251,126 (86.2%)	13,383 (4.6%)
	Feb 14-	All							
Cases	Mar 13,	ages	995,166 (100%)	995,166 (17.3%)	774,991 (77.9%)	35,325 (3.5%)	120,538 (12.1%)	619,128 (62.2%)	47,611 (4.8%)
	2022	≥18	841,958 (84.6%)	60,372 (7.2%)	740,601 (88.0%)	18,039 (2.1%)	104,580 (12.4%)	617,982 (73.4%)	40,985 (4.9%)
	2022	≥50	339,806 (34.1%)	8,713 (2.6%)	317,352 (93.4%)	2,356 (0.7%)	16,427 (4.8%)	298,569 (87.9%)	13,741 (4.0%)
	Feb 21-	All	1,237,498	1,237,498					
Cases	Mar 20,	ages	(100%)	(17.1%)	970,347 (78.4%)	39,117 (3.2%)	139,110 (11.2%)	792,120 (64.0%)	55,172 (4.5%)
	2022	≥18	1,045 (84.5%)	70,018 (6.7%)	928,447 (88.8%)	20,229 (1.9%)	117,728 (11.3%)	790,490 (75.6%)	47,259 (4.5%)
	2022	≥50	442,044 (35.7%)	10,397 (2.4%)	415,176 (93.9%)	2,733 (0.6%)	19,477 (4.4%)	392,966 (88.9%)	16,471 (3.7%)
	Feb 28-	All	1,553,609	1,553,609	1,228,616				
Cases		ages	(100%)	(16.6%)	(79.1%)	46,866 (3.0%)	170,597 (11.0%)	1,011,153 (65.1%)	66,636 (4.3%)
	Mar 27,	\	1 210 (04 00/)	OF 614 (6 F0/)	1,176,134	24 224 (1 99/)	142 064 (10 99/)	1 000 026 (76 50/)	E6 042 (4 29/)
	2022	≥18	1,318 (84.9%)	85,614 (6.5%)	(89.2%)	24,334 (1.8%)	142,964 (10.8%)	1,008,836 (76.5%)	56,942 (4.3%)
		≥50	572,612 (36.9%)	12,871 (2.2%)	539,347 (94.2%)	3,396 (0.6%)	24,122 (4.2%)	511,829 (89.4%)	20,394 (3.6%)

Table S6a: SARS-CoV2 cases reported by specimen date (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status since August 16, 2021 until May 27, 2022 until USHSA stopped reporting of SARS-CoV2 cases, hospitalization and deaths bases on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ‡ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. $^{\emptyset}$ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post third dose are considered vaccinated with the third dose. The age specified denominator (population) for the All ages, \geq 18 years & \geq 50 years of age groups based on the vaccination status (1 dose, two dose, third dose and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S6b: SARS-CoV2 Hospitalization within 28 days of a positive test resulting in overnight inpatient admission in NIMS-database based on vaccination status

	Study period (rolling		Total hospitalizations	Hospitalizations Unvaccinated	Hospitalizatio	ons Vaccinate	d		Vaccination status
Outcome	four weeks)	Age			All vaccinated	1 dose*	Two doses [‡]	Third dose	unknown
Hospitalizations	Aug 16-	All ages	8,356 (100%)	3,425 (41.0%)	4,810 (57.6%)	434 (5.2%)	4,376 (52.4%)		121 (1.4%)
	Sept 12,	≥18	7,817 (93.5%)	2,931 (37.5%)	4,794 (61.3%)	418 (5.3%)	4,376 (56.0%)		92 (1.2%)
	2021	≥50	5,431 (65.0%)	1,358 (25.0%)	4,043 (74.4%)	175 (3.2%)	3,868 (71.2%)		30 (0.6%)
Hospitalizations	Aug 23-	All ages	8,255 (100%)	3,220 (39.0%)	4,940 (59.8%)	383 (4.6%%)	4,557 (55.2%)		95 (1.2%)
	Sept 19,	≥18	7,744 (93.8%)	2,742 (35.4%)	4,925 (63.6%)	368 (4.8%)	4,557 (58.8%)		77 (1.0%)
	2021	≥50	5,589 (67.7%)	1,339 (24.0%)	4,227 (75.6%)	164 (2.9%)	4,063 (72.7%)		23 (0.4%)
Hospitalizations	Aug 30-	All ages	7,729 (100%)	2,922 (37.8%)	4,734 (61.2%)	356 (4.6%%)	4,378 (56.6%)		73 (0.9%)
	Sept 26,	≥18	7,204 (93.2%)	2,435 (33.8%)	4,710 (65.4%)	332 (4.6%)	4,378 (60.8%)		59 (0.8%)
	2021								
		≥50	5,227 (67.6%)	1,185 (22.7%)	4,024 (77.0%)	158 (3.0%)	3,866 (74.0%)		18 (0.3%)
	Sept 6- October								
Hospitalizations	3, 2021	All ages	6,691 (100%)	2,411 (36.0%)	4,206 (62.9%)	296 (4.4%%)	3,910 (58.4%)		74 (1.1%)
		≥18	6,205 (92.7%)	1,956 (31.5%)	4,195 (67.6%)	286 (4.6%)	3,909 (63.0%)		54 (0.9%)
		≥50	4,500 (67.3%)	931 (20.7%)	3,551 (78.9%)	139 (3.1%)	3,412 (75.8%)		18 (0.4%)
Hospitalizations	Sept 13-	All ages	5,148 (100%)	1,842 (35.8%)	3,258 (63.3%)	224 (4.4%%)	3,034 (58.9%)		48 (0.9%)
	Oct 10,	≥18	4,740 (92.1%)	1,456 (30.7%)	3,247 (68.5%)	214 (4.5%)	3,033 (64.0%)		37 (0.8%)
	2021	≥50	3,360 (65.3%)	660 (19.6%)	2,689 (80.0%)	106 (3.2%)	2,583 (76.9%)		11 (0.3%)
Hospitalizations	Sept 20-	All ages	7,392 (100%)	2,534 (34.3%)	4,791 (64.8%)	305 (4.1%%)	4,486 (60.7%)		67 (0.9%)
	Oct 17,	≥18	6,791 (91.9%)	1,974 (29.1%)	4,770 (70.2%)	286 (4.2%)	4,484 (66.0%)		47 (0.7%)
	2021	≥50	4,946 (66.9%)	926 (18.7%)	3,997 (80.8%)	169 (3.4%)	3,828 (77.4%)		23 (0.5%)
Hospitalizations		All ages	8,338 (100%)	2,832 (34.0%)	5,429 (65.1%)	305 (3.7%%)	5,124 (61.5%)		77 (0.9%)

	Sept 27-	≥18	7,705 (92.4%)	2,240 (29.1%)	5,405 (70.1%)	282 (3.7%)	5,123 (66.5%)	60 (0.8%)
	Oct 24,							
	2021	≥50	5,682 (68.1%)	1,087 (19.1%)	4,567 (80.4%)	158 (2.8%)	4,409 (77.6%)	28 (0.5%)
Hospitalizations	Oct 4-	All ages	8,722 (100%)	2,806 (32.2%)	5,831 (66.9%)	297 (3.4%%)	5,534 (63.4%)	85 (1.0%)
	Oct 31,	≥18	8,141 (93.3%)	2,267 (27.8%)	5,809 (71.4%)	276 (3.4%)	5,533 (68.0%)	65 (0.8%)
	2021							
		≥50	6,147 (70.5%)	1,158 (18.8%)	4,956 (80.6%)	151 (2.5%)	4,805 (78.2%)	33 (0.5%)
Hospitalizations	Oct 11-	All ages	10,179 (100%)	3,313 (32.5%)	6,786 (66.7%)	325 (3.2%%)	6,461 (63.5%)	80 (0.8%)
	Nov 7,	≥18	9,548 (93.8%)	2,722 (28.5%)	6,759 (70.8%)	300 (3.1%)	6,459 (67.6%)	67 (0.7%)
	2021	≥50	7,179 (70.5%)	1,390 (19.4%)	5,753 (80.1%)	153 (2.1%)	5,600 (78.0%)	36 (0.5%)
Hospitalizations	Oct 18-	All ages	9,831 (100%)	3,200 (32.6%)	6,560 (66.7%)	327 (3.3%%)	6,233 (63.4%)	71 (0.7%)
	Nov 14,	≥18	9,278 (94.4%)	2,692 (29.0%)	6,529 (70.4%)	296 (3.2%)	6,233 (67.2%)	57 (0.6%)
	2021	≥50	6,956 (70.8%)	1,391 (20.0%)	5,538 (79.6%)	149 (2.1%)	5,389 (77.5%)	27 (0.4%)
Hospitalizations	Oct 25-	All ages	9,174 (100%)	3,071 (33.5%)	6,023 (65.7%)	334 (3.6%%)	5,689 (62.0%)	80 (0.9%)
	Nov 21,	≥18	8,658 (94.4%)	2,604 (30.1%)	5,991 (69.2%)	303 (3.5%)	5,688 (65.7%)	63 (0.7%)
	2021	≥50	6,420 (70.0%)	1,358 (21.2%)	5,027 (78.3%)	154 (2.4%)	4,873 (75.9%)	35 (0.5%)
Hospitalizations	Nov 1-	All ages	6,639 (100%)	2,355 (35.5%)	4,231 (63.7%)	233 (3.5%%)	3,998 (60.2%)	53 (0.8%)
	Nov 28,	≥18	6,254 (94.2%)	2,004 (32.0%)	4,211 (67.3%)	214 (3.4%)	3,997 (63.9%)	39 (0.6%)
	2021	≥50	4,618 (69.6%)	1,077 (23.3%)	3,520 (76.2%)	110 (2.4%)	3,410 (73.8%)	21 (0.5%)
Hospitalizations	Nov 8-	All ages	8,156 (100%)	3,187 (39.1%)	4,875 (59.8%)	340 (4.2%%)	4,535 (55.6%)	94 (1.2%%)
	Dec 5,	≥18	7,575 (92.9%)	2,676 (35.3%)	4,830 (63.8%)	304 (4.0%)	4,526 (59.7%)	69 (0.9%)
	2021	≥50	5,330 (65.4%)	1,451 (27.2%)	3,845 (72.1%)	158 (3.0%)	3,687 (69.2%)	34 (0.6%)
Hospitalizations	Nov 15-	All ages	8,235 (100%)	3,532 (42.9%)	4,602 (55.9%)	346 (4.2%%)	4,256 (51.7%)	101 (1.2%)
	Dec 12,	≥18	7,601 (92.3%)	2,965 (39.0%)	4,556 (59.9%)	309 (4.1%)	4,247 (55.9%)	80 (1.1%)
	2021	≥50	5,153 (62.6%)	1,591 (30.9%)	3,524 (68.4%)	170 (3.3%)	3,354 (65.1%)	38 (0.7%)
Hospitalizations	Nov 22-	All ages	8,190 (100%)	3,693 (45.1%)	4,388 (53.6%)	361 (4.4%%)	4,027 (49.2%)	109 (1.3%)
	Dec 19,	≥18	7,542 (92.1%)	3,115 (41.3%)	4,339 (57.5%)	319 (4.2%)	4,020 (53.3%)	88 (1.2%)
	2021	≥50	5,007 (61.1%)	1,708 (34.1%)	3,253 (65.0%)	177 (3.5%)	3,076 (61.4%)	46 (0.9%)
Hospitalizations		All ages	9,981 (100%)	4,056 (40.6%)	5,791 (58.0%)	508 (5.1%%)	5,283 (52.9%)	134 (1.3%)
		≥18	9,082 (91.0%)	3,260 (35.9%)	5,735 (63.1%)	462 (5.1%)	5,273 (58.1%)	87 (1.0%)

	Dec 6,								
	2021-Jan 2, 2022	≥50	5,955 (59.7%)	1,756 (29.5%)	4,159 (69.8%)	234 (3.9%)	3,925 (65.9%)		40 (0.7%)
Hospitalizations	Dec 13,	All ages	13,514 (100%)	4,738 (35.1%)	8,566 (63.4%)	689 (5.1%%)	7,877 (58.3%)		210 (1.6%)
	2021-Jan	≥18	12,219 (90.4%)	3,614 (29.6%)	8,473 (69.3%)	608 (5.0%)	7,865 (64.4%)		132 (1.1%)
	9, 2022	≥50	8,206 (60.7%)	1,966 (24.0%)	6,192 (75.5%)	309 (3.8%)	5,883 (71.7%)		48 (0.6%)
Hospitalizations	Dec 20,	All ages	15,012 (100%)	4,752 (31.7%)	10,051 (67.0%)	781 (5.2%%)	4,127 (27.5%)	5,143 (34.3%)	209 (1.4%)
	2021-Jan	≥18	13,503 (89.9%)	3,445 (25.5%)	9,925 (73.5%)	670 (5.0%)	4,116 (30.5%)	5,139 (38.1%)	133 (1.0%)
	16, 2022	≥50	9,311 (62.0%)	1,880 (20.2%)	7,389 (79.4%)	340 (3.7%)	2,438 (26.2%)	4,611 (49.5%)	42 (0.5%)
Hospitalizations	Dec 27,	All ages	16,294 (100%)	4,807 (29.5%)	11,277 (69.2%)	829 (5.1%%)	3,999 (24.5%)	6,449 (39.6%)	210 (1.3%)
	2021-Jan	≥18	14,459 (88.7%)	3,210 (22.2%)	11,124 (76.9%)	701 (4.8%)	3,978 (27.5%)	6,445 (44.6%)	125 (0.9%)
	23, 2022	≥50	10,270 (63.0%)	1,753 (17.1%)	8,462 (82.4%)	338 (3.3%)	2,403 (23.4%)	5,721 (55.7%)	55 (0.5%)
Hospitalizations	Jan 10-	All ages	11,197 (100%)	3,261 (29.1%)	7,804 (69.7%)	607 (5.4%%)	2,121 (18.9%)	5,076 (45.3%)	132 (1.2%)
	Feb 6,	≥18	9,463 (84.5%)	1,737 (18.4%)	7,641 (80.7%)	476 (5.0%)	2,092 (22.1%)	5,073 (53.6%)	85 (0.9%)
	2022	≥50	6,814 (60.9%)	946 (13.9%)	5,827 (85.5%)	225 (3.3%)	1,235 (18.1%)	4,367 (64.1%)	41 (0.6%)
Hospitalizations	Jan 17-	All ages	10,222 (100%)	2,858 (28.0%)	7,294 (71.4%)	545 (5.3%%)	1,810 (17.7%)	4,939 (48.3%)	70 (0.7%)
	Feb 13,	≥18	8,599 (84.1%)	1,441 (16.8%)	7,118 (82.8%)	411 (4.8%)	1,769 (20.6%)	4,938 (57.4%)	40 (0.5%)
	2022	≥50	6,158 (60.2%)	791 (12.8%)	5,349 (86.9%)	199 (3.2%)	996 (16.2%)	4,154 (67.5%)	18 (0.3%)
Hospitalizations	Jan 24-	All ages	9,309 (100%)	2,341 (25.1%)	6,889 (74.0%)	463 (5.0%%)	1,490 (16.0%)	4,936 (53.0%)	79 (0.8%)
	Feb 20,	≥18	7,978 (85.7%)	1,209 (15.2%)	6,723 (84.3%)	340 (4.3%)	1,449 (18.2%)	4,934 (61.8%)	46 (0.6%)
	2022	≥50	5,858 (62.9%)	662 (11.3%)	5,183 (88.5%)	166 (2.8%)	844 (14.4%)	4,173 (71.2%)	12 (0.2%)
Hospitalizations	Jan 31-	All ages	7,975 (100%)	1,832 (23.0%)	6,098 (76.5%)	362 (4.5%%)	1,178 (14.8%)	4,558 (57.2%)	45 (0.6%)
	Feb 27,	≥18	7,015 (88.0%)	1,020 (14.5%)	5,973 (85.1%)	268 (3.8%)	1,149 (16.4%)	4,556 (64.9%)	22 (0.3%)
	2022	≥50	5,291 (66.3%)	560 (10.6%)	4,726 (89.3%)	135 (2.6%)	692 (13.1%)	3,899 (73.7%)	5 (0.1%)
Hospitalizations	Feb 7-	All ages	7,378 (100%)	1,504 (20.4%)	5,831 (79.0%)	301 (4.1%%)	1,025 (13.9%)	4,505 (61.1%)	43 (0.6%)
	Mar 6,	≥18	6,644 (90.1%)	882 (13.3%)	5,740 (86.4%)	238 (3.6%)	1,000 (15.1%)	4,502 (67.8%)	22 (0.3%)
	2022	≥50	5,095 (69.1%)	483 (9.5%)	4,607 (90.4%)	111 (2.2%)	627 (12.3%)	3,869 (75.9%)	5 (0.1%)
Hospitalizations	Feb 14-	All ages	6,573 (100%)	1,349 (20.5%)	5,193 (79.0%)	241 (3.7%%)	837 (12.7%)	4,115 (62.6%)	31 (0.5%)
	Mar 13,	≥18	5,915 (90.0%)	774 (13.1%)	5,124 (86.6%)	190 (3.2%)	822 (13.9%)	4,112 (69.5%)	17 (0.3%)
	2022	≥50	4,606 (70.1%)	409 (8.9%)	4,192 (91.0%)	94 (2.0%)	518 (11.2%)	3,580 (77.7%)	5 (0.1%)

Hospitalizations	Feb 21-	All ages	8,990 (100%)	1,848 (20.6%)	7,088 (78.8%)	309 (3.4%%)	1,025 (11.4%)	5,754 (64.0%)	54 (0.6%)
	Mar 20,	≥18	8,043 (89.5%)	1,015 (12.6%)	6,996 (87.0%)	252 (3.1%)	993 (12.3%)	5,751 (71.5%)	32 (0.4%)
	2022	≥50	6,328 (70.4%)	509 (8.0%)	5,807 (91.8%)	132 (2.1%)	615 (9.7%)	5,060 (80.0%)	12 (0.2%)
Hospitalizations	Feb 28-	All ages	10,389 (100%)	2,065 (19.9%)	8,261 (79.5%)	331 (3.2%%)	1,180 (11.4%)	6,750 (65.0%)	63 (0.6%)
	Mar 27,	≥18	9,293 (89.5%)	1,100 (11.8%)	8,157 (87.8%)	270 (2.9%)	1,142 (12.3%)	6,745 (72.6%)	36 (0.4%)
	2022	≥50	7,329 (70.5%)	530 (7.2%)	6,786 (92.6%)	148 (2.0%)	685 (9.3%)	5,953 (81.2%)	12 (0.2%)

Table S6b: SARS-CoV2 Hospitalization within 28 days of a positive test resulting in overnight inpatient admission (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status since August 16, 2021 until May 27, 2022 until USHSA stopped reporting of SARS-CoV2 cases, hospitalization and deaths bases on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. † SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. $^{\emptyset}$ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post third dose are considered vaccinated with the third dose. The age specified denominator (population) for the All ages, \geq 18 years & \geq 50 years of age groups based on the vaccination status (1 dose, two doses, third dose and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S6c: SARS-CoV2 deaths within 28 days of positive COVID-19 test by date of death in NIMS-database based on vaccination

	Study period			Unvaccinated	Vaccinated (deaths (n=%	for age group)		
Outcome	(rolling four weeks)	Age (yrs)	Total deaths (n=% of all ages)	deaths (n=% for age group)	All Vaccinated	1 dose*	Two doses [‡]	Third dose	Vaccination status unknown
Deaths	Aug 16-	All ages	2,961 (100%)	726 (24.5%)	2,206 (74.5%)	112 (3.8%)	2,094 (70.7%)		29 (1.0%)
	Sept 12,	≥18	2,957 (99.9%)	723 (24.5%)	2,206 (74.6%)	112 (3.8%)	2,094 (70.8%)		28 (0.9%)
	2021	≥50	2,775 (93.7%)	599 (21.6%)	2,153 (77.6%)	101 (3.6%)	2,052 (73.9%)		23 (0.8%)
Deaths	Aug 23-	All ages	3,158 (100%)	730 (23.1%)	2,395 (75.8%)	111 (3.5%)	2,284 (72.3%)		33 (1.0%)
	Sept 19,	≥18	3,152 (99.8%)	726 (23.0%)	2,395 (76.0%)	111 (3.5%)	2,284 (72.5%)		31 (1.0%)
	2021	≥50	2,983 (94.5%)	615 (20.6%)	2,342 (78.5%)	103 (3.5%)	2,239 (75.1%)		26 (0.9%)
Deaths	Aug 30-	All ages	3,165 (100%)	687 (21.7%)	2,448 (77.3%)	110 (3.5%)	2,338 (73.9%)		30 (0.9%)
	Sept 26,	≥18	3,159 (99.8%)	683 (21.6%)	2,448 (77.5%)	110 (3.5%)	2,338 (74.0%)		28 (0.9%)
	2021								
		≥50	3,005 (94.9%)	586 (19.5%)	2,396 (79.7%)	103 (3.4%)	2,293 (76.3%)		23 (0.8%)
Deaths	Sept 6-	All ages	3,026 (100%)	611 (20.2%)	2,382 (78.7%)	101 (3.3%)	2,281 (75.4%)		33 (1.1%)
	October	≥18	3,020 (99.8%)	609 (20.2%)	2,381 (78.8%)	100 (3.3%)	2,281 (75.5%)		30 (1.0%)
	3, 2021	≥50	2,887 (95.4%)	522 (18.1%)	2,341 (81.1%)	95 (3.3%)	2,246 (77.8%)		24 (0.8%)
Deaths	Sept 13-	All ages	2,805 (100%)	557 (19.9%)	2,228 (79.4%)	92 (3.3%)	2,136 (76.1%)		20 (0.7%)
	Oct 10,	≥18	2,801 (99.9%)	554 (19.8%)	2,227 (79.5%)	91 (3.2%)	2,136 (76.3%)		20 (0.7%)
	2021	≥50	2,689 (95.9%)	487 (18.1%)	2,185 (81.3%)	88 (3.3%)	2,097 (78.0%)		17 (0.6%)
Deaths	Sept 20-	All ages	2,745 (100%)	502 (18.3%)	2,224 (81.0%)	88 (3.2%)	2,136 (77.8%)		19 (0.7%)
	Oct 17,	≥18	2,740 (99.8%)	498 (18.2%)	2,223 (81.1%)	87 (3.2%)	2,136 (78.0%)		19 (0.7%)
_	2021	≥50	2,635 (96.0%)	433 (16.4%)	2,186 (83.0%)	86 (3.3%)	2,100 (79.7%)		16 (0.6%)
Deaths		All ages	2,772 (100%)	487 (17.6%)	2,270 (81.9%)	85 (3.1%)	2,185 (78.8%)		15 (0.5%)
		≥18	2,767 (99.8%)	483 (17.5%)	2,269 (82.0%)	84 (3.0%)	2,185 (79.0%)		15 (0.5%)

	Sept 27- Oct 24,							
	2021	≥50	2,666 (96.2%)	423 (15.9%)	2,230 (83.6%)	82 (3.1%)	2,148 (80.6%)	13 (0.5%)
Deaths	Oct 4-	All ages	3,085 (100%)	538 (17.4%)	2,532 (82.1%)	85 (2.8%)	2,447 (79.3%)	15 (0.5%)
	Oct 31,	≥18	3,079 (99.8%)	532 (17.3%)	2,532 (82.2%)	85 (2.8%)	2,447 (79.5%)	15 (0.5%)
	2021							
		≥50	2,972 (96.3%)	471 (15.8%)	2,488 (83.7%)	82 (2.8%)	2,406 (81.0%)	13 (0.4%)
Deaths	Oct 11-	All ages	3,430 (100%)	587 (17.1%)	2,822 (82.3%)	90 (2.6%)	2,732 (79.7%)	21 (0.6%)
	Nov 7,	≥18	3,422 (99.8%)	580 (16.9%)	2,822 (82.5%)	90 (2.6%)	2,732 (79.8%)	20 (0.6%)
	2021	≥50	3,297 (96.1%)	511 (15.5%)	2,769 (84.0%)	86 (2.6%)	2,683 (81.4%)	17 (0.5%)
Deaths	Oct 18-	All ages	3,676 (100%)	675 (18.4%)	2,975 (80.9%)	100 (2.7%)	2,875 (78.2%)	26 (0.7%)
	Nov 14,	≥18	3,665 (99.7%)	665 (18.1%)	2,975 (81.2%)	100 (2.7%)	2,875 (78.4%)	25 (0.7%)
	2021	≥50	3,522 (95.8%)	587 (16.7%)	2,914 (82.7%)	91 (2.6%)	2,823 (80.2%)	21 (0.6%)
Deaths	Oct 25-	All ages	3,726 (100%)	708 (19.0%)	2,992 (80.3%)	89 (2.4%)	2,903 (77.9%)	26 (0.7%)
	Nov 21,	≥18	3,717 (99.8%)	700 (18.8%)	2,992 (80.5%)	89 (2.4%)	2,903 (78.1%)	25 (0.7%)
	2021	≥50	3,556 (95.4%)	612 (17.2%)	2,923 (82.2%)	79 (2.2%)	2,844 (80.0%)	21 (0.6%)
Deaths	Nov 1-	All ages	3,571 (100%)	695 (19.5%)	2,846 (79.7%)	96 (2.7%)	2,750 (77.0%)	30 (0.8%)
	Nov 28,	≥18	3,563 (99.8%)	688 (19.3%)	2,846 (79.9%)	96 (2.7%)	2,750 (77.2%)	29 (0.8%)
	2021	≥50	3,415 (95.6%)	606 (17.7%)	2,785 (81.6%)	87 (2.5%)	2,698 (79.0%)	24 (0.7%)
Deaths	Nov 8-	All ages	3,310 (100%)	708 (21.4%)	2,572 (77.7%)	92 (2.8%)	2,480 (74.9%)	30 (0.9%)
	Dec 5,	≥18	3,306 (99.9%)	704 (21.3%)	2,572 (77.8%)	92 (2.8%)	2,480 (75.0%)	30 (0.9%)
	2021	≥50	3,151 (95.2%)	619 (19.6%)	2,506 (79.5%)	85 (2.7%)	2,421 (76.8%)	26 (0.8%)
Deaths	Nov 15-	All ages	3,087 (100%)	718 (23.3%)	2,341 (75.8%)	82 (2.7%)	2,259 (73.2%)	28 (0.9%)
	Dec 12,	≥18	3,083 (99.9%)	715 (23.2%)	2,340 (75.9%)	82 (2.7%)	2,258 (73.2%)	28 (0.9%)
	2021	≥50	2,920 (94.6%)	618 (21.2%)	2,277 (78.0%)	76 (2.6%)	2,201 (75.4%)	25 (0.9%)
Deaths	Nov 22-	All ages	2,956 (100%)	782 (26.5%)	2,140 (72.4%)	90 (3.0%)	2,050 (69.4%)	34 (1.2%)
	Dec 19,	≥18	2,952 (99.9%)	779 (26.4%)	2,139 (72.5%)	90 (3.0%)	2,049 (69.4%)	34 (1.2%)
	2021	≥50	2,772 (93.8%)	667 (24.1%)	2,074 (74.8%)	84 (3.0%)	1,990 (71.8%)	31 (1.1%)
Deaths		All ages	2,890 (100%)	809 (28.0%)	2,055 (71.1%)	106 (3.7%)	1,949 (67.4%)	26 (0.9%)
		≥18	2,885 (99.8%)	805 (27.9%)	2,054 (71.2%)	106 (3.7%)	1,948 (67.5%)	26 (0.9%)

	Dec 6, 2021-Jan								
	2, 2022	≥50	2,703 (93.5%)	694 (25.7%)	1,985 (73.4%)	99 (3.7%)	1,886 (69.8%)		24 (0.9%)
Deaths	Dec 13,	All ages	3,174 (100%)	924 (29.1%)	2,219 (69.9%)	130 (4.1%)	2,089 (65.8%)		31 (1.0%)
	2021-Jan	≥18	3,166 (99.7%)	916 (28.9%)	2,219 (70.1%)	130 (4.1%)	2,089 (66.0%)		31 (1.0%)
	9, 2022	≥50	2,964 (93.4%)	795 (26.8%)	2,140 (72.2%)	122 (4.1%)	2,018 (68.1%)		29 (1.0%)
Deaths	Dec 20,	All ages	3,893 (100%)	1,015 (26.1%)	2,845,73 (1%)	171,4 (4%)	1,418 (36.4%)	1,256 (32.3%)	33 (0.8%)
	2021-Jan	≥18	3,884 (99.8%)	1,006 (25.9%)	2,845,73 (2%)	171 (4.4%)	1,418 (36.5%)	1,256 (32.3%)	33 (0.8%)
	16, 2022	≥50	3,672 (94.3%)	898 (24.5%)	2,743 (74.7%)	158 (4.3%)	1,344 (36.6%)	1,241 (33.8%)	31 (0.8%)
Deaths	Dec 27,	All ages	4,637 (100%)	1,010 (21.8%)	3,591,77 (4%)	190 (4.1%)	1,561 (33.7%)	1,840 (39.7%)	36 (0.8%)
	2021-Jan	≥18	4,624 (99.7%)	1,000 (21.6%)	3,588,77 (6%)	188 (4.1%%)	1,560 (33.7%)	1,840 (39.8%)	36 (0.8%)
	23, 2022	≥50	4,423 (95.4%)	903 (20.4%)	3,486 (78.8%)	174 (3.9%)	1,489 (33.7%)	1,823 (41.2%)	34 (0.8%)
Deaths		All ages	5,554 (100%)	1,015 (18.3%)	4,501,81 (0%)	213 (3.8%)	1,703 (30.7%)	2,585 (46.5%)	38 (0.7%)
	Jan 3-Jan	≥18	5,542 (99.8%)	1,007 (18.2%)	4,497,81 (1%)	211 (3.8%)	1,701 (30.7%)	2,585 (46.6%)	38 (0.7%)
	30, 2022	≥50	5,310 (95.6%)	912 (17.2%)	4,362 (82.1%)	191 (3.6%)	1,624 (30.6%)	2,547 (48.0%)	36 (0.7%)
Deaths	Jan 10-	All ages	5,978 (100%)	911 (15.2%)	5,035 (84.2%)	208 (3.5%)	1,631 (27.3%)	3,196 (53.5%)	32 (0.5%)
	Feb 6,	≥18	5,967 (99.8%)	904 (15.1%)	5,031 (84.3%)	206 (3.5%)	1,629 (27.3%)	3,196 (53.6%)	32 (0.5%)
	2022	≥50	5,752 (96.2%)	829 (14.4%)	4,894 (85.1%)	189 (3.3%)	1,556 (27.1%)	3,149 (54.7%)	29 (0.5%)
Deaths	Jan 17-	All ages	5,592 (100%)	728 (13.0%)	4,836 (86.5%)	179 (3.2%)	1,350 (24.1%)	3,307 (59.1%)	28 (0.5%)
	Feb 13,	≥18	5,584 (99.9%)	723 (12.9%)	4,833 (86.6%)	178 (3.2%)	1,348 (24.1%)	3,307 (59.2%)	28 (0.5%)
	2022	≥50	5,404 (96.6%)	659 (12.2%)	4,720 (87.3%)	161 (3.0%)	1,299 (24.0%)	3,260 (60.3%)	25 (0.5%)
Deaths	Jan 24-	All ages	4,883 (100%)	559 (11.4%)	4,302 (88.1%)	147 (3.0%)	1,035 (21.2%)	3,120 (63.9%)	22 (0.5%)
	Feb 20,	≥18	4,877 (99.9%)	555 (11.4%)	4,300 (88.2%)	147 (3.0%)	1,033 (21.2%)	3,120 (64.0%)	22 (0.5%)
	2022	≥50	4,731 (96.9%)	506 (10.7%)	4,206 (88.9%)	131 (2.8%)	991 (20.9%)	3,084 (65.2%)	19 (0.4%)
Deaths	Jan 31-	All ages	3,957 (100%)	397 (10.0%)	3,542 (89.5%)	113 (2.9%)	725 (18.3%)	2,704 (68.3%)	18 (0.5%)
	Feb 27,	≥18	3,953 (99.9%)	394 (10.0%)	3,541 (89.6%)	112 (2.8%)	725 (18.3%)	2,704 (68.4%)	18 (0.5%)
	2022	≥50	3,843 (97.1%)	359 (9.3%)	3,469 (90.3%)	103 (2.7%)	689 (17.9%)	2,677 (69.7%)	15 (0.4%)
Deaths	Feb 7-	All ages	2,943 (100%)	286 (9.7%)	2,643 (89.8%)	79 (2.7%)	482 (16.4%)	2,082 (70.7%)	14 (0.5%)
	Mar 6,	≥18	2,940 (99.9%)	284 (9.7%)	2,642 (89.9%)	78 (2.7%)	482 (16.4%)	2,082 (70.8%)	14 (0.5%)
	2022	≥50	2,867 (97.4%)	260 (9.1%)	2,594 (90.5%)	70 (2.4%)	458 (16.0%)	2,066 (72.1%)	13 (0.5%)

Deaths	Feb 14-	All ages	2,421 (100%)	237 (9.8%)	2,173 (89.8%)	58 (2.4%)	382 (15.8%)	1,733 (71.6%)	11 (0.5%)
	Mar 13,	≥18	2,419 (99.9%)	236 (9.8%)	2,172 (89.8%)	57 (2.4%)	382 (15.8%)	1,733 (71.6%)	11 (0.5%)
	2022	≥50	2,364 (97.6%)	216 (9.1%)	2,139 (90.5%)	52 (2.2%)	365 (15.4%)	1,722 (72.8%)	9 (0.4%)
Deaths	Feb 21-	All ages	2,084 (100%)	202 (9.7%)	1,873 (89.9%)	49 (2.4%)	333 (16.0%)	1,491 (71.5%)	9 (0.4%)
	Mar 20,	≥18	2,083 (99.95%)	202 (9.7%)	1,872 (89.9%)	48 (2.3%)	333 (16.0%)	1,491 (71.6%)	9 (0.4%)
	2022	≥50	2,030 (97.4%)	186 (9.2%)	1,836 (90.4%)	45 (2.2%)	315 (15.5%)	1,476 (72.7%)	8 (0.4%)
Deaths	Feb 28-	All ages	2,144 (100%)	214 (10.0%)	1,773 (82.7%)	1 (0.05%)	215 (10.0%)	1,557 (72.6%)	10 (0.5%)
	Mar 27,	≥18	2,142 (99.9%)	213 (9.9%)	1,772 (82.7%)	1 (0.05%)	214 (10.0%)	1,557 (72.7%)	10 (0.5%)
	2022	≥50	2,090 (97.5%)	199 (9.5%)	1,736 (83.1%)	1 (0.05%)	200 (9.6%)	1,535 (73.4%)	9 (0.4%)

Table S6c: SARS-CoV2 deaths within 28 days of positive COVID-19 test by date of death (reported weekly for prior 4 weeks period) in NIMS-database based on vaccination status since August 16, 2021 until May 27, 2022 until USHSA stopped reporting of SARS-CoV2 cases, hospitalization and deaths bases on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. [‡]SARS-CoV2 cases tested positive with the specimen date ≥14 days post second dose are considered vaccinated with two doses. ^Ø SARS-CoV2 cases tested positive with the specimen date ≥14 days post third dose are considered vaccinated with the third dose. The age specified denominator (population) for the All ages, ≥18 years & ≥50 years of age groups based on the vaccination status (1 dose, two doses, third dose and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S7a: Vaccine effectiveness of over 18 years of age NIMS population

	SARS-	CoV2 ca	ses; ≥18 y	rs of age		Incider	ice rate	per			
Rolling	(during	g four we	eks perio	d)		100,00	0 popu	lation	Vaccine effectivene	ess (95% CI)	
Four weeks period	1 dose	2 dose	3rd dose	Unvaccinated	1 dose	2 doses	3rd dose	Unvaccinated	1 dose*	Two doses [‡]	Third dose
Aug 16-Sept											
12, 2021	81332	288470		101867	2706.5	789.2		956.2	-183.1% (-187% to - 178.9%)	17.5% (16.5% to 18.4%)	
Aug 23-Sept									·		
19, 2021	55159	276831		87377	2036.0	750.2		826.5	-146.3% (-150.3% to - 142.2%)	9.2% (8.1% to 10.3%)	
Aug 30-Sept 26, 2021	40434	272498		75925	1605.8	740.9		723.3	-122% (-126% to - 117.8%)	-2.4% (-3.7% to -1.2%)	
Sept 6-	10151	272430		73323	1003.0	740.5		723.3	117.070	2.470 (3.770 to 1.270)	
October 3, 2021	28361	265485		64589	1188.1	736.6		619.0	-91.9% (-96% to -87.7%)	-19.0% (-20.6% to - 17.4%)	
Sept 13-Oct 10, 2021	23218	287527		60497	1014.8	821.7		583.5	-73.9% (-78% to -69.9%)	-40.8% (-42.7% to - 39.0%)	
Sept 20-Oct 17, 2021	23238	339317		63961	1053.2	1003.9		620.7	-69.7% (-73.7% to - 65.7%)	-61.7% (-63.8% to -	
Sept 27-Oct				33332							
24, 2021	24038	390274		70006	1122.2	1205.2		683.7	-64.1% (-67.9% to - 60.4%)	-76.3% (-78.4% to - 74.2%)	
Oct 4-Oct											
31, 2021	25293	438972		76219	1211.9	1419.6		748.6	-61.9% (-65.5% to - 58.4%)	-89.6% (-91.8% to - 87.5%)	
Oct 11-Nov 7, 2021									-60.0% (63.5% to -	-96.3% (-98.5% to -	
	25554	450186		79516	1256.0	1540.8		785.1	56.5%)	94.1%)	

Oct 18-Nov	Ī		İ	I							
14, 2021									-58.3% (-61.8% to -	-102.7% (-105.0% to -	
	25350	448916		81589	1282.2	1642.0		810.1	54.9%)	100.5%)	
Oct 25-Nov											
21, 2021									-55.6% (-59.0% to -	-110.2% (-112.6% to -	
	24894	443166		83121	1291.3	1744.6		829.8	52.2%)	107.9%)	
Nov 1-Nov											
28, 2021									-52.9% (-56.2% to -	-119.3% (-121.7% to -	
NO D	24489	437450		85038	1305.0	1872.1		853.7	49.6%)	116.9%)	
Nov 8-Dec									=0 40/ / = 0 =0/ ·	105 60/ / 100 10/ /	
5, 2021	26242	469465		92746	1420.0	2208.1		937.1	-53.4% (-56.7% to -	-135.6% (-138.1% to -	
Nov 15-Dec	20242	409405		92746	1438.0	2208.1		937.1	50.2%)	133.2%)	
12, 2021									-54.9% (-58.0% to -	-157.5% (-160.1% to -	
12, 2021	29274	517061		104612	1649.3	2740.9		1064.4	-34.9% (-38.0% to - 51.9%)	155.0%)	
Nov 22-Dec	23274	317001		104012	1043.3	2740.3		1004.4	31.370	155.070)	
19, 2021									-67.0% (-69.9% to -	-276.9% (-280.1% to -	
	39618	736016		132809	2283.1	5153.1		1367.3	64.1%)	273.6%)	
Dec 6, 2021-											
Jan 2, 2022									-95.5% (-97.9% to -	-535.8% (-539.7% to -	
	84102	1654525		240879	4927.5	16023.7		2520.4	93.2%)	531.9%)	
Dec 13,											
2021-Jan 9,											
2022									-98.9% (-101.1% to -	-626.3% (-630.3% to -	
	103771	2073522		292438	6136.3	22404.2		3084.8	96.8%)	622.3%)	
Dec 20,											
2021-Jan 16,											
2022	400000	4005330	024045	205040	E002.0	42552.7	2075.2	2027.0	-97.3% (-99.5% to -	-313.2% (-315.8% to -	-1.2% (-1.9%
Dec 27,	100960	1095228	934915	285948	5993.8	12552.7	3075.2	3037.8	95.2%)	310.7%)	to -0.6%)
2021-Jan 23,											20.50//
2021-3811 23,									-92.5% (-94.7% to -	-257.2% (-259.6% to -	-20.6% (- 21.4% to -
2022	88213	825293	1013017	255701	5259.6	9761.1	3296.0	2732.5	90.2%)	254.8%)	19.8%)
Jan 3-Jan	55225	020200		255.01	3233.0	3.32.1	3200.0		/-/		-31.9% (-
30, 2022									-82.5% (-84.8% to -	-184.2% (-186.3% to -	32.8% to -
•	75802	583313	1018299	231750	4543.0	7076.5	3284.3	2489.9	80.2%)	182.1%)	31.0%)
Jan 10-Feb											-64.9% (-
6, 2022									-81.2% (-84.0% to -	-147.0% (-149.3% to -	66.2% to -
	51615	344772	884793	159596	3118.9	4251.0	2837.3	1720.9	78.5%)	144.7%)	63.6%)

Jan 17-Feb											-93.1% (-
13, 2022									-85.3% (-88.5% to -	-138.4% (-140.9% to -	94.8% to -
	42017	264366	839411	128278	2570.7	3306.4	2677.9	1387.0	82.2%)	135.9%)	91.4%)
Jan 24-Feb											-118.1% (-
20, 2022									-88.0% (-91.6% to -	-132.0% (-134.8% to -	120.2% to -
	33209	200489	750857	100923	2055.5	2537.0	2385.4	1093.5	84.4%)	129.2%)	116.1%)
Jan 31-Feb											-139.5% (-
27, 2022									-88.3% (-92.6% to -	-126.6% (-129.8% to -	142.2% to -
	24454	144037	614846	74831	1530.3	1840.8	1946.2	812.5	84.2%)	123.4%)	136.9%)
Feb 7-Mar											-163.4% (-
6, 2022									-83.3% (-88.0% to -	-116.5% (-120.0% to -	166.6% to -
	18878	109575	543808	59904	1194.5	1410.8	1716.4	651.6	78.7%)	113.1%)	160.2%)
Feb 14-Mar											-195.8% (-
13, 2022									-75.6% (-80.2% to -	-106.0% (-109.3% to -	199.3% to -
	18039	104580	617982	60372	1155.3	1355.1	1945.4	657.7	71.2%)	102.8%)	192.3%)
Feb 21-Mar											-224.9% (-
20, 2022									-71.7% (-75.9% to -	-100.8% (-103.9% to -	228.5% to -
	20229	117728	790490	70018	1311.9	1534.3	2482.4	764.0	67.6%)	97.9%)	221.4%)
Feb 28-Mar											-237.9% (-
27, 2022									-70.5% (-74.3% to -	-100.3% (-103.1% to -	241.3% to -
	24334	142964	1008836	85614	1594.9	1873.8	3160.9	935.3	66.8%)	97.7%)	234.7%)

Table S7a: Vaccine effectiveness of over 18 years of age NIMS population (rolling four weeks cases reported weekly) since August 16, 2021 to March 27, 2022 until UKHSA stopped reporting data of weekly cases among age groups based on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ‡ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. $^{\emptyset}$ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post third dose are considered vaccinated with the third dose. The age specified denominator (population) for the \geq 18 years of age group based on the vaccination status (1 dose, two doses, third dose and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S7b: Vaccine effectiveness of over 50 years of age confirmed Delta variant SARS-CoV2 cases reported by Public Health England

Time period	Confirmed Decases (≥50 yrs		COVID-19	Incidence rate p	er 100,000 po	pulation	Vaccine effectiveness	(95% CI)
	1 dose	2 doses	Unvaccinated	1 dose	2 doses	Unvaccinated	1 dose	2 doses
Feb 1-June							-797.9% (-889.6% to	53.1% (48.4%
20, 2021	4651	5234	1267	516.7	27.0	57.5	-717.1%)	to 57.2%)
June 21-July							-173.7% (-217.1% to	18.0% (9.8% to
18, 2021	795	8193	1070	138.1	41.4	50.5	-135.8%)	25.2%)
July 19-Aug 1,							-43.3% (-71.1% to -	23.2% (15.6%
2021	389	8045	1103	75.5	40.5	52.7	19.0%)	to 29.8%)
Aug 2-Aug 15,							-40.7% (-65.0% to -	18.6% (11.7%
2021	468	11356	1451	98.5	56.9	70.0	19.1%)	to 24.8%)
Aug 16-Aug							-50.4% (-73.3% to -	-4.3% (-11.9%
29, 2021	596	18592	1833	134.1	93.0	89.1	29.8%)	to 2.5%)
Aug 30-Sept							-43.5% (-66.0% to -	-14.9% (-23.1%
12, 2021	544	20571	1827	128.3	102.7	89.4	23.3%)	to -7.5%)

Table S7b: Vaccine effectiveness of over 50 years of age confirmed Delta variant SARS-CoV2 cases reported by Public Health

England until September 12, 2021. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. † SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. The age specified denominator (population) for the \geq 50 years of age group based on the vaccination status (1 dose, two doses and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S7c: Vaccine effectiveness of over 50 years of age NIMS population

Rolling	COVID	-19 case	s; ≥50 yrs	of age							
Four	(during	g four we	eks perio	d)	Incidenc	e rate per 10	00,000 p	opulation	Vaccine effective	eness (95% CI)	
weeks	1	Two	Third			_	3rd				
period	dose*	doses [‡]	dose ^ø	Unvaccinated	1 dose	2 doses	dose	Unvaccinated	1 dose	2 doses	3rd dose
Aug 16-											
Sept 12,									-183.1% (-187% to -	17.5% (16.5% to	
2021	81332	288470		101867	843.4	711.7		551.3	178.9%)	18.4%)	
Aug 23-									446 20/ / 450 20/ 1		
Sept 19, 2021	55159	276831		87377	755.4	674.7		503.1	-146.3% (-150.3% to -142.2%)	9.2% (8.1% to 10.3%)	
Aug 30-	33139	270031		6/3//	755.4	674.7		303.1	-142.270)	9.2% (8.1% (0.10.5%)	
Sept 26,									-122% (-126% to -	-2.4% (-3.7% to -	
2021	40434	272498		75925	692.7	646.3		449.8	117.8%)	1.2%)	
Sept 6-									,	,	
October									-91.9% (-96% to -	-19.0% (-20.6% to -	
3, 2021	28361	265485		64589	651.6	635.4		397.1	87.7%)	17.4%)	
Sept 13-											
Oct 10,									-73.9% (-78% to -	-40.8% (-42.7% to -	
2021	23218	287527		60497	656.8	712.5		381.1	69.9%)	39.0%)	
Sept 20-									-69.7% (-73.7% to -	-61.7% (-63.8% to -	
Oct 17, 2021	23238	339317		63961	753.7	902.2		413.2	65.7%)	59.7%)	
Sept 27-	23236	333317		03901	733.7	902.2		413.2	03.770]	33.770)	
Oct 24,									-64.1% (-67.9% to -	-76.3% (-78.4% to -	
2021	24038	390274		70006	841.2	1155.6		473.3	60.4%)	74.2%)	
Oct 4-Oct									-61.9% (-65.5% to -	-89.6% (-91.8% to -	
31, 2021	25293	438972		76219	941.3	1444.1		529.4	58.4%)	87.5%)	
Oct 11-											
Nov 7,									-60.0% (63.5% to -	-96.3% (-98.5% to -	
2021	25554	450186		79516	974.0	1672.1		557.2	56.5%)	94.1%)	
Oct 18-									E0 20/ / 64 00/ :	402 70/ / 405 00/ :	
Nov 14, 2021	25350	448916		01500	986.9	1906.1		580.0	-58.3% (-61.8% to - 54.9%)	-102.7% (-105.0% to -	
Oct 25-	25350	448916		81589	986.9	1906.1		580.0	J4.9%J	100.5%)	
Nov 21,									-55.6% (-59.0% to -	-110.2% (-112.6% to -	
2021	24894	443166		83121	1001.2	2136.7		586.9	•	107.9%)	

Nov 1-	Ī		ĺ	1	ĺ	1	ĺ		I		1
Nov 28,									-52.9% (-56.2% to -	-119.3% (-121.7% to -	
2021	24489	437450		85038	1008.7	2442.3		600.4	49.6%)	116.9%)	
Nov 8-									,		
Dec 5,									-53.4% (-56.7% to -	-135.6% (-138.1% to -	
2021	26242	469465		92746	1119.7	3083.5		651.9	50.2%)	133.2%)	
Nov 15-									,	,	
Dec 12,									-54.9% (-58.0% to -	-157.5% (-160.1% to -	
2021	29274	517061		104612	1209.8	4066.0		704.8	51.9%)	155.0%)	
Nov 22-									,	·	
Dec 19,									-67.0% (-69.9% to -	-276.9% (-280.1% to -	
2021	39618	736016		132809	1402.3	6920.1		818.3	64.1%)	273.6%)	
Dec 6,											
2021-Jan									-95.5% (-97.9% to -	-535.8% (-539.7% to -	
2, 2022	84102	1654525		240879	2774.2	23991.2		1421.8	93.2%)	531.9%)	
Dec 13,											
2021-Jan									-98.9% (-101.1% to -	-626.3% (-630.3% to -	
9, 2022	103771	2073522		292438	3462.9	35837.9		1746.3	96.8%)	622.3%)	
Dec 20,											
2021-Jan									-97.3% (-99.5% to -	-313.2% (-315.8% to -	-1.2% (-1.9%
16, 2022	100960	1095228	934915	285948	3518.0	8823.1	2910.4	1783.9	95.2%)	310.7%)	to -0.6%)
Dec 27,											-20.6% (-
2021-Jan									-92.5% (-94.7% to -	-257.2% (-259.6% to -	21.4% to -
23, 2022	88213	825293	1013017	255701	3132.7	6802.7	2876.2	1625.9	90.2%)	254.8%)	19.8%)
											-31.9% (-
Jan 3-Jan									-82.5% (-84.8% to -	-184.2% (-186.3% to -	32.8% to -
30, 2022	75802	583313	1018299	231750	2502.4	4536.1	2429.3	1378.3	80.2%)	182.1%)	31.0%)
Jan 10-											-64.9% (-
Feb 6,									-81.2% (-84.0% to -	-147.0% (-149.3% to -	66.2% to -
2022	51615	344772	884793	159596	1786.6	2700.8	1890.4	985.7	78.5%)	144.7%)	63.6%)
Jan 17-											-93.1% (-
Feb 13,									-85.3% (-88.5% to -	-138.4% (-140.9% to -	94.8% to -
2022	42017	264366	839411	128278	1494.3	2044.6	1751.5	797.0	82.2%)	135.9%)	91.4%)
Jan 24-									00.00//.5:/:	100 00/ / 155 55/	-118.1% (-
Feb 20,	22222	200402	750057	400000	4250.0	1626.2	4600	65- 6	-88.0% (-91.6% to -	-132.0% (-134.8% to -	120.2% to -
2022	33209	200489	750857	100923	1250.3	1628.2	1633.4	657.0	84.4%)	129.2%)	116.1%)
Jan 31-									00 20/ / 02 50/ :	426 60/ / 420 00/ :	-139.5% (-
Feb 27,	2445:	4.4400=	64.40.46	74004	4000 -	4246.2	4440 =	52.0	-88.3% (-92.6% to -	-126.6% (-129.8% to -	142.2% to -
2022	24454	144037	614846	74831	1002.5	1246.0	1418.7	524.8	84.2%)	123.4%)	136.9%)

Feb 7-											-163.4% (-
Mar 6,									-83.3% (-88.0% to -	-116.5% (-120.0% to -	166.6% to -
2022	18878	109575	543808	59904	838.4	1037.5	1335.0	446.6	78.7%)	113.1%)	160.2%)
Feb 14-											-195.8% (-
Mar 13,									-75.6% (-80.2% to -	-106.0% (-109.3% to -	199.3% to -
2022	18039	104580	617982	60372	863.1	1072.1	1585.9	466.3	71.2%)	102.8%)	192.3%)
Feb 21-											-224.9% (-
Mar 20,									-71.7% (-75.9% to -	-100.8% (-103.9% to -	228.5% to -
2022	20229	117728	790490	70018	1009.3	1279.1	2085.9	556.7	67.6%)	97.9%)	221.4%)
Feb 28-											-237.9% (-
Mar 27,									-70.5% (-74.3% to -	-100.3% (-103.1% to -	241.3% to -
2022	24334	142964	1008836	85614	1262.0	1596.3	2714.8	689.7	66.8%)	97.7%)	234.7%)

Table S7c: Vaccine effectiveness of over 50 years of age NIMS population (rolling four weeks cases reported weekly) since August 16, 2021 to March 27, 2022 until UKHSA stopped reporting data of weekly cases among age groups based on vaccination status. *SARS-CoV2 cases tested positive with the specimen date post receiving the first dose without additional doses of vaccination are considered one dose. ‡ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. 6 SARS-CoV2 cases tested positive with the specimen date \geq 14 days post third dose are considered vaccinated with the third dose. The age specified denominator (population) for the \geq 50 years of age group based on the vaccination status (1 dose, two doses, third dose and unvaccinated), for each specified period ending date was shown on the Table S3a.

Table S7d: The comparable SARS-CoV2 cases per 100,000 population of entire population (all ages), based on the NIMS population estimate and England vaccinated population database estimate

Study period	SARS-C	CoV2 infec	tions (all	ages, n=total ca	ases)		n (NIM	r 100,000 6 database	Incidence rate per 100,000 population (England vaccinated database estimate)			
	1 dose only	Two doses (no 3rd dose)	Third dose	Unvaccinated	1 dose only	Two doses (no 3rd dose)	Third dose	Unvaccinated	1 dose only	Two doses (no 3rd dose)	This dose	Unvaccinated
Feb 1-June 20, 2021	26495	10834		71932	278.8	41.2		263.5	276.9	40.8		351.8
June 21-July 18, 2021	27596	17939		49470	322.6	59.9		201.3	319.0	59.4		279.7
July 19-Aug 1, 2021	16016	18235		29652	225.6	57.2		122.8	222.5	56.8		172.0
Aug 2-Aug 15, 2021	19850	26364		32079	353.8	78.2		135.1	345.9	77.6		190.5
Aug 16-Aug 29, 2021	18913	40451		36583	427.5	114.0		157.8	413.6	113.3		225.0
Aug 30-Sept 12, 2021	11942	43577		37641	332.4	119.0		164.7	317.1	118.2		236.5
Aug 16-Sept 12, 2021	93143	289279		263285	2592.3	789.7		1151.7	2473.4	784.7		1653.9
Aug 23-Sept 19, 2021	67187	277504		275845	2019.7	750.3		1212.7	1915.2	745.1		1746.2
Aug 30-Sept 26, 2021	53070	273180		316002	1669.8	741.0		1396.7	1578.1	728.3		2015.8
Sept 6- October 3, 2021	39232	266094		337570	1240.5	736.4		1504.2	1177.1	730.8		2176.5
Sept 13-Oct 10, 2021	37578	288181		371696	1173.4	821.1		1672.5	1127.1	812.9		2423.0
Sept 20-Oct 17, 2021	44937	340060		415109	1370.8	1002.4		1888.2	1336.5	990.2		2739.8
Sept 27-Oct 24, 2021	54490	391095		425014	1611.0	1202.4		1955.9	1570.6	1186.9		2853.5

Oct 4-Oct	61288	439790		413112	1768.8	1414.9		1919.9	1712.9	1396.6		2818.6
31, 2021												
Oct 11-Nov	62154	450992		378023	1725.9	1534.4		1778.1	1673.5	1512.3		2625.3
7, 2021												
Oct 18-Nov	63339	449755		337344	1719.3	1633.8		1602.8	1641.6	1617.0		2392.2
14, 2021												
Oct 25-Nov	62428	444031		326843	1676.4	1734.1		1564.9	1597.6	1715.8		2345.9
21, 2021												
Nov 1-Nov	65115	438404		344912	1762.1	1856.0		1661.9	1669.1	1837.2		2501.1
28, 2021												
Nov 8-Dec 5,	73786	470605		390096	2031.5	2179.3		1891.8	1907.9	2158.4		2860.6
2021						1						
Nov 15-Dec	79378	518373		417606	2225.9	2690.6		2037.7	2078.9	2660.1		3093.6
12, 2021	0.470.4	720404		445227	2525.5	5000.0	-	2402.0	2540.0	4000.4		2240.5
Nov 22-Dec	94734	738184		445337	2696.6	5000.9		2193.0	2510.8	4888.4		3348.5
19, 2021	462026	4662620		F40063	4772.0	45400.0		2720.0	4427.4	44040 5		4246.2
Dec 6, 2021-	163826	1663628		549062	4773.0	15199.9		2738.8	4437.1	14948.5		4216.3
Jan 2, 2022	202226	2000052		640960	6001.1	20025.7		2210.7	FF63.0	20500.0		4070.0
Dec 13, 2021-Jan 9,	202336	2088952		640869	6001.1	20935.7		3219.7	5563.9	20590.9		4979.0
2021-Jan 9,												
Dec 20,	206329	1112775	935833	697751	6238.1	11656.3	3072.4	3526.4	5765.3	11471.5	3065.6	5475.0
2021-Jan 16,	200323	1112//3	333033	037731	0230.1	11030.3	3072.4	3320.4	3703.3	11471.5	3003.0	3473.0
2022												
Dec 27,	199979	844861	1014108	762421	6215.7	8997.3	3291.9	3872.7	5727.5	8863.9	3283.2	6032.3
2021-Jan 23,												
2022												
Jan 3-Jan 30,	205387	607331	1019610	844279	6587.8	6532.8	3279.8	4307.9	6043.0	6441.5	3270.0	6731.5
2022												
Jan 10-Feb	171086	369295	886117	726829	5641.9	3987.0	2833.3	3721.5	5161.7	3932.6	2824.0	5830.3
6, 2022												
Jan 17-Feb	146856	289924	840753	589449	4978.1	3137.2	2673.9	3028.1	4542.9	3095.7	2664.5	4754.3
13, 2022												
Jan 24-Feb	109803	224505	752126	404030	3795.5	2437.7	2381.5	2081.0	3460.8	2406.4	2372.5	3272.6
20, 2022												
Jan 31-Feb	67669	162998	615949	244313	2380.7	1776.5	1942.3	1261.3	2169.8	1753.8	1934.5	1986.7
27, 2022												
Feb 7-Mar 6,	41523	124333	544745	167402	1489.6	1357.9	1711.8	865.9	1356.1	1342.1	1704.1	1365.6
2022							1					
Feb 14-Mar	35325	120538	619128	172564	1293.5	1318.5	1939.2	894.1	1177.1	1303.8	1930.1	1411.4
13, 2022											1	

Feb 21-Mar	39117	139110	792120	211979	1463.5	1523.5	2473.5	1100.0	1331.9	1507.4	2461.2	1737.4
20, 2022												
Feb 28-Mar	46866	170597	1011153	258357	1787.0	1871.2	3148.5	1342.5	1625.8	1851.7	3132.5	2122.0
27, 2022												

Table S7d: The comparable SARS-CoV2 cases per 100,000 population of entire population (all ages), of the Delta variant SARS CoV2 cases in England (Feb 1 - Sept 12, 2021) and NIMS database linked SARS-CoV2 cases (August 16, 2021 - March 27, 2022) based on the NIMS population estimate and England vaccinated population database estimate. The denominator (population) for each period ending date was based on the respective population numbers among vaccinated groups of NIMS database (Table S3a) and England vaccination database (Table S3c). As shown on the table the incidence rate per 100,000 population is similar among vaccinated populations (1 dose, two doses and third dose) and how ever the unvaccinated population differences as shown Tables Table S3a and Table S3c variability among unvaccinated incidence rate per 100,000 population.

Table S7e: The comparable vaccine effectiveness of entire population (all ages) based on the NIMS population denominator estimate and the England vaccinated population database denominator estimate.

Study period	Vaccine effectivene NIMS vaccinated Po	•		Vaccine effectiven England vaccinate	•	
	1 dose VE (95%CI)	2 doses VE (95%CI)	VE 3rd dose (95% CI)	1 dose (95% CI)	2 doses VE (95%CI)	VE 3rd dose (95% CI)
Feb 1-June 20, 2021	-5.8% (-8.2% to -3.5%)	84.4% (83.9% to 84.8%)		21.3% (19.5% to 23.0%)	88.8% (88.0% to 88.7%)	
June 21-July 18, 2021	-60.2% (-64.0% to - 56.5%)	70.3% (69.5% to 71.1%)		-14.1% (-16.8% to - 11.4%)	78.7% (78.2% to 79.3%)	
July 19-Aug 1, 2021	-83.7% (-89.4% to - 78.1%)	53.4% (52.0% to 54.8%)		-29.4% (-33.4% to - 25.4%)	67.6% (66.0% to 67.9%)	
Aug 2-Aug 15, 2021	-161.9% (-169.4% to - 154.6%)	42.1% (40.6% to 43.6%)		- 81.6% (-86.8% to - 76.5%)	59.5% (58.2% to 60.3%)	
Aug 16-Aug 29, 2021	-170.9% (-178.6% to - 163.4%)	27.7% (26.1% to 29.4%)		-83.8 (-89.0% to - 78.8%)	49.4% (48.5% to 50.8%)	
Aug 30-Sept 12, 2021	-101.9% (-108.4% to - 95.5%)	27.8% (26.1% to 29.3%)		-34.1% (-38.5% to - 29.9%)	50.5% (48.9% to 51.1%)	
Aug 16-Sept 12, 2021	-125.1% (-127.7% to - 122.5%)	31.4% (30.9% to 32.0%)		-49.6% (-51.3% to - 47.8%)	52.6% (52.2% to 53.0%)	
Aug 23-Sept 19, 2021	-66.5% (-68.7% to - 64.4%)	38.1% (37.6% to 38.6%)		-9.7% (-11.1% to - 8.3%)	57.3% (57.0% to 57.7%)	
Aug 30-Sept 26, 2021	-19.5% (-21.2% to - 17.9%)	46.9% (46.5% to 47.4%)		21.7% (20.6% to - 22.8%)	63.9% (63.6% to 64.2%)	
Sept 6-October 3, 2021	17.5% (16.3% to - 18.8%)	51.0% (50.6% to 51.4%)		45.9% (45.1% to - 46.7%)	66.4% (66.1% to 66.7%)	
Sept 13-Oct 10, 2021	29.8% (28.8% to - 30.9%)	50.9% (50.5% to 51.3%)		53.5% (52.8% to - 54.2%)	66.4% (66.2% to 66.7%)	
Sept 20-Oct 17, 2021	27.4% (26.4% to - 28.4%)	46.9% (46.5% to 47.3%)		51.2% (50.5% to - 51.9%)	63.9% (63.6% to 64.1%)	
Sept 27-Oct 24, 2021	17.6% (16.6% to - 18.7%)	38.5% (38.1% to 39.0%)		45.0% (44.2% to - 45.7%)	58.4% (58.1% to 58.7%)	
Oct 4-Oct 31, 2021	7.9% (6.7% to -9.0%)	26.3% (25.8% to 26.8%)		39.2% (38.5% to - 40.0%)	50.5% (50.1% to 50.8%)	
Oct 11-Nov 7, 2021	2.9% (1.7% to -4.1%)	13.7% (13.1% to 14.3%)		36.3% (35.5% to - 37.1%)	42.4% (42.0% to 42.8%)	
Oct 18-Nov 14, 2021	-7.3% (-8.6% to -5.9%)	-1.9% (-2.7% to -1.2%)		31.4% (30.5% to - 32.2%)	32.4% (31.9% to 32.9%)	

Oct 25-Nov 21, 2021	-7.1% (-8.5% to -5.8%)	-10.8% (-11.6% to -		31.9% (31.0% to -	26.9% (26.3% to 27.4%)	
		10.0%)		32.8%)		
Nov 1-Nov 28, 2021	-6.0% (-7.4% to -4.7%)	-11.7% (-12.5% to -		33.3% (32.4% to -	26.5% (26.0% to 27.1%)	
		10.9%)		34.1%)		
Nov 8-Dec 5, 2021	-7.4% (-8.6% to -6.1%)	-15.2% (-16.0% to -		33.3% (32.5% to -	24.5% (24.0% to 25.1%)	
		14.4%)		34.1%)		
Nov 15-Dec 12, 2021	-9.2% (-10.5% to -	-32.0% (-32.9% to -		32.8% (32.0% to -	14.0% (13.5% to 14.6%)	
	8.0%)	31.2%)		33.6%)		
Nov 22-Dec 19, 2021	-23.0% (-24.3% to -	-128.0% (-129.4% to -		25.0% (24.2% to -	-46.0% (-46.8% to -	
	21.7%)	126.7%)		25.8%)	45.1%)	
Dec 6, 2021-Jan 2, 2022	-74.3% (-75.7% to -	-455.0% (-457.5% to -		-5.2% (-6.1% to -4.4%)	-254.5% (-256.2% to -	
	72.8%)	452.5%)			252.9%)	
Dec 13, 2021-Jan 9,	-86.4% (-87.8% to -	-550.2% (-552.9% to -		-11.7% (-12.6% to -	-313.6% (-315.3% to -	
2022	85.0%)	547.5%)		10.9%)	311.9%)	
Dec 20, 2021-Jan 16,	-76.9% (-78.2% to -	-230.5% (-232.1% to -	12.9% (12.4% to	-5.3% (-6.1% to -4.5%)	-109.5% (-110.5% to -	44.0% (43.7% to
2022	75.6%)	229.0%)	13.3%)		108.6%)	44.3%)
Dec 27, 2021-Jan 23,	-60.5% (-61.7% to -	-132.3% (-133.5% to -	15.0% (14.6% to	5.1% (4.4% to -5.7%)	-46.9% (-47.7% to -	45.6% (45.3% to
2022	59.3%)	131.2%)	15.4%)		46.2%)	45.8%)
Jan 3-Jan 30, 2022	-52.9% (-54.0% to -	-51.6% (-52.4% to -	23.9% (23.5% to	10.2% (9.6% to -	4.3% (3.8% to 4.8%)	51.4% (51.2% to
	51.8%)	50.9%)	24.2%)	10.9%)		51.6%)
Jan 10-Feb 6, 2022	-51.6% (-52.8% to -	-7.1% (-7.8% to -6.5%)	23.9% (23.5% to	11.5% (10.8% to -	32.5% (32.1% to 33.0%)	51.6% (51.3% to
	50.4%)		24.2%)	12.2%)		51.8%)
Jan 17-Feb 13, 2022	-64.4% (-65.8% to -	-3.6% (-4.3% to -2.9%)	11.7% (11.2% to	4.4% (3.6% to -5.3%)	34.9% (34.4% to 35.3%)	44.0% (43.7% to
	63.0%)	,	12.2%)			44.3%)
Jan 24-Feb 20, 2022	-82.4% (-84.2% to -	-17.1% (-18.1% to -	-14.4% (-15.1% to -	-5.7% (-6.8% to -4.7%)	26.5% (25.9% to 27.1%)	27.5% (27.1% to
	80.6%)	16.2%)	13.8%)			27.9%)
Jan 31-Feb 27, 2022	-88.7% (-91.2% to -	-40.8% (-42.3% to -	-54.0% (-55.1% to -	-9.2% (-10.6% to -	11.7% (10.8% to 12.6%)	2.6% (1.9% to
	86.3%)	39.4%)	52.9%)	7.8%)		3.3%)
Feb 7-Mar 6, 2022	-72.0% (-74.9% to -	-56.8% (-58.7% to -	-97.7% (-99.4% to -	0.7% (-0.9% to -2.3%)	1.7% (0.6% to 2.9%)	-24.8% (-25.8%
•	69.2%)	55.0%)	96.0%)			to -23.7%)
Feb 14-Mar 13, 2022	-44.7% (-47.2% to -	-47.5% (-49.2% to -	-116.9% (-118.7%	16.6% (15.2% to -	7.6% (6.5% to 8.7%)	-36.8% (-37.9%
	42.2%)	45.7%)	to -115.1%)	18.0%)		to -35.6%)
Feb 21-Mar 20, 2022	-33.0% (-35.2% to -	-38.5% (-40.0% to -	-124.9% (-126.5%	23.3% (22.1% to -	13.2% (12.3% to 14.2%)	-41.7% (-42.7%
,	30.9%)	37.0%)	to -123.2%)	24.6%)	,	to -40.6%)
Feb 28-Mar 27, 2022	-33.1% (-35.1% to -	-39.4% (-40.7% to -	-134.5% (-136.1%	23.4% (22.3% to -	12.7% (11.9% to 13.6%)	-47.6% (-48.6%
•	31.2%)	38.0%)	to -133.0%)	24.5%)	,	to -46.7%)

Table S7e: The comparable vaccine effectiveness of entire population (all ages) of the Delta variant SARS CoV2 cases in England (Feb 1-Sept 12, 2021) and NIMS database linked SARS-CoV2 cases (August 16, 2021-March 27, 2022) based on the NIMS

population denominator estimate and the England vaccinated population database denominator estimate. The denominator (population) for each period ending date was based on the respective population numbers among vaccinated groups of NIMS database (Table S3a) and England vaccination database (Table S3c).

Table S8a-f: Proportion test of SARS-CoV2 cases, hospitalizations and deaths among NIMS vaccinated population of over 18 and over 50 years of age.

Study period (rolling 4 weeks)		Proportio (cases/po	n of population	on	Compared groups	Statistical analysis
	All vaccinated	2 doses [‡]	Third dose	Unvaccinated		Two-Proportions test with continuity adjustment (X2=; df=; p-value)
Aug 16-Sept 12, 2021	0.009345	0.007892		0.009562	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 42.277, df = 1, p- = 1 X ² = 2804.2, df = 1, p-= 1
Aug 23-Sept 19, 2021	0.008373	0.007502		0.008265	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 11.686, df = 1, p = 0.0003149 X ² = 627.65, df = 1, p = 1
Aug 30-Sept 26, 2021	0.007877	0.007409		0.007233	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 448.21, df = 1, p<0.001 X ² = 34.737, df = 1, p<0.001
Sept 13-Oct 10, 2021	0.007797	0.008217		0.005835	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 4317.8, df = 1, p<0.001 X ² = 5961.9, df = 1, p<0.001
Oct 11-Nov 7, 2021	0.011865	0.015408		0.007851	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 11915, df = 1, p<0.001 X ² = 32339, df = 1, p<0.001
Nov 8-Dec 5, 2021	0.012292	0.022081		0.009371	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 5855.7, df = 1, p<0.001 X ² = 61570, df = 1, p<0.001
Dec 6, 2021-Jan 2, 2022	0.042753	0.160237		0.025204	All vaccinated vs. Unvaccinated Two doses vs. Unvaccinated	X ² = 62948, df = 1, p<0.001 X ² = 1049374, df = 1, p<0.001
Dec 20, 2021-Jan 16, 2022	0.052219	0.125527	0.030752	0.030378	All vaccinated vs. Unvaccinated Third dose vs. Unvaccinated Two doses vs. Unvaccinated Third dose vs. Two doses	X ² = 79651, df = 1, p<0.001 X ² = 33.892, df = 1, p<0.001 X ² = 582725, df = 1, p<0.001 X ² = 1237850, df = 1, p = 1

Dec 27, 2021-Jan	0.062683	0.097611	0.032960	0.027325	All vaccinated vs. Unvaccinated	X ² = 174246, df = 1, p<0.001
23, 2022					Third dose vs. Unvaccinated	X ² = 7433.2, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 384927, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 619910, df = 1, p = 1
Jan 3-Jan 30, 2022	0.054101	0.070765	0.032843	0.024899	All vaccinated vs. Unvaccinated	X ² = 135316, df = 1, p<0.001
·					Third dose vs. Unvaccinated	X ² = 15037, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 207668, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 239234, df = 1, p = 1
Jan 17-Feb 13, 2022	0.027963	0.033064	0.026779	0.013870	All vaccinated vs. Unvaccinated	X ² = 60619, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 51150, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 71007, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 9227.7, df = 1, p = 1
Jan 31-Feb 27, 2022	0.019099	0.018408	0.019462	0.008125	All vaccinated vs. Unvaccinated	X ² = 53922, df = 1, p<0.001
,					Third dose vs. Unvaccinated	X ² = 55147, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 35266, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 368.53, df = 1, p<0.001
	0.018043	0.013551	0.019454	0.006577	All vaccinated vs. Unvaccinated	X ² = 62838, df = 1, p<0.001
Feb 14-Mar 13,					Third dose vs. Unvaccinated	X ² = 72465, df = 1, p<0.001
2022					Two doses vs. Unvaccinated	X ² = 21090, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 12041, df = 1, p<0.001
Feb 28-Mar 27,	0.028637	0.018738	0.031609	0.009353	All vaccinated vs. Unvaccinated	X ² = 113642, df = 1, p<0.001
2022					Third dose vs. Unvaccinated	X ² = 135833, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 27278, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 36077, df = 1, p<0.001

Table S8a: Two-proportions test with continuity adjustment of SARS-CoV2 cases among NIMS vaccinated population of over 18 years of age since August 16, 2021 to March 27, 2022. †SARS-CoV2 cases tested positive with the specimen date ≥14 days post second dose are considered vaccinated with two doses. ^Ø SARS-CoV2 cases tested positive with the specimen date ≥14 days post third dose are considered vaccinated with the third dose.

Study period (rolling 4 weeks)	Proportion of	population	(hospitalizatio	ons/population)	Groups compared	Statistical analysis
	All vaccinated	2 doses [‡]	Third dose	Unvaccinated		Two-Proportions test with continuity adjustment (X2=; df=; p-value)
Aug 16-Sept 12, 2021	0.000121	0.000120		0.000275	All vaccinated vs. Unvaccinated	X ² = 1292.9, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 1286.1, df = 1, p = 1
Aug 23-Sept 19, 2021	0.000124	0.000123		0.000259	All vaccinated vs. Unvaccinated	$X^2 = 998.05$, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 985.86, df = 1, p = 1
Aug 30-Sept 26, 2021	0.000119	0.000119		0.000232	All vaccinated vs. Unvaccinated	X ² = 750.01, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 721.94, df = 1, p = 1
Sept 13-Oct 10, 2021	0.000081	0.000087		0.000140	All vaccinated vs. Unvaccinated	X ² = 304.78, df = 1, p = 1
					Two doses vs. Unvaccinated	X-squared = 232.96, df = 1, p = 1
Oct 11-Nov 7, 2021	0.000169	0.000221		0.000269	All vaccinated vs. Unvaccinated	X ² = 429.48, df = 1, p- = 1
					Two doses vs. Unvaccinated	X ² = 73.123, df = 1, p = 1
Nov 8-Dec 5, 2021	0.000120	0.000213		0.000270	All vaccinated vs. Unvaccinated	X ² = 1205.4, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 96.403, df = 1, p = 1
Nov 22-Dec 19, 2021	0.000107	0.000281		0.000321	All vaccinated vs. Unvaccinated	X ² = 2407.3, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 29.835, df = 1, p = 1
Dec 6, 2021-Jan 2, 2022	0.000141	0.000511		0.000341	All vaccinated vs. Unvaccinated	X ² = 1728.9, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 332.3, df = 1, p<0.001
Dec 20, 2021-Jan 16,	0.000243	0.000472	0.000169	0.000366	All vaccinated vs. Unvaccinated	X ² = 432.84, df = 1, p= 1
2022					Third dose vs. Unvaccinated	X ² = 1292.4, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 121.31, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 2625.6, df = 1, p = 1
Dec 27, 2021-Jan 23,	0.000272	0.000470	0.000210	0.000343	All vaccinated vs. Unvaccinated	X ² = 133.64, df = 1, p = 1
2022					Third dose vs. Unvaccinated	X ² = 529.15, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 178.58, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 1695.2, df = 1, p = 1

Jan 10-Feb 6, 2022	0.000187	0.000258	0.000163	0.000187	All vaccinated vs. Unvaccinated	X ² = 0.016292, df = 1, p = 0.5508
3411 10 1 65 0, 2022					Third dose vs. Unvaccinated	X ² = 25.596, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 97.746, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 319.9, df = 1, p = 1
Jan 17-Feb 13, 2022	0.000174	0.000221	0.000158	0.000156	All vaccinated vs. Unvaccinated	X ² = 14.103, df = 1, p<0.001
,					Third dose vs. Unvaccinated	X ² = 0.12568, df = 1, p- = 0.3615
					Two doses vs. Unvaccinated	X ² = 98.344, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 151.35, df = 1, p = 1
Jan 24-Feb 20, 2022	0.000164	0.000183	0.000157	0.000131	All vaccinated vs. Unvaccinated	X ² = 52.732, df = 1, p<0.001
,					Third dose vs. Unvaccinated	X ² = 33.446, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 75.858, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 25.972, df = 1, p = 1
Jan 31-Feb 27, 2022	0.000146	0.000147	0.000144	0.000111	All vaccinated vs. Unvaccinated	X ² = 65.454, df = 1, p<0.001
,					Third dose vs. Unvaccinated	X ² = 58.17, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 42.996, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 0.28271, df = 1, p = 0.7025
Feb 14-Mar 13, 2022	0.000125	0.000107	0.000129	0.000084	All vaccinated vs. Unvaccinated	X ² = 104.5, df = 1, p<0.001
·					Third dose vs. Unvaccinated	X ² = 121.11, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 21.615, df = 1, pp<0.001
					Third dose vs. Two doses	X ² = 25.946, df = 1, p<0.001
Feb 28-Mar 27, 2022	0.000199	0.000150	0.000211	0.000120	All vaccinated vs. Unvaccinated	X ² = 249.43, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 309.05, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 26.895, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 117.1, df = 1, p<0.001

Table S8b: Two-proportions test with continuity adjustment of SARS-CoV2 hospitalizations among NIMS vaccinated population of over 18 years of age since August 16, 2021 to March 27, 2022. †SARS-CoV2 cases tested positive with the specimen date ≥14 days post second dose are considered vaccinated with two doses. Ø SARS-CoV2 cases tested positive with the specimen date ≥14 days post third dose are considered vaccinated with the third dose.

Study period (rolling 4 weeks)	Proportion	of population	n (deaths/pop	ulation)	Groups compared	Statistical analysis
	All vaccinated	2 doses [‡]	Third dose	Unvaccinated		Two-Proportions test with continuity adjustment (X2=; df=; p- value)
Aug 16-Sept 12, 2021	0.000056	0.000057		0.000068	All vaccinated vs. Unvaccinated	X ² = 20.926, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 15.286, df = 1, p = 1
Aug 23-Sept 19, 2021	0.000060	0.000062		0.000069	All vaccinated vs. Unvaccinated	X ² = 9.0561, df = 1, p=0.9987
					Two doses vs. Unvaccinated	$X^2 = 5.8408$, df = 1, p = 0.9922
Aug 30-Sept 26, 2021	0.000062	0.000064		0.000065	All vaccinated vs. Unvaccinated	X ² = 1.5266, df = 1, p = 0.8917
					Two doses vs. Unvaccinated	$X^2 = 0.26222$, df = 1, p = 0.6957
Sept 13-Oct 10, 2021	0.000056	0.000061		0.000053	All vaccinated vs. Unvaccinated	X ² = 0.84631, df = 1, p= 0.1788 X ² = 7.6872, df = 1, p =
					Two doses vs. Unvaccinated	0.002781
Oct 11-Nov 7, 2021	0.000070	0.000094		0.000057	All vaccinated vs. Unvaccinated	X ² = 20.339, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 116.92, df = 1, p<0.001
Nov 8-Dec 5, 2021	0.000064	0.000117		0.000071	All vaccinated vs. Unvaccinated	X ² = 6.4766, df = 1, p= 0.9945
					Two doses vs. Unvaccinated	X ² = 136.46, df = 1, p<0.001
Nov 22-Dec 19, 2021	0.000053	0.000143		0.000080	All vaccinated vs. Unvaccinated	$X^2 = 100.78$, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 195.77, df = 1, p<0.001
Dec 6, 2021-Jan 2, 2022	0.000051	0.000189		0.000084	All vaccinated vs. Unvaccinated	X ² = 154.01, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 390.22, df = 1, p<0.001
Dec 20, 2021-Jan 16,	0.000070	0.000163	0.000041	0.000107	All vaccinated vs. Unvaccinated	X ² = 137.28, df = 1, p<0.001
2022					Third dose vs. Unvaccinated	X ² = 542.63, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 104.52, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 1455.7, df = 1, p = 1
Dec 27, 2021-Jan 23,	0.000088	0.000185	0.000060	0.000107	All vaccinated vs. Unvaccinated	$X^2 = 30.094$, df = 1, p = 1
2022					Third dose vs. Unvaccinated	$X^2 = 223.02$, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 185.8, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 1186, df = 1, p = 1

Jan 10-Feb 6, 2022	0.000123	0.000201	0.000102	0.000097	All vaccinated vs. Unvaccinated	X ² = 41.017, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 1.7226, df = 1, p= 0.09468
					Two doses vs. Unvaccinated	X ² = 316.69, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 506.48, df = 1, p = 1
Jan 17-Feb 13, 2022	0.000118	0.000169	0.000106	0.000078	All vaccinated vs. Unvaccinated	X ² = 107.58, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 53.465, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 291.24, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 213.81, df = 1, p = 1
Jan 24-Feb 20, 2022	0.000105	0.000131	0.000100	0.000060	All vaccinated vs. Unvaccinated	X ² = 156.88, df = 1, p<0.001
,					Third dose vs. Unvaccinated	X ² = 122.84, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 229.37, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 57.692, df = 1, p = 1
Jan 31-Feb 27, 2022	0.000086	0.000093	0.000086	0.000043	All vaccinated vs. Unvaccinated	X ² = 181.54, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 171.55, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 159.44, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 3.5199, df = 1, p = 0.9697
Feb 14-Mar 13, 2022	0.000053	0.000049	0.000055	0.000026	All vaccinated vs. Unvaccinated	X ² = 115.23, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 122.59, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 64.207, df = 1, p<0.001
					Third dose vs. Two doses	V = 2.8687, df = 1, p = 0.04516
Feb 28-Mar 27, 2022	0.000043	0.000028	0.000049	0.000023	All vaccinated vs. Unvaccinated	X ² = 74.306, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 106.86, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 3.5483, df = 1, p = 0.0298
					Third dose vs. Two doses	X ² = 58.664, df = 1, p<0.001

Table S8c: Two-proportions test with continuity adjustment of SARS-CoV2 deaths among NIMS vaccinated population of over 18 years of age from August 16, 2021 to March 27, 2022. †SARS-CoV2 cases tested positive with the specimen date ≥14 days post second dose are considered vaccinated with two doses. ^Ø SARS-CoV2 cases tested positive with the specimen date ≥14 days post third dose are considered vaccinated with the third dose.

Study period (rolling 4 weeks*)		Proportion of (cases/popula	• •		Compared groups	Statistical analysis
	All vaccinated	2 doses [‡]	Third dose ^Ø	Unvaccinated		Two-Proportions test with continuity adjustment (X2=; df=; p- value)
until June 20, 2021	0.000486989	0.000269881		0.000575473	All vaccinated vs. Unvaccinated	X ² = 31.212, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 612.53, df = 1, p = 1
June 21-July 18, 2021	0.000441024	0.000413819		0.000504709	All vaccinated vs. Unvaccinated	$X^2 = 17.288$, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 37.234, df = 1, p = 1
July 19-Aug 1, 2021	0.000413326	0.000404604		0.000526581	All vaccinated vs. Unvaccinated	X ² = 57.242, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 67.473, df = 1, p = 1
Aug 2-Aug 15, 2021	0.000578857	0.000569373		0.000699815	All vaccinated vs. Unvaccinated	X ² = 46.5, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 54.749, df = 1, p = 1
Aug 30-Sept 12, 2021	0.000938593	0.00092997		0.000891319	All vaccinated vs. Unvaccinated	X ² = 4.4235, df = 1, p = 0.018
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 2.9683, df = 1, p = 0.042
Aug 16-Sept 12, 2021*	0.00714124	0.00711672		0.00551307	All vaccinated vs. Unvaccinated	X ² = 708.94, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 688.86, df = 1, p<0.001
Aug 23-Sept 19, 2021*	0.00675283	0.00674656		0.00503149	All vaccinated vs. Unvaccinated	X ² = 837.18, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 830.53, df = 1, p<0.001
Aug 30-Sept 26, 2021*	0.00635938	0.00646325		0.00449816	All vaccinated vs. Unvaccinated	X ² = 1039.4, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 1138.5, df = 1, p<0.001
Sept 13-Oct 10, 2021*	0.00635639	0.00712503		0.00381063	All vaccinated vs. Unvaccinated	X ² = 1954.1, df = p<0.001
					Two doses vs. Unvaccinated	v = 2953.9, df = 1, p<0.001
Oct 11-Nov 7, 2021*	0.01033954	0.01672072		0.00557227	All vaccinated vs. Unvaccinated	X ² = 4197.6, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 14260, df = 1, p<0.001
Nov 8-Dec 5, 2021*	0.00883519	0.03083521		0.00651932	All vaccinated vs. Unvaccinated	X ² = 1119, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 35890, df = 1, p<0.001
Dec 6, 2021-Jan 2, 2022*	0.02429517	0.23991204		0.01421828	All vaccinated vs. Unvaccinated	X ² = 7742.2, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 441724, df = 1, p<0.001

Dec 20, 2021-Jan 16, 2022*	0.03417810	0.08823135	0.02910401	0.01783886	All vaccinated vs. Unvaccinated	X ² = 14577, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 7987, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 91810, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 168485, df = 1, p = 1
Dec 27, 2021-Jan 23, 2022*	0.03200767	0.06802698	0.02876190	0.01625914	All vaccinated vs. Unvaccinated	X ² = 14404, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 9969.2, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 61097, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 76888, df = 1, p = 1
Jan 3-Jan 30, 2022*	0.02597837	0.04536145	0.02429350	0.01378302	All vaccinated vs. Unvaccinated	X ² = 10531, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 8281.8, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 31550, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 26421, df = 1, p = 1
Jan 17-Feb 13, 2022*	0.01770613	0.02044630	0.01751527	0.00797034	All vaccinated vs. Unvaccinated	X ² = 9808.3, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 9486.1, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 9912.7, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 722.09, df = 1, p = 1
Jan 31-Feb 27, 2022*	0.01292623	0.01245956	0.01418682	0.00524788	All vaccinated vs. Unvaccinated	X ² = 8334.2, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 10303, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 5228.9, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 309.3, df = 1, p<0.001
Feb 14-Mar 13, 2022*	0.01538218	0.01072085	0.01585947	0.00466257	All vaccinated vs. Unvaccinated	X ² = 13786, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 14569, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 4210.6, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 2455.8, df = 1, p<0.001
Feb 28-Mar 27, 2022*	0.02480554	0.01596269	0.02718747	0.00689690	All vaccinated vs. Unvaccinated	X ² = 24098, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 28284, df = 1, p<0.001
					Two doses vs. Unvaccinated	X ² = 6334.1, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 6868.5, df = 1, p<0.001

Table S8d: Two-proportions test with continuity adjustment of SARS-CoV2 cases among NIMS vaccinated population of over 50 years of age from August 16, 2021 to March 27, 2022 and the Delta variant cases until September 12, 2021. †SARS-CoV2 cases tested

positive with the specimen date \geq 14 days post second dose **are** considered vaccinated with two doses. ^Ø SARS-CoV2 cases tested positive with the specimen date \geq 14 days post third dose **are** considered vaccinated with the third dose.

Study period (rolling 4 weeks*)		•	of population		Compared groups	Statistical analysis
weeks y	All vaccinated	2 doses [‡]	Third dose	Unvaccinated	compared groups	Two-Proportions test with continuity adjustment (X2=; df=; p- value)
until June 20, 2021	0.00002049	0.00001366		0.00008857	All vaccinated vs. Unvaccinated	X ² = 336.46, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 517.31, df = 1, p = 1
June 21-July 18, 2021	0.00002434	0.00002212		0.00011556	All vaccinated vs. Unvaccinated	X ² = 482.5, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 533.6, df = 1, p = 1
July 19-Aug 1, 2021	0.00002313	0.00002153		0.00010980	All vaccinated vs. Unvaccinated	X ² = 454.62, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 490.35, df = 1, p = 1
Aug 2-Aug 15, 2021	0.00003779	0.00003545		0.00015385	All vaccinated vs. Unvaccinated	X ² = 520.52, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 562.56, df = 1, p = 1
Aug 16-Aug 29, 2021*	0.00004241	0.00004067		0.00016193	All vaccinated vs. Unvaccinated	X ² = 498.22, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 525.21, df = 1, p = 1
Aug 16-Sept 12, 2021*	0.00019764	0.00019316		0.00066460	All vaccinated vs. Unvaccinated	X ² = 1686, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 1738.6, df = 1, p = 1
Aug 23-Sept 19, 2021*	0.00020657	0.00020296		0.00065748	All vaccinated vs. Unvaccinated	X ² = 1520.9, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 1557.6, df = 1, p = 1
Aug 30-Sept 26, 2021*	0.00019658	0.00019615		0.00058376	All vaccinated vs. Unvaccinated	X ² = 1194.4, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 1188.7, df = 1, p = 1
Sept 13-Oct 10, 2021*	0.00013129	0.00014412		0.00032709	All vaccinated vs. Unvaccinated	X ² = 471.89, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 372.25, df = 1, p = 1
Oct 11-Nov 7, 2021*	0.00028050	0.00044881		0.00069854	All vaccinated vs. Unvaccinated	X ² = 997.52, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 221.12, df = 1, p = 1
Nov 8-Dec 5, 2021*	0.00018716	0.00063849		0.00074169	All vaccinated vs. Unvaccinated	X ² = 2331.7, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 23.277, df = 1, p = 1
Dec 6, 2021-Jan 2, 2022*	0.00020196	0.00191293		0.00092076	All vaccinated vs. Unvaccinated	X ² = 3428.6, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 678.34, df = 1, p<0.001
Dec 20, 2021-Jan 16, 2022*	0.00035854	0.00140191	0.00024814	0.00099393	All vaccinated vs. Unvaccinated	X ² = 1697, df = 1, p = 1

					Third dose vs. Unvaccinated	X ² = 3010.4, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 126.61, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 6101.6, df = 1, p = 1
Dec 27, 2021-Jan 23, 2022*	0.00041049	0.00142582	0.00030687	0.00092962	All vaccinated vs. Unvaccinated	X ² = 1024.9, df = 1, p = 1
					Third dose vs. Unvaccinated	X ² = 1823.1, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 188.07, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 4841.4, df = 1, p = 1
Jan 17-Feb 13, 2022*	0.00025935	0.00062660	0.00022149	0.00042185	All vaccinated vs. Unvaccinated	X ² = 165.77, df = 1, p = 1
					Third dose vs. Unvaccinated	X ² = 284.7, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 69.562, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 948.59, df = 1, p = 1
Jan 31-Feb 27, 2022*	0.00022910	0.00044469	0.00020744	0.00029924	All vaccinated vs. Unvaccinated	X ² = 35.636, df = 1, p = 1
					Third dose vs. Unvaccinated	X ² = 66.058, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 48.828, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 357.61, df = 1, p = 1
Feb 14-Mar 13, 2022*	0.00020319	0.00033807	0.00019016	0.00021887	All vaccinated vs. Unvaccinated	X ² = 1.9844, df = 1, p-value = 0.92 X ² = 7.1195, df = 1, p-value =
					Third dose vs. Unvaccinated	0.996
					Two doses vs. Unvaccinated	$X^2 = 43.462$, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 153.28, df = 1, p = 1
Feb 28-Mar 27, 2022*	0.00032888	0.00045991	0.00031621	0.00028400	All vaccinated vs. Unvaccinated	X ² = 10.468, df = 1, p<0.001
					Third dose vs. Unvaccinated	X ² = 5.523, df = 1, p = 0.0093
					Two doses vs. Unvaccinated	X ² = 70.784, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 87.958, df = 1, p = 1

Table S8e: Two-proportions test with continuity adjustment of SARS-CoV2 hospitalizations among NIMS vaccinated population of over 50 years of age from August 16, 2021 to March 27, 2022 and the Delta variant cases until September 12, 2021. †SARS-CoV2 cases tested positive with the specimen date ≥14 days post second dose are considered vaccinated with two doses. ^Ø SARS-CoV2 cases tested positive with the specimen date ≥14 days post third dose are considered vaccinated with the third dose.

Study period (rolling 4 weeks*)	Proportion of population (deaths/population)			1	Compared groups	Statistical analysis
	All vaccinated	2 doses [‡]	Third dose ^Ø	Unvaccinated		Two-Proportions test with continuity adjustment (X2=; df=; p- value)
until June 20, 2021	0.00000778	0.00000598		0.00003225	All vaccinated vs. Unvaccinated	X ² = 114.41, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 154.52, df = 1, p = 1
June 21-July 18, 2021	0.00000594	0.00000525		0.00002830	All vaccinated vs. Unvaccinated	X ² = 116.63, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 132.9, df = 1, p = 1
July 19-Aug 1, 2021	0.00000887	0.00000850		0.00003533	All vaccinated vs. Unvaccinated	X ² = 115.01, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 120.95, df = 1, p = 1
Aug 2-Aug 15, 2021	0.00001395	0.00001319		0.00005450	All vaccinated vs. Unvaccinated	X ² = 172.67, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 185.31, df = 1, p = 1
Aug 30-Sept 12, 2021	0.00002138	0.00002011		0.00005787	All vaccinated vs. Unvaccinated	X ² = 99.209, df = 1, p = 1
(Delta Variant)					Two doses vs. Unvaccinated	X ² = 110.91, df = 1, p = 1
Aug 16-Sept 12, 2021*	0.000105248	0.00010247		0.00029315	All vaccinated vs. Unvaccinated	X ² = 534.8, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 559.64, df = 1, p = 1
Aug 23-Sept 19, 2021*	0.00011445	0.00011185		0.00030198	All vaccinated vs. Unvaccinated	X ² = 494.27, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 515, df = 1, p-value = 1
Aug 30-Sept 26, 2021*	0.00011705	0.00011634		0.00028868	All vaccinated vs. Unvaccinated	X ² = 409.22, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 411.49, df = 1, p = 1
Sept 13-Oct 10, 2021*	0.00010668	0.00011701		0.00024135	All vaccinated vs. Unvaccinated	X ² = 279.44, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 215.47, df = 1, p = 1
Oct 11-Nov 7, 2021*	0.00013501	0.00021503		0.00025680	All vaccinated vs. Unvaccinated	X ² = 183.77, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 13.381, df = 1, p = 0.9999
Nov 8-Dec 5, 2021*	0.00012198	0.00041925		0.00031641	All vaccinated vs. Unvaccinated	X ² = 484.81, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 39.061, df = 1, p<0.001
Dec 6, 2021-Jan 2, 2022*	0.00009639	0.00091918		0.00036390	All vaccinated vs. Unvaccinated	X ² = 1046.9, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 467.11, df = 1, p<0.001
Dec 20, 2021-Jan 16, 2022*	0.00013310	0.00077283	0.00006678	0.00047476	All vaccinated vs. Unvaccinated	X ² = 1247.8, df = 1, p = 1

1		i I	I		I	V2 2724 4 45 1 5 4
					Third dose vs. Unvaccinated	$X^2 = 2731.4$, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 129.96, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 6227.2, df = 1, p = 1
Dec 27, 2021-Jan 23, 2022*	0.00016911	0.00088350	0.00009779	0.00047887	All vaccinated vs. Unvaccinated	X ² = 848.38, df = 1, p = 1
					Third dose vs. Unvaccinated	X ² = 1870.2, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 217.07, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 5852.6, df = 1, p = 1
Jan 3-Jan 30, 2022*	0.00021155	0.00099077	0.00013624	0.00048501	All vaccinated vs. Unvaccinated	X ² = 548.74, df = 1, p = 1
					Third dose vs. Unvaccinated	$X^2 = 1234.4$, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 310.4, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 5361.9, df = 1, p = 1
Jan 17-Feb 13, 2022*	0.00022885	0.00081722	0.00017383	0.00035145	All vaccinated vs. Unvaccinated	X ² = 107.58, df = 1, p = 1
					Third dose vs. Unvaccinated	X ² = 282.23, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 329.59, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 2704.6, df = 1, p = 1
Jan 31-Feb 27, 2022*	0.00016817	0.00044276	0.00014243	0.00019183	All vaccinated vs. Unvaccinated	X ² = 5.5114, df = 1, p-value = 0.9906
					Third dose vs. Unvaccinated	X ² = 27.948, df = 1, p = 1
					Two doses vs. Unvaccinated	X ² = 174.2, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 782.09, df = 1, p = 1
Feb 14-Mar 13, 2022*	0.00010368	0.00023821	0.00009147	0.00011559	All vaccinated vs. Unvaccinated	X ² = 2.2098, df = 1, p-value = 0.9314 X ² = 10.304, df = 1, p-value =
					Third dose vs. Unvaccinated	0.9993
					Two doses vs. Unvaccinated	X ² = 73.402, df = 1, p<0.001
					Third dose vs. Two doses	X ² = 296.23, df = 1, p = 1
Feb 28-Mar 27, 2022*	0.00008413	0.00013235	0.00008154	0.00010663	All vaccinated vs. Unvaccinated	X ² = 9.8147, df = 1, p-value = 0.9991 X ² = 12.465, df = 1, p-value =
					Third dose vs. Unvaccinated Two doses vs. Unvaccinated	0.9998 X ² = 4.4595, df = 1, p-value = 0.0173
					Third dose vs. Two doses	X ² = 41.747, df = 1, p = 1
					Tillia aose vs. Two aoses	

Table S8f: Two-proportions test with continuity adjustment of SARS-CoV2 deaths among NIMS vaccinated population of over 50 years of age from August 16, 2021 to March 27, 2022 and the Delta variant cases until September 12, 2021. ‡ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post second dose are considered vaccinated with two doses. $^{\emptyset}$ SARS-CoV2 cases tested positive with the specimen date \geq 14 days post third dose are considered vaccinated with the third dose.

REFERENCES:

- UK Health Security Agency. COVID-19 vaccine weekly surveillance reports (weeks 39 to 17, 2021 to 2022). Published online 2022. Accessed May 6, 2022. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
- UK Health Security Agency (UKHSA). National flu and COVID-19 surveillance reports: 2021 to 2022 season. Published online 2022. Accessed May 7, 2022. https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021to-2022-season
- 3. GOV.UK Coronavirus (COVID-19) in the UK. Coronavirus (COVID-19) in the UK. Published online 2022. Accessed April 22, 2022. https://coronavirus.data.gov.uk/
- 4. Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020. Published online 2021. Accessed June 24, 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/latest
- 5. Public Health England. Investigation of SARS-CoV-2 variants of concern: technical briefings:Technical briefing documents on novel SARS-CoV-2 variants. Published online 2021. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201
- 6. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine*. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
- 7. National Health Service (NHS) England. COVID-19 Hospital Activity. Accessed October 22, 2021. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/
- 8. NHS England and NHS Improvement. COVID-19 Daily Deaths. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/
- UK Prime Minister's Office. Schools and colleges to reopen from tomorrow as part of Step One of the roadmap. Published online 2021. Accessed March 6, 2021. https://www.gov.uk/government/news/schools-and-colleges-to-reopen-from-tomorrow-as-partof-step-one-of-the-roadmap

- 10. UK Prime Minister's Office. Further easing of Covid restrictions confirmed for 12 April -Outdoor pubs, shops, gyms and hairdressers to reopen. Published online 2021. Accessed April 4, 2021. https://www.gov.uk/government/news/further-easing-of-covid-restrictions-confirmed-for-12-april
- 11. UK Prime Minister's Office. Further easing of COVID restrictions confirmed for 17 May -Planned Step 3 easements will go ahead on 17 May. Published online 2021. Accessed May 9, 2021. https://www.gov.uk/government/news/further-easing-of-covid-restrictions-confirmed-for-17-may
- 12. UK Prime Minister's Office. Prime Minister to set out plans ahead of step 4 . Published online 2021. Accessed July 4, 2021. https://www.gov.uk/government/news/prime-minister-to-set-out-plans-ahead-of-step-4
- 13. UK Health Security Agency (UKHSA). COVID-19 vaccine surveillance report Week 13. Published online 2022. Accessed March 30, 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1066759/Vaccine-surveillance-report-week-13.pdf